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General introduction 
Background
Coronary heart disease (CHD) is the leading cause of death and disability worldwide. 
According to the World Health Organisation, an estimated 7.4 million deaths worldwide 
(13.2% of all deaths) result from CHD each year.1 Despite major advances in 
prevention and treatment, morbidity and mortality in patients with an acute myocardial 
infarction remain significant. In the setting of a myocardial infarction, acute occlusion 
of a coronary artery induces focal myocardial ischemia. Establishing early myocardial 
reperfusion is the most effective strategy to reduce myocardial injury and limit infarct 
size to improve clinical outcome.2 Restoration of blood flow to the ischemic 
myocardium itself however, can also contribute to myocardial injury. This  phenomenon 
is called  ‘lethal reperfusion injury’.3 During early reperfusion various intracellular and 
extracellular events occur, including increased oxidative stress, pH changes, calcium 
overload, an acute inflammatory response and metabolic changes which cause 
tissue injury themselves and contribute to final myocardial infarct size.3  Studies in 
animal models of myocardial infarction suggest that up to 50% of the final infarct size 
is accounted for by reperfusion injury.3  Therefore, additional strategies that could 
limit ischemia and reperfusion (IR) injury might have a significant impact on the 
prognosis following myocardial infarction. Both pharmacological and non-pharma-
cological interventions have been developed with the aim to  prevent myocardial 
IR-injury. 
Pathophysiology of myocardial ischemia  
reperfusion injury 
Ischemia
During myocardial ischemia, the arterial blood flow cannot provide enough oxygen to 
meet the energy demands of the tissue and therefore to maintain tissue function.4 
Within seconds after occlusion of a coronary artery (and in absence of collateral 
interarterial connections), anaerobic glycolysis becomes the dominant energy- 
generating pathway. This anaerobic glycolysis will lower cell pH.4 To compensate for 
this accumulation of hydrogen ions, the Na+/H+ exchanger removes the excess 
hydrogen ions in exchange for sodium ions, which produces a large influx of sodium 
ions. Ischemia also depletes cellular ATP which inactivates ATPases, reduces active 
Ca2+ efflux and  limits reuptake of calcium by the endoplasmic reticulum, thereby 
producing calcium overload in the cell.5 In the heart these cumulative metabolic 
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changes will ultimately lead to damaged myofibrils, hypercontracture and contracture 
band necrosis. The extent of tissue injury depends on the magnitude and duration of 
the ischemic stimulus.6
Reperfusion injury
Although reperfusion is essential to prevent complete necrosis of the myocardial 
cells by restoring the delivery of oxygen and substrates required for aerobic ATP 
generation and normalization of extracellular pH by washing out accumulated H+, 
reperfusion itself also has detrimental consequences3. As stated before, the process 
of reperfusion triggers various events, including an increase in reactive oxygen 
species (ROS), decrease in intracellular pH, calcium overload, an acute inflammatory 
response and metabolic changes, which ultimately cause endothelial dysfunction 
and tissue injury themselves and contribute to the final myocardial infarct size.3 Many 
of these factors promote the opening of the mitochondrial permeability transition 
pore (mPTP), a critical determinant of cell death in the setting of acute IR-injury. 
Opening of this channel induces a collaps of the mitochondrial membrane potential 
and uncouples oxidative phosphorylation, resulting in ATP depletion and cell death.7 
In clinical practice, myocardial reperfusion injury has a number of detrimental clinical 
consequences. First, the sudden reperfusion of ischemic myocardium may be 
accompanied by ventricular arrhythmias. Second, due to oxidative stress and 
intracellular calcium overload reversible post-ischemic contractile dysfunction occurs 
which has been termed myocardial stunning. Third, myocardial reperfusion injury 
may lead to endothelial damage with impaired vasodilation and endothelial cell 
swelling which may impede adequate restoration of blood flow. At last, reperfu-
sion-induced death of cardiomyocytes may occur, a phenomenon that is referred to 
as ‘lethal reperfusion injury’.8
Prevention of ischemia reperfusion injury
With the beneficial effects of early reperfusion well established, but offset by 
reperfusion injury, efforts have been put forward to reduce reperfusion injury and 
improve outcome. Of all myocardial infarction patients, 15% are hospitalized within 
the first year and of these patients one-year mortality is up to 50%.9 If further 
improvement in survival and quality of life is desired, strategies to limit not only 
ischemia, but also reperfusion injury should be developed. Currently, percutaneous 
interventions (PCI) and coronary artery bypass grafting (CABG) are the most 
important techniques to restore myocardial perfusion and  therapeutic strategies to 
limit reperfusion injury in clinical practice should be related to these therapeutic 
strategies.   
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(Pharmacological) conditioning
Already in 1986, Murry et al. reported that myocardial infarct size could be reduced 
by brief intermittent periods of myocardial ischemia and reperfusion preceding the 
lethal ischemic insult, a phenomenon which has been termed ‘ischemic precondi-
tioning’.10 Robust infarct-size limitation by ischemic preconditioning has been 
confirmed repeatedly in various animal species and in different organs (e.g. kidney, 
brain).11-13 Two different phases of preconditioning can be distinguished: an ‘early 
phase’ which induces immediate protection but only for the first 2 hours after the 
preconditioning stimulus and a ‘delayed form’, which reappears after approximately 
24 hours after the preconditioning stimulus and lasts longer but provides weaker 
protection.14   
Despite the attractive properties of ischemic preconditioning, application in the real 
life setting is limited as ischemic events, e.g. acute myocardial infarction, occur randomly 
and unexpected. To overcome these limitations, other conditioning strategies were 
developed. In 2003 Zhou et al. were the first to describe the concept of ‘ischemic 
postconditioning’.15 Where preconditioning is triggered by brief episodes of ischemia 
and reperfusion performed just before a prolonged coronary artery occlusion, post-
conditioning is induced by a comparable sequence of reversible ischemia and 
reperfusion but is applied just after the prolonged ischemic event.16 In dogs a single 
cycle of 5 minutes left anterior descending artery occlusion and 10 minutes of 
reperfusion reduced myocardial infarct size induced by a subsequent 60 minute LAD 
occlusion. Several clinical studies already suggest that postconditioning after 
coronary angioplasty protects the human heart during acute myocardial infarction.16 
The observation that postconditioning limits final infarct size is the most direct 
illustration that reperfusion injury exists and importantly contributes to infarct size. 
Interestingly, the heart is protected against IR-injury not only by brief preceding pre-
conditioning episodes of the heart itself, but also when this preconditioning stimulus 
is applied to other organs than the heart, called remote ischemic preconditioning 
(RIPC). In RIPC brief, reversible episodes of ischemia and reperfusion applied to one 
vascular bed, tissue or organ induce global protection, rendering remote tissues and 
organs resistant to subsequent ischemia and reperfusion.17 In the past decades, the 
concept of RIPC has been successfully explored, showing that protection against 
IR-injury can be transferred between various organs and tissues in different species; 
e.g. brief occlusion of the renal artery protects the heart against a subsequent 
ischemic insult, or brief occlusion of the limb protects the kidney against a subsequent 
ischemic insult.17 
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How does ischemic conditioning protect the heart? Up to now, thousands of studies 
have been published which report more than 100 different signalling molecules and 
mechanisms of conditioning. Briefly, during the preconditioning ischemia, several 
substances are released that ‘trigger’ protection of myocardial cells. These triggers 
include adenosine, bradykinin, reactive oxygen species (ROS), opioids and nitric 
oxide. Binding of these triggers to receptors activates several intracellular signalling 
pathways, such as the reperfusion injury salvage kinase (RISK) pathway, endothelial 
NOS/protein kinase G (PKG) pathway and the survival activating factor enhancement 
(SAFE) pathway.18 Finally, the state of the mPTP is crucial for cell survival. Opening of 
the mPTP at reperfusion leads to dissipation of the inner mitochrondrial membrane 
potential and this ultimately results in cellular desintegration.18 Most prosurvival 
pathway ultimately converge on the mPTP and prevent the mPTP from opening at 
reperfusion and therefore salvage these cells.  
Pharmacological preconditioning: targeting the adenosine pathway
Now that we know the intracellular signalling pathways that are activated by ischemic 
preconditioning, it is tempting to try to mimic the cardioprotective effect by drugs that 
activate these pathways. In preclinical studies, both pharmacological activation of the 
RISK pathway and pharmacological prevention of the mPTP opening reduces 
myocardial IR-injury.3 Drugs that effectively reduce myocardial infarct size in animal 
models include statins, erythropoietin, atrial natriuretic peptide, cyclosporine, 
adenosine, dipyridamole, and metformin.3,19 The endogenous nucleoside adenosine 
is one of the main ligands that trigger activation of the prosurvival pathways during 
ischemic preconditioning.20 Interestingly, intravenous administration of exogenous 
adenosine also reduced infarct size by 75% in animals.21 Later, these protective 
effects of adenosine were confirmed in human atrial tissue in vitro and in human in 
vivo experimental models.22,23 In the Acute Myocardial Infarction STudy of ADenosine 
(AMISTAD) I and II trials, adenosine was used as an adjunct to thrombolytic treatment 
or primary angioplasty in patients with STEMI.24, 25 The results of the AMISTAD I were 
encouraging in those patients who had anterior myocardial infarction and in those 
who were treated with higher doses of adenosine. The larger AMISTAD II trial, in 
which adenosine was administered intravenously for 3 hours, 15 minutes before the 
start of thrombolytic therapy or coronary intervention, failed to demonstrate an effect 
on morbidity and mortality.25 In a retrospective analysis of the AMISTAD II data, 
Kloner et al. did find a significant reduction of infarct size in a subgroup of patients 
who were treated early after the onset of symptoms.26 
So, the adenosine pathways is an attractive pharmacological target to mimic ischemic 
conditioning. The administration of adenosine, however has several drawbacks: 1) an 
extremely short plasma half-life of less than 1 second, and 2) a strong metabolic 
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barrier function of the endothelium for adenosine, prevent effective availability of 
adenosine in the interstitial compartment.27 
Furthermore, potential side effects of intravenous infusion of adenosine are the 
occurrence of cardiac arrhythmias, and hypotension.28-30 Thus, although the key role 
of endogenous adenosine in the protective mechanisms of ischemic conditioning is 
indisputable, the intravascular injection of adenosine is not the most appealing 
method to acquire the desired cardioprotection. 
To circumvent the abovementioned limitations of administering adenosine, drugs 
have been developed to increase the endogenous adenosine concentration. 
To understand how pharmacological compounds can increase the endogenous 
adenosine concentration, we will briefly describe the metabolism of adenosine. 
The physiological effects of endogenous adenosine depend on the extracellular 
adenosine concentration, which is a net result of intracellular and extracellular 
formation and degradation of adenosine (see figure 1). For this reason, several pharma - 
cological methods to increase the extracellular concentration of endogenous 
adenosine have been explored. 
The adenosine metabolism
Under ischemic circumstances, changes in the metabolism of adenosine (see figure 1) 
result in a rapid increase of the extracellular adenosine concentration.31,32 Adenosine is 
formed intracellularly mainly by cytosolic 5’-nucleotidase, which  dephosphorylates AMP. 
A second, but less important pathway, is hydrolysis of S-adenosylhomocysteine. 
AMP is competitively converted by the enzyme AMP deaminase (AMPD) into inosine 
monophosphate (IMP).33 In cardiomyocytes, under well-oxygenated conditions, 
AMP is mainly converted to IMP, whereas in ischemic or hypoxemic situations, 
conversion to adenosine is predominant.33-35   Extracellular formation of adenosine is 
mediated by dephosphorylation of AMP via membrane- bound ecto-5’-nucleotidase 
(CD73).33,36 Degradation of adenosine occurs mainly in the intracellular compartment, 
where adenosine is rephosphorylated to AMP by adenosine kinase or deaminated 
to inosine by adenosine deaminase.33 
During well-oxygenated conditions approximately 90% of adenosine is produced 
 intracellularly.37 The cytosolic adenosine concentration remains very low due to the 
effective intracellular rephosporylation of adenosine to 5’-AMP by adenosine kinase 
and this in turn leads to a transmembrane concentration gradient driving extracellular 
adenosine into the cytosol under normal physiological conditions.37 Adenosine is a 
relatively hydrophilic molecule and therefore transport of adenosine across the 
cellular membrane is facilitated by a concentration gradient driven equilibrative 
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nucleoside transporter (ENT).38 Currently, four different subtypes of ENT are described 
(ENT 1-4), ENT1 and 2 being the most important for adenosine transport in humans39 
During ischemic or hypoxemic conditions, the extracellular adenosine concentration 
increases due to several adaptation in the metabolism: hypoxia upregulates  ecto-  
5’-nucleotidase (CD73) and ecto-nucleoside 5’-triphosphate diphosphohydrolase 
(CD39) which will increase extracellular adenosine formation.40,41 Second, a reduction 
in intracellular degradation due to hypoxic inhibition of adenosine kinase will reduce 
the transmembrane concentration gradient which will diminish the influx of extracellular 
adenosine.42 Finally, a reduction in the transport capacity of ENT’s may reduce 
cellular uptake of adenosine and therefore increase extracellular adenosine 
concentration.43,44
Figure 1   Schematic overview of the metabolism of adenosine and the effect of 
pharmacological agents studied in this thesis. 
ADA, adenosine deaminase; ADP, adenosine diphosphatase; AK, adenosine kinase; AMP, 
adenosine monophosphate; ATP, adenosine triphosphate; CD 73, ecto-5’nucleotidase; ENT, 
equilibrative nucleoside transporter; CD 39, ecto-nucleoside 5’-triphosphate diphospho-
hydrolase; IMP, inosine monophosphate, SAH, S-adenosylhomocysteine.
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ATP/ADP
CD39
ADPMetformin
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Drugs that influence adenosine signalling
This thesis focuses on three drugs that potentially target the adenosine pathway: 
metformin, dipyridamole and ticagrelor. 
Metformin
Several large observational studies in patients with type 2 diabetes have reported 
that treatment with the glucose lowering drug metformin limits cardiovascular 
morbidity and mortality, independent from its glucose-lowering action.45 This suggests 
that metformin might have direct cardioprotective properties. Many preclinical studies 
report beneficial effects of metformin on atherosclerosis development, myocardial 
IR-injury, and postinfarction remodeling.46 In murine models of myocardial infarction, 
the administration of metformin, either before ischemia or at the onset of reperfusion, 
consistently limits infarct size. Chapter 3 of this thesis gives a more detailed overview 
of the preclinical studies on the cardioprotective effects of metformin and the 
mechanisms underlying these effects. Briefly, the administration of metformin at 
reperfusion leads to activation of several kinases of the RISK pathway, including 
phosphatidylinositol-3-kinase (PI3K) and Akt, which in turn prevents opening of the 
mPTP. In addition to the RISK pathway, the cardioprotective effect of metformin is 
also critically dependent on activation of AMPK and eNOS and most recently, Paiva 
et al. showed that the cardioprotective effects of metformin are mediated through the 
increased intracellular formation of adenosine and subsequent adenosine receptor 
stimulation.47-49 Although preclinical data convincingly show that metformin limits 
myocardial IR-injury, human data on a cardioprotective effect of metformin are 
scarce.46 Therefore, in chapter 4 of this thesis we investigated for the first time in 
humans whether short-term treatment with metformin reduces endothelial IR-injury 
in-vivo by measuring brachial artery flow mediated dilation (FMD) before and after 
prolonged ischemia and reperfusion of the forearm in healthy volunteers. 
In addition, in chapter 5 we investigate whether metformin can limit myocardial injury 
in the setting of CABG surgery. 
Dipyridamole
The platelet aggregation inhibitor dipyridamole is registered for the secondary 
prevention of cerebrovascular events. Dipyridamole is a potent inhibitor of the 
hENT1.50,51 Dipyridamole therefore leads to increased extracellular adenosine 
concentrations and subsequent adenosine receptor stimulation. In preclinical 
animals studies, and studies in healthy volunteers and patients undergoing coronary 
angioplasty (PCI), dipyridamole limits IR-injury.51-58 In chapter 6, we tested whether 
administration of dipyridamole limits myocardial injury during CABG surgery. 
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Ticagrelor
Ticagrelor is a novel direct-acting and reversibly binding P2Y12 receptor antagonist. 
In the PLATO (PLATelet inhibition and patient Outcomes) trial, the administration of 
ticagrelor to patients with an acute coronary syndrome resulted in a striking reduction 
in the primary endpoint of death from vascular causes, myocardial infarction, or 
stroke compared to clopidogrel.59 Moreover, all-cause mortality was reduced, and 
this was driven not only by vascular mortality, but also by fewer deaths attributed to 
sepsis.59 In the past years, evidence has accumulated that ticagrelor inhibits ENT 
and therefore leads to a subsequent increase in extracellular adenosine concentration 
and adenosine receptor stimulation.60 This mechanism has been proposed to 
mediate the effects of ticagrelor observed in the PLATO study. Most of the current 
evidence on the effect of ticagrelor on adenosine metabolism is derived from in vitro 
studies, or studies in patients in which the adenosine metabolism could be affected 
by other factors, such as co-medications. Therefore, in chapter 7 we aimed to test 
the hypothesis that ticagrelor inhibits the ENT transporter in healthy humans in vivo. 
We used venous occlusion plethysmography of the forearm to measure the vasodilator 
response to local administered adenosine and to forearm ischemia, as validated 
surrogates for adenosine uptake inhibition. 
Experimental models used in this thesis 
This paragraph summarizes the different models that we used in this thesis to study 
IR-injury and to provide mechanistic insights in humans.  
Flow mediated dilation following brachial artery occlusion 
Flow mediated dilation (FMD) represents a non-invasive technique to measure endo-
thelium-dependent vasodilation as a marker of endothelial function (figure 2).61 The 
endothelial cells are highly susceptible to IR injury: during myocardial ischemia 
endothelial swelling and impaired endothelium-dependent relaxation can further 
impede proper tissue reperfusion.62 FMD following forearm ischemia and reperfusion 
is a generally accepted model to study endothelial IR-injury in humans in vivo. Several 
previous studies have reported that twenty minutes of forearm ischemia followed by 
twenty minutes of reperfusion (induced by inflation/deflation of a pneumatic cuff 
around the proximal upper arm) impairs subsequent FMD of the brachial artery.63,64 
Furthermore, several studies demonstrated that this IR-injury-induced endothelial 
dysfunction could be prevented by (remote) ischemic preconditioning or postcondi-
tioning.63-66 Also, pharmacological interventions (e.g. statins) significantly reduced 
endothelial IR-injury in this model.67 
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Venous occlusion plethysmography 
Another safe and well-validated technique to assess endothelial function is venous 
occlusion plethysmography (figure 3).68,69 Administration of vaso-active drugs into 
the brachial artery results in a high local concentration in the forearm arterial bed. 
Inflation of an upper arm cuff to 40 mmHg allows for unhindered arterial inflow but 
hampers venous return. This results in swelling of the forearm. The rate at which this 
occurs can be measured by mercury-in-silastic strain gauges and correlates with 
forearm blood flow (FBF). To restrict blood flow measurement to skeletal muscle 
blood flow as much as possible, the circulation of the hand, which is mainly skin 
circulation, is excluded from the experimental preparation by inflation of a wrist cuff to 
200 mmHg during each measurement. Intrabrachial administration of adenosine 
increases FBF due to a direct vasodilator effect. We and others have previously 
reported that concomitant administration of an ENT-inhibitor profoundly augments 
adenosine-induced vasodilation.70 As such, we used adenosine-induced vasodilation 
as a surrogate marker for ENT inhibition to investigate the effects of ticagrelor.  
Figure 2   Experimental set-up during brachial artery flow mediated dilation to 
measure endothelium-dependent vasodilation as a marker of endothelial 
function. A rapid inflation and deflation pneumatic cuff is used to induces 
forearm ischemia. In this thesis a 20 minutes ischemia-reperfusion 
protocol was used. 
18
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Coronary artery bypass grafting
The impact of ischemic conditioning has been widely studied in patients undergoing 
coronary artery bypass grafting (CABG).71-75 During this intervention, to create a 
blood-less field, the aorta is cross-clamped to isolate the heart from the systemic 
circulation, which induces global myocardial ischemia. After surgical insertion of the 
grafts, the cross-clamp is removed from the aorta, a process which subjects the 
heart to acute global myocardial reperfusion. Therefore, CABG surgery results in 
myocardial IR-injury, which is reflected by a post-operative increase in plasma 
troponin, which is a biomarker for myocardial injury. The plasma troponin concentration in 
the first 24 hours after surgery is positively associated with a worse clinical outcome.76 
Figure 3   Illustration of the technique of venous occlusion plethysmography to 
measure forearm blood flow (A). 
An intrabrachial cannula allows administration of drugs into the brachial artery. The rate of 
swelling of the forearm during venous occlusion is measured with a mercury-in-silastic strain 
gauge, which is connected to a computer (B), and is expressed in ml/min per dl of forearm 
volume. Reproduced with permission from Riksen et al., Eur J Pharmacol. 2008 May 13;585 
(2-3):220-7.
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Already in 1993, Yellon et al where the first to apply ischemic preconditioning to 
patients scheduled for CABG surgery, by clamping the aorta for 2 minutes and 
unclamping the aorta for 2 minutes prior to the sustained global myocardial 
ischemia.77,78 They found that those patients that received this form of preconditioning 
showed less peri-operative myocardial injury as evidenced by preserved ATP levels 
in ventricular biopsies54 and lower serum troponin I concentrations.78 In a study by 
Hausenloy et al., remote ischemic precondition consisting of three 5-minute cycles of 
right upper limb ischemia, induced by an automated cuff-inflator placed on the upper 
arm and inflated to 200 mmHg resulted in a significant 43% reduction in overall serum 
troponin-T release at 6, 12, 24 and 48 hours after surgery.72  Since these pioneering 
clinical trials, several clinical studies have investigated ischemic preconditioning in 
the setting of CABG surgery.79 
Post-ischemic recovery of contractile function in isolated human 
atrial trabeculae
Coronary artery bypass grafting also offers the opportunity to harvest atrial tissue to 
measure in an ex-vivo model the effects of simulated ischemia and reperfusion on 
contractile function of isolated atrial trabeculae. This experimental set up was first 
described by the group of Yellon and has been used since then for investigating the 
effects of pre- and postconditioning of the human heart.80-82 In summary, the right 
atrial appendage is harvested during cardiac surgery before the introduction of the 
extracorporal circulation. After dissecting separate atrial trabeculae, these are 
suspended in an organ bath and linked to a force transducer. In this thesis a modified 
setup was used in which two trabeculae could be measured simultaneously.83 After a 
recovery phase in which the trabeculae are superfused with a nutrient-supplemented 
and well-oxygenated solution, the trabeculae are exposed to 90 minutes of simulated 
ischemia, which is accomplished by removing oxygen and nutrients from the 
superfusate. Than reperfusion (during a period of 100 minutes) is simulated by 
restoring oxygen and nutrient supply to the trabeculae. Recovery of contractile 
function is used as surrogate marker for IR-injury.  
Aim and outline of this thesis
Most research on cardioprotection is performed in animal models. In this thesis, we 
aim to 1) develop novel models to study IR-injury in humans, 2) use existing human 
models of IR-injury to try to confirm beneficial effects of dipyridamole and metformin 
on IR-injury in humans in vivo, and 3) to provide more insight into the mechanism as 
to how metformin and ticagrelor could limit IR-injury.  
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In chapter 2, we aim to develop a novel human in vivo model of IR injury. We 
hypothesized that  strenuous exercise increases plasma high-sensitive troponin 
levels in healthy volunteers, and that this can be prevented by Remote Ischemic Pre-
conditioning (RIPC). 
In chapter 3 we give a more detailed introduction of pharmacological precondition-
ing with the glucose lowering drug metformin, mainly focusing on preclinical data 
and large observational clinical trials.
In chapter 4 we test whether short-term treatment with metformin reduces endothelial 
IR-injury in healthy volunteers measured by flow mediated dilation following forearm 
ischemia.
In chapter 5 and 6, we move to the clinical setting and test the hypotheses that 
metformin and dipyridamole limit myocardial injury during CABG surgery. 
Finally, in chapter 7 we investigate whether ticagrelor blocks ENT transport at relevant 
plasma concentrations. This finding would provide an explanation for the beneficial 
effect of ticagrelor in patients with an acute myocardial infarction, over and above 
platelet aggregation inhibition. 
21
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Following prolonged endurance exercise (e.g. marathon running), circulating levels of 
cardiac troponin are increased in more than 50% of individuals.1 Also after controlled 
laboratory-based exercise of shorter duration, plasma troponin concentration 
increases, but these data are sparse.2, 3 Up to now, the underlying mechanism of 
troponin appearance after strenuous exercise in humans is unknown. Many theories 
have been posed, including exercise-induced increase in cardiomyocyte membrane 
permeability or cardiomyocyte injury due to ischemia reperfusion (IR).1 In this study 
we aimed to investigate whether IR-injury contributes to the rise in circulating troponin 
after strenuous exercise in healthy volunteers. Remote ischemic preconditioning 
(RIPC) is a powerful strategy to limit IR-injury.4 Therefore, in a randomized controlled 
cross-over study in healthy volunteers, we studied the effect of RIPC on exercise- 
induced troponin I release. If IR-injury contributes to the plasma appearance of troponin 
in this model, than exercise-induced troponin release can be used as a model of 
myocardial IR-injury in healthy volunteers. 
The study was approved by the local ethics committee. After informed consent, twenty 
healthy volunteers (age 22±4 years, 10 male) participated. Before randomization, all 
volunteers underwent a maximal cycling test to determine maximum heart rate. 
Subsequently, in a crossover design, all volunteers performed a submaximal exercise 
test preceded by RIPC or a control intervention. The tests were separated by two 
weeks and the order was randomized. After 30 minutes of  supine rest, subjects 
performed bicycle exercise at 80% of their maximum heart rate or heart rate reserve 
(whatever resulted in the highest target heart rate) for 70 minutes, immediately 
followed by cycling at 95% of maximal heart rate reserve until exhaustion or for a 
maximum of 15 minutes. The RIPC stimulus was applied during the 30 minutes 
immediately before the exercise test. RIPC consisted of three 5-min cycles of bilateral 
forearm ischemia, induced by inflation of an upper-arm cuff to 200 mm Hg, separated 
by 5 minutes of deflation. Five minutes after the last period of ischemia, the exercise 
test was performed. All experiments were performed in the morning, after a light 
breakfast and at least 24 hours of caffeine and alcohol abstinence. Forty-eight hours 
before each test, participants were instructed to abstain from strenuous exercise. On 
both study days, blood was sampled from an indwelling forearm catheter  before, 
and at 0 , 1, 2, 3, 4, and 8 hours after the exercise test to determine high sensitive 
troponin I (hs-troponin). N-terminal pro-B type natriuretic peptide (NT-Pro-BNP) was 
measured 1 and  3 hours post exercise. Creatine kinase (CK) was measured at t= 3 
hours post exercise.  Results are described as mean ± SE. The effect of RIPC on 
troponin release was tested with an ANOVA for repeated measures.
30
CHAPTER 2
The workload and heart rate were not significantly different between exercise and 
RIPC+exercise (workload 146±12 vs. 140±12 Watt; heart rate 168±1.5 vs. 169±1.4 
beats/min, respectively, all P>0.05).  In both groups a consistent rise and fall in 
hs-troponin levels was found after exercise. There was no significant difference in 
hs-troponin levels between the groups with and without RIPC (figure 1). Also, 
post-exercise NT-Pro-BNP and CK levels were not different between both conditions 
(NT-pro-BNP t=1 h exercise 67.5±7.9 vs. RIPC 93.1±19.5 ng/L; NT-pro-BNP t=3 h 
exercise 61.5±5.9 vs. RIPC 88.2±17.7 ng/L; CK exercise 323±85 vs. RIPC 431±118 
U/L; P>0.1 for all comparisons). 
Our study is the first to measure hs-troponin levels on multiple time points after brief 
strenuous exercise in healthy volunteers. In accordance with previous studies of 
prolonged exercise, the plasma hs-troponin I concentration significantly increased in 
the majority of subjects with a peak concentration 4 hours post-exercise. 3, 5 RIPC did 
not alter exercise-induced hs-troponin release. This observation strongly suggests 
that myocardial IR-injury does not contribute to the exercise-induced increase in 
troponin. Therefore, this experiment cannot be used as a model to study IR-injury in 
humans in vivo. 
A number of studies have demonstrated that strenuous exercise increases troponin 
levels in healthy individuals.1, 3 The mechanism of this release, however, is still a 
matter of debate.1 In cardiomyocytes, most troponin is bound to tropomyosin, and 
only a small amount resides in unbound form in the cytosol. Several mechanisms of 
Figure 1   Circulating hs-troponin I concentration (mean ± SE) before (B) and  
after (0, 1, 2, 3, 4 and 8 h) cycling exercise with (open circles) of without 
(filled squares) preceding RIPC.
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exercise-induced troponin release have been suggested, including an exercise-in-
duced increase in myocardial sarcolemmal permeability, leading to leakage of 
unbound cytosolic troponin.1 This increased membrane permeability can be due to 
mechanical stress, free oxygen radical formation or changes in pH levels.1, 2 An 
alternative explanation might be stimulation of integrines due to myocardial stretch.6 
Stimulating integrines mediates the transport of intact troponin molecules out of the 
cardiomyocyte. Finally, troponin release can be due to sustained myocardial cell 
injury with cell death.5   Troponins are also expressed in skeletal striated muscle, but 
since the amino-acid sequence of the skeletal and cardiac isoforms of troponin T and 
I are dissimilar, they are well-differentiable by monoclonal antibody-based assays.7
Should IR-injury contribute to the hs-troponin release after exercise, we would have 
expected RIPC to prevent this release, since RIPC consistently limits IR-injury in 
various situation of (myocardial) IR-injury. 8, 9 The observation that RIPC does not 
affect the appearance of troponin strongly argues against IR-injury to contribute 
significantly to the troponin release. In addition, we found no rise in NT-pro-BNP 
levels, suggesting no significant increase in intracardiac pressure. Hs-troponin release 
due to increased myocardial stretch is therefore unlikely. The mechanism responsible 
for the increased post-exercise hs-troponin levels still has to be elucidated. Taken 
together, the kinetics of the appearance of troponin, and the lack of protection by 
RIPC supports the concept that the troponin appearance is due to leakage of 
cytosolic troponin by mechanisms other than IR-injury. 
In summary, we investigated whether myocardial IR-injury contributes to the exercise- 
induced increase in plasma hs-troponin I, using RIPC as a potent strategy to limit 
IR-injury. Based on our findings, IR-injury does not importantly contribute to the 
increase in hs-troponin levels after exercise as it cannot be prevented by RIPC. 
Strenuous exercise, therefore, is not a valid model to study myocardial IR-injury. 
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Abstract
In patients with diabetes mellitus, the incidence of cardiovascular disease is increased, 
and the outcome following cardiovascular events is worse. The antihyperglycemic 
drug metformin appears to limit cardiovascular death in patients with type 2 diabetes. 
Indeed, preclinical studies have demonstrated that metformin limits (myocardial) 
ischemia and reperfusion injury, independent from its glucose-lowering effect. This 
cardioprotection is mediated by activation of the Reperfusion Injury Salvage Kinase 
(RISK) pathway, activation of AMPK and by an increased formation of adenosine. 
In addition, metformin can modulate several cardiovascular risk factors and reduces 
the development of heart failure in murine models. Consequently, treatment with 
metformin might potentially improve cardiovascular outcome in patients at risk for 
myocardial ischemia, even these patients do not have diabetes. In the current paper, 
we  focus on the direct cardioprotective actions of metformin and the mechanisms 
that underlie these effects.
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Introduction
Coronary artery disease (CAD) is the leading cause of morbidity and mortality 
worldwide, accounting for nearly one third of all deaths.1 In patients with diabetes 
mellitus, cardiovascular morbidity and mortality is even more pronounced. In part, 
this is explained by an accelerated development of atherosclerosis.2 In addition, 
when suffering a myocardial infarction, the outcome is worse3-6, with also success 
rates of angioplasty and coronary artery bypass grafting being lower.7-9 Patients with 
diabetes also have a high prevalence of congestive heart failure secondary to diabetic 
changes in the myocardium. This unique clinical entity, which is characterized by fibrotic 
changes in the myocardium and functional alterations in diastolic relaxation and 
ventricular compliance, is referred to as ‘diabetic cardiomyopathy’.10 The pathological 
changes occurring in diabetic cardiomyopathy include increased reactive oxygen 
species (ROS),11 abnormal handling of calcium and increased release of inflammatory 
mediators.12 Although in part related to myocardial infarction, this type of heart failure in 
diabetics can occur independent from cardiovascular risk factors and ischemia.12 
The prevalence of patients with diabetes and heart failure is rapidly increasing, and 
these patients have a worse outcome than heart failure patients without diabetes.13 
These observations, alongside the evidence that diabetic patients have a worse 
prognosis following myocardial infarction, suggest that the diabetic heart is more 
vulnerable to ischemic damage.
Therefore, novel strategies to prevent the development of atherosclerosis, and to 
increase the intrinsic tolerance of the myocardial cells to ischemia and reperfusion 
are urgently needed. In accordance with current guidelines, establishing early reperfusion 
is the primary therapy in patients with a myocardial infarction.14 The beneficial effect 
of re-establishing coronary blood flow, however, is limited by a phenomenon called 
‘reperfusion injury’.14 The process of reperfusion triggers various pathways, including 
oxidative stress, pH changes, calcium overload, an acute inflammatory response and 
metabolic changes, which cause tissue injury themselves, and contribute to the final 
myocardial infarct size. Many of these factors promote the opening of the mitochondrial 
permeability transition pore (mPTP), a critical determinant of cell death in the setting 
of acute ischemia reperfusion (IR)-injury.1, 15 To further optimize the results of coronary 
angioplasty and coronary artery bypass grafting, strategies to limit IR-injury are 
needed. In the past two decades, both pharmacological and non-pharmacological 
interventions have been developed which can limit or prevent acute myocardial 
IR-injury. 
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As a nonpharmacological cardioprotective strategy, ischemic preconditioning (IPC) 
has received much attention for its potent infarct size-limiting effect since it was first 
reported by Murry et al. in 1986.16 Murry demonstrated that short intermittent episodes 
of ischemia prior to a prolonged ischemic event  potently limit the final infarct size. 
Over the years, a tremendous amount of effort has been done to mimic the cardio-
protective effect of IPC with pharmacological agents.17, 18 Interestingly, several large 
studies have suggested that the glucose lowering drug metformin might have such a 
cardioprotective effect, independent of its glucose lowering effect.13 In this article we 
aim to summarize these cardioprotective effects of metformin and the underlying 
mechanisms.
The effect of metformin on cardiovascular outcome 
in patients with type 2 diabetes
Metformin, a biguanide glucose-lowering agent, is the first-line oral treatment option for 
patients with type 2 diabetes mellitus.19 Metformin lowers plasma glucose levels by 
reducing insulin resistance, particularly in the liver and skeletal muscle cells. It supresses 
hepatic gluconeogenesis, increases insulin sensitivity, enhances peripheral glucose 
utilization and has beneficial effects on lipid metabolism. The mechanisms underlying 
these effects have yet to be fully elucidated, although recent data have implicated 
AMP-activated protein kinase (AMPK) activation as an important mediator.20, 21  One 
of the most significant breakthroughs in the understanding of the cellular mechanism 
of metformin was made in the early 2000s by two independent research groups 
reporting that metformin induces specific inhibition of complex 1 of the mitochondrial 
respiratory chain.22, 23 It has been hypothesized that metformin activates AMPK by 
inhibiting complex 1 of the mitochondrial respiratory chain, resulting in a fall in the 
intracellular adenosine triphosphate (ATP) concentration and an increase in the 
adenosine monophosphate (AMP) to ATP ratio. In turn, AMPK activation leads to 
enhanced glucose uptake in skeletal muscle, stimulates oxidation of free fatty acids 
and inhibits glucose production by hepatocytes.24 The AMPK hypothesis however, 
has recently been challenged by Foretz et al.25 In their study they demonstrated that 
administration of metformin in mice suppressed hepatic gluconeogenesis directly by 
a decrease in hepatic energy state independent from AMPK activation.
Several large observational studies in patients with type 2 diabetes have reported 
that treatment with metformin limits cardiovascular morbidity and mortality independent 
from its glucose-lowering action.26 In the United Kingdom Prospective Diabetes 
Study (UKPDS) treatment of diabetic patients with metformin was associated with 
lower mortality rates compared to treatment with sulphonylurea derivatives (SUD’s).27 
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The study showed that patients with type 2 diabetes treated with metformin had a 
36% lower all-cause mortality and a 39% lower risk of myocardial infarction compared 
with conventional treatment. This risk reduction was greater for metformin than for 
treatment with insulin or SUD’s, despite similar glycaemic control. Also in patients with 
diabetes  who have suffered from a myocardial infarction in the past, treatment with 
metformin is associated with a lower mortality rate than treatment with SUD’s.28, 29 
The reduction in cardiovascular mortality by metformin was confirmed by a systematic 
review  and a recently published Cochrane analysis. 30, 31 Selvin et al concluded that 
treatment with metformin of overweight diabetic patients was associated with a 
decreased risk of cardiovascular mortality (pooled OR 0.74;95% CI, 0.62-0.89) 
compared with any other oral antidiabetic agent or placebo. The results for 
cardiovascular morbidity and all-cause mortality showed a similar trend, but this was 
not statistically significant. It needs to be mentioned however, that this analysis was 
restricted to the overweight patients. 
A more recent meta-analysis was performed by Lamanna et al. in which they studied 
35 clinical trials including 18.472 participants treated with metformin or comparator.32 
In this meta-analysis the overweight group and the non-overweight group were 
combined. In addition to patients with diabetes, they included studies on non-diabetic 
patients with HIV or polycystic ovary syndrome. In an overall analysis, metformin 
therapy when compared to an active comparator, did not produce any significant 
effect on the incidence of cardiovascular events. Monotherapy with metformin, 
however, induced a trend towards improved overall mortality, which was abolished 
when metformin was administered in addition to sulphonylurea derivatives. 
The contradicting results of the recent meta-analysis and the striking beneficial effect 
of metformin in the UKPDS study, might be related to the fact that the UKPDS was 
performed in a much earlier time period where the treatment of other cardiovascular 
risk factors and the treatment of acute coronary events was inferior to the treatment 
in the present era. Therefore,  in the current era establishing a beneficial cardiopro-
tective effect of metformin on top of its glucose-lowering effect is a greater challenge. 
Laboratory studies, animal studies, and studies in healthy volunteers and patients 
with diabetes have provided evidence that metformin modulates several risk factors 
for atherosclerosis, increases the intrinsic tolerance of the myocardium to ischemia 
and reperfusion, and attenuates the subsequent development of heart failure. We will 
consecutively discuss these studies and focus on the direct cardioprotective effects 
of metformin.
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Effect of metformin on other cardiovascular risk factors
In addition to its glucose lowering effect, metformin therapy also has beneficial effects 
on other cardiovascular risk factors. Patients with diabetes exhibit an atherogenic 
lipid profile characterized by hypertriglyceridemia, decreased levels of high-density 
lipoprotein (HDL) cholesterol and elevated levels of small, dense atherogenic low density 
lipoprotein (LDL) cholesterol particles.33, 34 Free fatty acid levels are increased, and 
consequently, hepatic production of very low density lipoprotein (VLDL)  is increased 
and clearance of VLDL particles is reduced. 35, 36 Metformin seems to improve the 
lipid profile by lowering triglyceride levels, total cholesterol and LDL cholesterol levels 
while maintaining or increasing HDL levels.37-42  By lowering glucose levels metformin 
also seems to reduce oxidative stress and lipid oxidation.43, 44   
An increase in bodyweight is also associated with an increased risk for cardiovascular 
disease and is deemed an independent risk factor for CVD  by the Framingham Heart 
Study.45 Metformin reduces bodyweight by enhancing carbohydrate utilization in the 
gastrointestinal tract, adverse gastrointestinal side effect, carbohydrate malabsorption, 
and/or through associated anorexia.37  
Another suggested beneficial effect of metformin is its ability to lower blood pressure. 
Even a small elevation in blood pressure significantly increases death from cardio-
vascular disease and risk for myocardial infarction, stroke and congestive heart failure 
in patients with diabetes.46  Therefore even a minimal reduction in blood pressure 
during treatment with metformin may contribute to a significant decrease in diabetes 
related morbidity and mortality. Several studies indicate an antihypertensive effect 
of metformin in animals and humans.38, 47-52 Data regarding the effect of metformin 
on blood pressure however, are not entirely consistent. In a study by Nagi et al 
metformin had no effect on blood pressure in patients with diabetes and a recent 
study by He et al showed the same results for non-diabetics.53, 54
Platelet aggregation plays an important role in the pathophysiology of myocardial 
infarction. Metformin has been shown to reverse platelet hyperaggregation, but this 
effect is more pronounced in animal experimental models than in humans.55 
Gin et al was able to demonstrate that in patients with diabetes mellitus treated with 
insulin, administration of metformin  decreased the maximum platelet aggregation 
induced by adenosine diphosphate (ADP) in vitro.56 Another study however failed 
to demonstrate any effect on platelet aggregation or platelet aggregation induced 
by ADP.53 
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Another risk factor for cardiovascular arterial thrombotic events is an elevated fibrinogen 
level.57 In patients with insulin resistance, fibrinolysis is reduced, which seems correlated 
to increased levels of plasminogen activator inhibitor (PAI-)1.58 Metformin appears 
to reduce PAI-1 levels in patients with and without diabetes, hereby reducing the risk of 
developing cloth formation.59-61 
Endothelial dysfunction, as characterized by an impairment in endothelium dependent 
relaxation and reduced nitric oxide (NO) bioavailibility, is an early characteristic of 
atherogenesis. Studies have shown that treatment with metformin improves endothe-
lium-dependent vasodilation by increased availability of NO.62 
All of the abovementioned beneficial effects of metformin on cardiovascular risk 
factors could potentially lead to slowing down the process of atherosclerosis and 
therefore decrease the incidence of cardiovascular events.
Direct cardiovascular effects of metformin
Effect of metformin on ischemia reperfusion injury
The administration of metformin, either before the ischemic stimulus or at the moment 
of coronary reperfusion, profoundly reduces infarct size in murine models of 
myocardial infarction.  Already in 1988, Charlon et al showed that oral administration 
of metformin could reduce infarct size in rats.63  Solskov et al also showed in a rat 
isolated perfused heart model that the administration of a single dose of metformin 
24 hours before transient coronary artery occlusion reduced infarct size.64 In 
subsequent studies in isolated rat hearts, coronary perfusion with metformin during 
the first 15 minutes of reperfusion reduced infarct size with approximately 40-50%.65-67 
This was also confirmed in in-vivo studies in rats and mice.66, 68  Recently, several 
intracellular mechanisms that mediate this cardioprotective effect have been 
discovered.
Reperfusion Injury Salvage Kinase (RISK) pathway
Opening of the mitochondrial permeability transition pore (mPTP) during (early) 
reperfusion is a pivotal mechanism of ischemia-reperfusion (IR)-injury. This non - 
selective pore in the mitochondrial inner membrane is closed during ischemia. 
Immediately after reperfusion, the mPTP opens, which will induce ATP depletion and 
release of pro-apoptotic factors, including cytochrome C, ultimately leading to 
necrosis and apoptosis.69, 70 It has been demonstrated that the administration of 
metformin at reperfusion leads to activation of several kinases of the Reperfusion 
Injury Salvage Kinase (RISK) pathway, including phosphatidylinositol-3-kinase (PI3K) 
and Akt, which in turn can prevent opening of the mPTP. 
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In an isolated rat heart model, Bhamra et al. found that the administration of metformin 
during the first 15 minutes of reperfusion reduced infarct size in nondiabetic Wistar 
rats and type 2 diabetic Goto-Kakizaki rats.65 Metformin also induced a significant 
increase in Akt phosphorylation after reperfusion. Concomitant administration of 
LY294002, a PI3K inhibitor, prevented Akt phosphorylation and abolished the 
protective effect on infarct size. In isolated rat cardiomyocytes, incubation with 
metformin prevented mPTP opening by activation of the PI3K/Akt pathway. The 
authors concluded that the protective effect of metformin against myocardial IR-injury 
is PI3K dependent and that the effect of metformin on Akt phosphorylation is similar 
in both nondiabetic and diabetic rats.
AMPK
In addition to the RISK pathway, the cardioprotective effect of metformin is also 
critically dependent on activation of AMPK. AMPK is a major regulator of energy 
balance in the cell. Environmental stress including exercise, starvation, inflammation 
and hypoxia increases AMPK activity. AMPK also fulfils a crucial role in preserving 
myocardial viability during myocardial infarction. By increasing ATP synthesis and 
lowering ATP utilization, AMPK functions to maintain normal cellular energy stores 
during ischemia.24 Calvert et al. showed that the protective effect of metformin is 
AMPK dependent.68 Immediately after the onset of myocardial ischemia, phos-
phorylation of AMPK occurs, and remains active for more than 24 h following 
reperfusion in a murine model of coronary artery occlusion. Pretreatment with a very 
low dose of metformin increased the phosphorylation of AMPK in hearts not exposed 
to ischemia as well as in hearts exposed to ischemia reperfusion. Metformin failed 
to provide protection in cardiac-specific AMPKα2 dominate-negative transgenic 
mice, demonstrating that AMPK activation is essential for metformin-induced 
protection. In an additional experiment, it was shown that metformin increased 
eNOS phosphorylation via activation of AMPK and that eNOS activation was 
also indispensible for its cardioprotective action.68  Yellon’s group also studied the 
involvement of AMPK in metformin-induced cardioprotection. 67  In a rat isolated 
heart model, metformin was added for 15 min at the onset of reperfusion alone or 
with the AMPK inhibitor Compound C. Metformin significantly reduced infarct-size, 
which was completely abolished by adding Compound C simultaneously. Interestingly, 
delayed administration of Compound C after 5 minutes of reperfusion did no longer 
block the protective effect of metformin. The authors concluded that the cardio-
protective effect of metformin was mediated by AMPK activation very early during 
reperfusion 
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Adenosine
Most recently, the endogenous nucleoside adenosine has been shown to be involved 
in metformin-induced cardioprotection. Metformin induces phosphorylation of 
AMPK, which is mediated, at least in part, by an increase in the cytosolic AMP 
concentration.71  The concentration of free AMP in the cytosol is also a major 
determinant of the intracellular formation of  adenosine.  It is well known that adenosine 
receptor stimulation limits infarct size by activation of the RISK pathway.17, 72 Therefore, 
Paiva et al. hypothesized that adenosine receptor stimulation contributes to the infarct 
size limiting effect of metformin.66  In isolated perfused nondiabetic rat hearts, 
perfusion with metformin during the first 15 minutes of reperfusion limited infarct size. 
Both 8-p-sulfophenyltheophylline (a nonspecific adenosine receptor blocker) and ni-
trobenzylthioinosine (transmembranous adenosine transport inhibitor) completely 
prevented the protective effect, suggesting that intracellular formation of adenosine, 
and subsequent adenosine receptor stimulation mediates the protective effect of 
metformin. 
In conclusion, metformin potently reduces myocardial infarct size by activation of 
multiple, and probably parallel, intracellular pathways. These pathways include activation 
of the RISK pathway, activation of AMPK and eNOS and increased adenosine 
receptor stimulation, resulting in the prevention of MmTP opening at reperfusion. 
These signaling pathways are illustrated in Fig. 1.
Effect of metformin on cardiac remodelling and heart failure
In patients suffering a myocardial infarction, the prognosis is determined not only by 
the final infarct size, but also by long-term changes that occur in the myocardium 
following an infarction. Following IR-injury, but also in patients suffering from volume 
overload (e.g. due to valvular disease), pressure overload (e.g. due to hypertension) 
and diabetic cardiomyopathy, a complex cascade of events occurs in the myocardial 
cells, including inflammation and fibrosis, ultimately leading to changes in size, shape 
and function of the heart, a process which has collectively been termed ‘remodeling’.73, 74 
In time this cardiac remodelling will lead in a significant part of the patients to clinically 
overt heart failure. Several experimental animal studies showed that metformin, 
in addition to limiting IR-injury, can also limit the process of cardiac remodelling 
and the development of heart failure.75 
Gundewar et al have shown in a series of experiments that metformin significantly 
improves left ventricular function and survival in a murine model of heart failure.76 
The administration of a single dose of metformin at reperfusion following 60 minutes 
of coronary artery occlusion reduced infarct size, but did not prevent the development 
of severe cardiomyopathy. In contrast, when metformin was administered daily for a 
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period of 4 weeks, the development of cardiac hypertrophy was limited and heart 
function was preserved. In a model of permanent coronary artery ligation, treatment 
with metformin did not reduce infarct size and did not affect ejection fraction, although 
this treatment increased overall survival. 
In their rat model of permanent coronary artery ligation , Yin et al have recently shown 
that the long term administration of metformin  preserves left ventricular function.77 
In this study, animals were randomly allocated to the treatment with normal water 
or metformin-containing water (250 mg/kg/day). In the rats that received permanent 
Figure 1   Inhibition of complex 1 increases the AMP concentration. 
This activates AMPK and increases the formation of adenosine. AMPK activation increases 
tolerance against ischaemia and reperfusion and, by phosphorylation of eNOS, prevents MPTP 
opening at reperfusion. In addition, increased adenosine receptor stimulation activates the 
PI3K/Akt pathway, which contributes to eNOS activation (Reproduced with permission from 
El Messaoudi et al,  Curr Opin Lipidol. 2011;22:445-453).
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coronary artery ligation, infarct size was significantly smaller after 12 weeks of 
metformin treatment compared to the control group. Moreover, metformin treatment 
resulted in less left ventricular dilatation and preservation of left ventricular ejection 
fraction compared with the control group. In addition, in a  dog model of cardiac 
pacing-induced heart failure and in a mouse model of heart failure due to thoracic 
aortic constriction, the chronic administration of metformin attenuated the hemo - 
dynamic and structural changes that were characteristic of the development of heart 
failure.78, 79  In contrast, metformin did not prevent heart failure development in a rat 
model of volume overload-induced heart failure.80 
Probably, several mechanisms contribute to this protective effect. Metformin is 
thought to improve myocardial mitochondrial respiration and ATP synthesis by an 
underlying mechanism requiring the activation of AMPK and its downstream 
mediators eNOS and peroxisome proliferator-activated receptor-γ  coactivator- (PGC) 
1α.76 Also, metformin seems to reduce collagen expression that occurs after coronary 
artery ligation.77 Yin et al also suggested that the beneficial effect of metformin on 
post-myocardial infarction remodelling could be attributed to a decrease in plasma 
insulin concentration, given the observation that hyperinsulinemia is associated with 
exacerbation of cardiac remodelling.77, 81 
Alternative glucose lowering drugs and cardioprotection
Interestingly, metformin is not the only glucose-lowering agent that can modulate 
(myocardial) IR-injury. Sulphonylurea derivatives (SUDs) do not induce cardioprotection, 
but have been shown to prevent the cardioprotective effect of ischemic preconditioning 
and pharmacological preconditioning, most likely due to prevention of opening of 
the mitochondrial ATP-sensitive K+ channel.28, 29, 82-84  This effect of SUD’s might 
contribute to the findings that patients who are treated with a combination of SUD and 
metformin appeared to have a worse outcome on mortality as compared with those 
who are treated with metformin alone.32 A recent national cohort study of veterans 
initiating oral treatment for diabetes mellitus found that sulfonylurea use was 
associated with an increased hazard of acute myocardial infarction, stroke, or death 
compared with metformin use. The findings do not clarify whether the difference in 
cardiovascular disease risk is due to harm from sulfonylureas, benefit from metformin, 
or both.27 Recent comparative effectiveness reviews and meta-analyses concluded 
that metformin was associated with a slightly lower risk for all-cause mortality compared 
with sulfonylureas, but results were inconsistent and imprecise.30, 85, 86 This study 
provides further evidence of a risk difference in cardiovascular outcomes for 
sulfonylurea and metformin users. Insulin, on the other hand, profoundly protects the 
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myocardium from IR-injury via activation of the RISK pathway.87 Similarly, the novel 
antihyperglycemic glucagon like-peptide-1 ( GLP-1) analogues and the dipeptidyl-
peptidase-4 (DPP-4) inhibitors have also been shown to exert direct cardioprotective 
effects in murine models of myocardial infarction. Very recently, the GLP-1 analogue 
exenatide was tested in patients suffering an acute ST-segment elevation myocardial 
infarction.88 It appeared that a six-hours intravenous administration of exenatide, 
commencing immediately before reperfusion, significantly reduced infarct size, 
measured with cardiac magnetic resonance. Since this is outside the scope of our 
review, we would like to refer the reader to contemporary reviews on these alternative 
glucose-lowering drugs.89-91 
Conclusion
Animal studies have provided consistent evidence that metformin can limit myocardial 
ischemia reperfusion injury and infarct size. Metformin therapy also seems to 
attenuate postinfarction cardiac remodelling. In addition, metformin can modulate 
several risk factors for atherosclerosis, independent of glucose control, although 
these findings are less consistent. The most likely underlying mechanisms of cardio-
protection are activation of the RISK-pathway, activation of AMPK, and increased 
adenosine receptor stimulation. Currently, several randomized clinical trials are being 
performed to explore the cardioprotective effect of metformin in nondiabetic patients 
suffering a myocardial infarction92 and in nondiabetic patients undergoing cardiac 
surgery (ClinicalTrials.gov registration number NCT01439723). Metformin is cheap, 
and its longterm safety has been well established. Therefore, a positive result from 
these clinical studies could result in a quick implementation of metformin in clinical 
management to prevent and treat cardiovascular events, also in patients without 
diabetes mellitus.
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Abstract
Introduction: Large prospective studies in patients with type 2 diabetes mellitus 
have demonstrated that metformin treatment improves cardiovascular prognosis, 
independent of glycemic control. Administration of metformin potently limits infarct 
size in murine models of myocardial infarction. This study examined, for the first time 
in humans, whether metformin limits ischemia-reperfusion (IR) injury in vivo using a 
well-validated forearm model of endothelial IR-injury.
Methods: Twenty-six healthy volunteers (age 41±6 years, 10 male/16 female) were 
randomized between pretreatment with metformin (500 mg three times a day for 
3 days) or no treatment in a Prospective Randomized Open Blinded Endpoint study. 
Brachial artery flow mediated dilation (FMD) was measured before and after 
20 minutes of forearm ischemia and 20 minutes of reperfusion. FMD analysis was 
performed offline by investigators blinded for the treatment arm.
Results: Baseline FMD did not differ between metformin pretreatment and no 
pretreatment (6.9±3.6% and 6.1±3.5%, respectively, p=0.27, n=26). FMD was 
significantly lower after forearm IR in both treatment arms (4.4±3.3% and 4.3±2.8%, 
respectively, P<0.001 in both conditions). A linear mixed model analysis revealed that 
metformin treatment did not prevent the decrease in FMD by IR.
Conclusion: A 3 day treatment with metformin in healthy, middle-aged subjects does 
not protect against endothelial ischemia reperfusion injury, measured with brachial 
artery FMD after forearm ischemia. Further studies are needed to clarify what 
mechanism underlies the cardiovascular benefit of metformin treatment.
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Introduction 
Despite optimal reperfusion strategies, morbidity and mortality remain significant in 
patients suffering an acute myocardial infarction. Therefore, much effort is put into 
developing novel strategies to limit ischemia-reperfusion (IR) injury.1 Interestingly, 
large observational and intervention studies have shown that overall cardiovascular 
mortality is lower in patients with type 2 diabetes mellitus who are treated with 
metformin, than in patients treated with alternative glucose-lowering drugs, despite 
similar glycemic control.2-6 This observation suggests that metformin has direct 
 cardioprotective effects.7 Indeed, in murine models of myocardial infarction, performed 
in diabetic as well as in non-diabetic animals, administration of metformin limits 
myocardial infarct size.8-11 This cardioprotective effect is mediated by activation of 
adenosine monophosphate activated protein kinase (AMPK) and adenosine receptor 
stimulation.9, 10  Whether metformin treatment also directly protects against IR injury 
in humans is currently unknown.
Myocardial IR also induces endothelial dysfunction, causing endothelial swelling 
and impaired endothelium-dependent relaxation, which can further impede proper 
tissue reperfusion.12 Several strategies, including ischemic preconditioning and 
 postconditioning have been reported to limit IR-induced endothelial dysfunction in 
healthy humans.13, 14
In this study, we investigate for the first time in humans whether metformin limits 
endothelial IR injury in vivo by measuring flow mediated dilation (FMD) of the brachial 
artery before and after prolonged ischemia and reperfusion of the forearm. We test 
the hypothesis that short-term pretreatment with metformin limits endothelial IR injury 
in humans in vivo. 
Methods
Ethics Statement
The protocol is approved by the Institutional Review Board of the Radboud University 
Medical Centre, and was performed in the Radboud University Medical Centre in 
compliance with the recommendations of the Declaration of Helsinki. All patients 
signed for informed consent before participation. The study is registered at www.
clinicaltrials.gov (NCT01610401). The authors confirm that all ongoing and related 
trials for this drug/intervention are registered.
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Participants
We included 28 healthy, non-smoking adult volunteers in this study. All subjects were 
free of cardiovascular disease, diabetes mellitus, hypertension (systolic blood 
pressure ≥140 and/or diastolic ≥90 mmHg) and hypercholesterolemia (random total 
cholesterol > 6.5 mmol/L). We also excluded professional athletes and those who 
were taking concomitant medication. Oral contraceptive use by female participants 
was permitted and these females were asked to continue their contraceptive through - 
out the study to maintain stable hormone levels. Females not on oral contraceptives 
were measured at identical times in their menstrual cycle, to exclude any confounding 
effects of circulating hormones on endothelial function.15, 16 Two participants withdrew 
during the study. Therefore, 26 subjects finished the trial protocol (Figure 1).
Experimental Design
In a prospective randomized open blinded end-point (PROBE) study,  subjects were 
allocated to treatment with either metformin 500 mg (Mylan, Bunschoten, The Netherlands) 
three times a day for 3 days, to ensure a steady state plasma concentration, or no 
pretreatment (figure 1). Simple random allocation was performed by an independent 
researcher by dice-throwing for each individual patient (even number: starting with 
metformin; uneven number: starting with no treatment). The last dose of metformin 
was given approximately 3 hours before the experiments. Subjects attended our 
laboratory twice, separated by at least 14 days to prevent any cross-over effect of 
metformin. Brachial artery endothelial function was measured with flow-mediated 
dilation (FMD) in the right arm, before and after 20 minutes of forearm ischemia. 
Forearm ischemia was induced by inflating a pneumatic cuff around the upper arm 
for 20 minutes and this was followed by 20 minutes of reperfusion. Patient recruitment 
was performed between May 15th 2012 and October 4th 2012. The first patient was 
included on May 15th 2012 and the last visit of the last patient was November 20th 
2013.
Measurements
All subjects had to abstain from caffeine consumption and strenuous exercise for at 
least 24 hours before the measurement. Measurements were performed after an 
overnight fast of at least 6 hours. Before the test, venous blood was taken to assess 
metformin and caffeine levels. After removing phospholipids and proteins with 
 HybridSPE-phospholipids columns (Supelco), the plasma metformin concentration 
was determined with LC-MS/MS, using an Accela U-HPLC (Thermo Fischer Scientific) 
coupled to a TSQ Vantage (Thermo Fisher Scientific) triple quadropole mass 
spectrometer. The compounds were separated on a Zorbax HILIC Plus (100x2.1 mm, 
3.5 µm particle size; Agilent Technologies). As internal standard we used metformin-d6 
(Toronto Research Chemicals Inc.) The elution gradient was as follows: 0 min, 100% 
57
METFORMIN AND ENDOTHELIAL ISCHEMIA-REPERFUSION INJURY
4
B; 5 min, 50% B; and 6 min, 100% B. Solvent A consisted of 2 mM NH4format+0.1% 
formic acid in H2O and Solvent B consisted of 2mM NH4format+0.1% formic acid in 
90% Acetonitril. The column temperature was set at 40°C, and the flow rate was 
200µl/min. The effluent from the U-HPLC was passed directly into the electrospray 
ion source. Positive  electrospray ionization was achieved using a nitrogen sheath 
gas with ionization voltage at 3500 Volt. The capillary temperature was set at 290°C. 
Detection of metformin and the internal standard was based on isolation of the 
protonated molecular ion, [M + H]+ and subsequent MS/MS fragmentations and a 
Figure 1   Consort 2012 flow diagram of the study. 
Assessed for eligibility (n=33)  
Excluded  (n=5)  
Not meeting inclusion criteria (n=5)  
Analysed  (n=16) 
Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Allocated to metformin (n=10) 
Received allocated intervention (n=10)
Did not receive allocated intervention (n=0)
Lost to follow-up (n=0) 
Allocated to no pretreatment (n=18) 
Received allocated intervention (n=17)
Did not receive allocated intervention  
(no show) (n=1)
Analysed (n=10) 
Excluded from analysis (n=0)
Allocation  
Analysis 
Follow-Up 
Randomized (n=28) 
Enrollment  
Cross-over to metformin (n=17) 
Received allocated intervention (n=16)
Did not receive allocated intervention (patient 
withdrew before starting metformin (n=1)
Cross-over to no pretreatment (n=10) 
Received allocated intervention (n=10)
Did not receive allocated intervention (n=0)
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selected reaction monitoring (SRM) were carried out. The following SRM transitions 
were used: for metformin m/z 130,1(parent ion) to m/z 60,1 and 71,1 (both product 
ions) and for d6-metformin m/z 136,1 (parent ion) to m/z 77,1 (product ion).
Plasma caffeine concentrations were determined by use of reversed phase HPLC 
with UV detection set at 273 nm, as previously described.17
Flow mediated dilation (FMD). Endothelium-dependent vasodilation was assessed 
using FMD according to recent guidelines.18 Participants rested in the supine position 
in a temperature-controlled room (22°C) for at least 15 minutes to allow baseline 
assessment of heart rate and blood flow. The subjects were tested at the same time 
of day to prevent diurnal variation in FMD responses. Mean arterial pressure was 
determined using a manual sphygmomanometer placed around the left arm. 
To examine brachial artery FMD, the right arm was extended and positioned at an 
angle of ~80° abduction from the torso. A rapid inflation and deflation pneumatic cuff 
(D.E. Hokanson, Bellevue, WA) was placed distal to the olecranon process to provide 
an ischemic stimulus distal from the brachial artery. A 10-MHz (T3000, Terason, 
Aloka, UK) multi-frequency linear array probe attached to a high-resolution ultrasound 
machine was used to perform imaging. The brachial artery was imaged in the distal 
third of the upper arm. Ultrasound parameters were set to optimize longitudinal 
B-mode images of the lumen/arterial wall interface. A continuous Doppler velocity 
assessment was obtained simultaneously, and data were collected using the lowest 
possible insonation angle (always <60°), which did not vary during each study. 18 
After a resting period of at least 15 minutes, 1 minute of baseline recording of the 
arterial diameter and velocity was performed. Subsequently, the occlusion cuff was 
inflated to 220 mmHg for 5 minutes. The arterial diameter and velocity recordings 
were restarted at least 30 seconds before cuff deflation and continued for at least 3 
minutes after deflation. Peak arterial diameter and flow, and the time to reach this 
peak after cuff deflation, were recorded. Subsequently, the rapid inflation/deflation 
pneumatic cuff was positioned proximally around the upper arm to provide an 
occlusion for 20 minutes, so that the brachial artery was within the ischemic zone and 
was exposed to IR. The cuff was inflated for 20 minutes to 220 mmHg, which was 
followed by 20 minutes of reperfusion. Finally, the FMD measurement was repeated 
20 minutes after reperfusion.  All measurements were performed by the same, 
well-experienced sonographer who was blinded for the treatment allocation.
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Brachial artery diameter and blood flow analysis
Analysis of the brachial artery diameter was performed by an investigator who was 
blinded for the experimental treatment, using custom-designed edge-detection and 
wall-tracking software, which is independent of investigator bias.19 Baseline data 
were calculated across the 1 minute preceding cuff inflation. Following cuff deflation, 
peak diameter was automatically detected according to an algorithm as described in 
detail elsewhere.20 Within-subject reproducibility of the FMD using this semi-automated 
software is 6.7-10.5% (coefficient of variation).21 Post-deflation shear rate data, 
derived from velocity and diameter measures, was used to calculate the area under 
the shear rate curve (SRAUC). 
Statistical analysis
All data were analyzed using the Statistical Package for the Social Sciences (SPSS, 
version 16). Data are presented as mean±SD unless stated otherwise. Baseline 
parameters between testing days were compared by paired t-tests. 
In a previous study from our laboratory, IR injury reduced FMD with 2.6% with a SD of 
3.7%. Assuming a correlation coefficient of 0.7 in our study, given the cross-over 
design, the expected SD of the effect of IR on FMD in our study therefore equals 2.85. 
With n = 26 subjects, we will be able to detect a difference of 1.65% with a power of 
80% and a type I error probability of 5%, which is a relevant difference. 
In order to evaluate the impact of IR on endothelial function (measured as FMD), and 
whether metformin can (partially) prevent endothelial IR, we employed a linear mixed 
model analysis and a two-way repeated measures ANOVA. Furthermore, according 
to a recent study by Atkinson et al., inadequate scaling for FMD would be present 
if the upper confidence limit of the regression slope of the relationship between 
 logarithmically transformed base diameter and peak diameter is less than one.22 
In such an event, FMD% is not an appropriate measure to estimate endothelial 
function. We checked our data for this phenomenon, and subsequently performed 
the allometric modelling solution proposed by Atkinson et al.22 Subsequently, the 
FMD-values were re-analysed with a linear mixed model analysis with random factor 
subject and fixed factors IR (pre versus post), intervention (metformin versus no 
treatment), but also whether the type of intervention was associated with the different 
impact of IR on the change in FMD (i.e. interaction IR*intervention). We used a 
 Kolmogorov-Smirnov test to demonstrate a normal distribution of our outcome 
measures (FMD% and allometrically scaled FMD; P>0.1). The level of statistical 
significance was set at 0.05. 
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Results
Baseline characteristics are presented in Table 1. All values were within the normal 
range.
The metformin plasma concentration immediately before the experiment averaged 
1357±588 ng/ml and were all within the therapeutic range (494 – 3237 ng/ml). Median 
plasma caffeine concentration was 0.12 (range 0-2.11 ) mg/dl, with 7 subjects >1 mg/dl. 
An overview of the FMD measurements is presented in table 2. There were no serious 
adverse events during the trial. At baseline, we found no differences in brachial artery 
characteristics (i.e. baseline diameter, time-to-peak diameter, and shear rate area-
under-the-curve) between both testing days (Table 2). Baseline FMD% did not differ 
between metformin pretreatment and no pretreatment (6.9±3.6% and 6.1±3.5%, 
respectively, p=0.27).
The IR protocol induced a significant increase in baseline brachial artery diameter 
and a decrease in shear rate stimulus that was not affected by metformin treatment 
(Table 2). Both in absence as well as in presence of metformin, brachial artery FMD% 
was significantly lower after forearm IR (4.4±3.3% and 4.3±2.7% respectively, p<0.01 
in both conditions). A two-way repeated measures ANOVA revealed that metformin 
treatment did not affect the decrease in FMD by IR (Figure 2; p=0.52). Subsequent 
linear mixed model analysis, in which we included baseline diameter and SRAUC as 
covariates to correct for the changes in these parameters after IR, confirmed our 
Table 1   Baseline characteristics.
Variable Value 
Age (yrs) 41.3±6.4
Body weight (kg) 74±13
Heigth (cm) 174±8
BMI (kg/m2) 24.2±2.9
Systolic blood pressure (mmHg) 120±9
Diastolic blood pressure (mmHg) 75±6
Creatinine (µmol/L) 73±13
MDRD-GFR (mL/min/1.73m2) 85±7
Glucose (mmol/L) 4.5±0.3
Cholesterol (mmol/L) 4.7±0.8
BMI; body mass index, MDRD; modification of diet in renal disease, GFR; glomerular filtration rate
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primary finding, in that the decrease in FMD% after IR was not altered by 3-days of 
metformin intake. A limited number of subjects (n=7) had a caffeine concentration >1 
µg/ml. Exclusion of these subjects did not change our conclusion (data not shown).
Table 2   Brachial artery characteristics before and after ischemia-reperfusion (IR)  
when preceded by metformin pretreatment or no pretreatment (n=26). 
Data is presented as mean±SD.
No pretreatment Metformin P-values
Baseline IR Baseline IR IR Metformin IR*Metformin
FMD (%) 6.1±3.5 4.3±2.7 6.9±3.6 4.4±3.3 <0.001 0.52 0.23
FMD (mm) 0.19±0.09 0.15±0.09 0.22±0.08 0.15±0.11 <0.001 0.60 0.09
Diameter (mm) 3.5±0.9 3.8±0.9 3.5±0.8 3.7±0.9 <0.001 0.52 0.15
Time-to-peak 
diameter (s)
49±16 54±25 54±17 48±23 0.94 0.92 0.17
SRAUC (s, 103) 30.2±11.3 21.8±11.7 28.4±11.2 21.1±9.5 <0.001 0.51 0.86
FMD: flow mediated dilation; FMD (%) percent change to baseline; FMD (mm) absolute change to baseline; 
IR: ischemia-reperfusion; SRAUC : shear rate area under the curve.
Figure 2   Brachial artery flow mediated dilation (presented as percentage change 
from baseline ±SE) before (black) and after (white) 20-minutes for 
forearm ischemia and 20-minutes reperfusion  preceded by pretreatment 
with metformin or no pretreatment.
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Discussion
Our current study is the first to investigate whether metformin limits IR-injury in humans 
in vivo. Using a well-validated model of forearm endothelial IR-injury in healthy middle- 
aged subjects, we demonstrated that a three day treatment with metformin does not 
protect against IR-induced endothelial dysfunction.
Our hypothesis that metformin ameliorates IR-injury is based on previous epidemiological 
studies and clinical trials in patient with diabetes and on preclinical animal studies. First, 
the United Kingdom Prospective Diabetes Study (UKPDS) reported that patients with 
type 2 diabetes mellitus who were treated with metformin had a significant lower 
cardiovascular mortality than patients treated with alternative glucose- lowering drugs, 
despite similar glycemic control.2 Secondly, recent experimental studies in mice and 
rats showed that acute administration of metformin potently reduced myocardial infarct 
size. In diabetic and nondiabetic mice, administration of a single dose of metformin 
either before ischemia or at the moment of coronary reperfusion decreased final infarct 
size.8-11 This cardioprotective effect appeared to be mediated by activation of AMPK 
and endothelial Nitric Oxide Synthase (NOS).9 In addition, Yellon’s group reported that 
in diabetic and nondiabetic rat hearts, administration of metformin reduced infarct 
size.8, 10, 23 In these studies, the cardioprotective effect was dependent on adenosine 
receptor stimulation and activation of important signalling molecules of the Reperfusion 
Injury Salvage Kinase (RISK) pathway. Finally, not only acute single-dose administration 
of metformin confers  cardioprotection, but also chronic administration of metformin 
limits infarct size23 and beneficially affects postinfarction myocardial remodelling.11, 24 
Based on these studies, we have recently proposed that metformin treatment is an 
attractive strategy to limit IR injury in patients suffering a myocardial infarction or patients 
undergoing cardiac surgery.7, 25
To test our hypothesis, we used a well-validated model of IR-induced endothelial 
dysfunction in the forearm. Endothelial IR-injury is relevant for two reasons. First, 
myocardial ischemia and reperfusion not only inflicts direct injury to cardiomyocytes, 
but the endothelial cells are also highly susceptible to IR-injury.12 Indeed, structural 
endothelial injury occurs during ischemia and reperfusion, which induces cell swelling 
and impairment of endothelial-dependent relaxation, which contributes to the 
so-called ‘no-reflow’ phenomenon and  impedes effective coronary reperfusion.26, 27 
Secondly, endothelial dysfunction is an early sign of cardiovascular disease and is 
associated with future cardiovascular events.28-31 Importantly, endothelial dysfunction 
is associated with a worse outcome in several clinical settings.32, 33, 34, 35 Thus, IR 
injury to coronary endothelium could contribute to the increased risk of recurrent 
atherothrombosis as observed in patients who present with an acute coronary event.
63
METFORMIN AND ENDOTHELIAL ISCHEMIA-REPERFUSION INJURY
4
Several previous studies have reported that twenty minutes of forearm ischemia 
impairs subsequent flow mediated dilation (FMD) of the brachial artery.13, 14 Indeed, 
this finding was confirmed in our current study, in which post-IR FMD was 36% lower 
than baseline FMD. This observation of a lower FMD, even after correction for the 
potential influence of changes in diameter and the eliciting shear rate stimulus, is in 
agreement with the concept that IR causes endothelial dysfunction. Subsequent 
studies demonstrated that this IR-induced endothelial dysfunction can be prevented 
by ischemic preconditioning, postconditioning, and remote conditioning.13, 14, 36, 37 
Also, statins significantly reduced endothelial IR-injury in this model.38 
In contrast to the preclinical studies, we did not observe any protective effect of 
metformin against endothelial IR-injury in our study. There are several potential 
explanations for this discrepancy. First, murine models of IR-injury might not reflect 
the human situation. In this regard, many interventions that are promising in animal 
models do not appear to be effective in clinical trials.39 In the field of ischemic stroke, 
only two of approximately 500 neuroprotective strategies that were beneficial in 
animal models, improved outcome in patients.39 This translational failure can be due 
to differences between animal and human (patho)physiology, due to methodological 
flaws in animal studies, or due to shortcomings of the clinical trial. In the case of met-
formin-induced cardioprotection, the evidence is rather strong, with cardioprotection 
shown in mice and rats, with or without diabetes, and with acute as well as chronic 
administration. The design of our current study is also robust and uses a well-validated 
model of endothelial IR-injury. Although  the study was not blinded, we used a PROBE 
design, which is a well-accepted design for this kind of studies.  
A second explanation could relate to the duration and dose of metformin pretreatment. 
Interestingly, in several patient groups, including patients with type 1 diabetes and 
patients with polycystic ovarian syndrome, long-term administration of metformin 
improves endothelial function, measured with FMD.40, 41 In our study, however, a 
three day treatment with metformin did not improve baseline FMD. Animal studies on 
the cardioprotective effect of metformin, however, have demonstrated that either an 
acute single dose administration of metformin9, 10 as well as chronic administration of 
metformin confer cardioprotection.23 The dose of metformin used in these preclinical 
studies was comparable to or even considerably lower than the dose used to treat 
patients with diabetes in clinical practice.9, 10 Based on these studies, we used a 
dose of 3dd500 mg, which is a dose often used to treat patients in clinical practice. 
Subjects were pretreated for three days to ensure an effective steady-state plasma 
concentration. The last dose of metformin was taken 3 hours prior to the ischemic 
episode, which allows for a maximum plasma concentration of metformin at the 
moment of forearm ischemia. Indeed, the circulating plasma concentration of 
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metformin immediately before the experiment was comparable to the previous 
animal studies.
A third potential explanation for the discrepancy between our results and results from 
previous animal studies  is that the mechanism of endothelial IR-injury might differ 
from IR-injury in cardiomyocytes. However, most strategies that limit myocardial 
infarct size in animal models also conferred protection against endothelial IR-injury, 
although some studies could not observe protection.13, 34, 36, 37 
Fourthly, the findings in the brachial artery may not be representative for the coronary 
circulation. However, previous studies have reported a good correlation between 
endothelial responses to flow and vasoactive substances between the brachial and 
coronary arteries.42, 43 
In conclusion, we can state that short-term metformin pretreatment does not protect 
against endothelial dysfunction induced by ischemia-reperfusion in healthy middle 
aged subject. However, whether these results predict the effect of metformin on myo- 
cardial IR-injury and can be extrapolated to subjects with a history of cardiovascular 
disease or diabetes mellitus is a matter of debate. It is important to realize that many 
comorbidities, including diabetes mellitus, and comedications can affect the tolerance 
against ischemia-reperfusion and the efficacy of cardioprotective strategies. Therefore, 
with interest we await further studies on the effect of metformin on myocardial injury 
in patients with a myocardial infarction and patients undergoing coronary artery 
bypass grafting (NCT01217307 and NCT01438723 respectively). 
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CHAPTER 5
Abstract
Background: During coronary artery bypass grafting (CABG), ischemia and reperfusion 
damages myocardial tissue, and increased postoperative plasma troponin is associated 
with a worse outcome. We investigated whether metformin pretreatment limits cardiac 
injury, assessed by troponin concentrations, during CABG surgery in patients without 
diabetes.
Methods: we did a placebo-controlled, double blind, single-centre study in an academic 
hospital in Nijmegen (Netherlands) in adult patients without diabetes undergoing an 
elective on-pump CABG procedure. We randomly assigned patients (1:1) in blocks of 
ten via a computer-generated randomisation sequence to either metformin hydro -
chloride (500 mg three times a day) or placebo (three times a day) for 3 days before 
surgery. The last dose was given roughly 3h before surgery. The primary endpoint 
was the plasma concentration of high-sensitive troponin I at 6, 12, and 24h post-
reperfusion after surgery, analysed in the per-protocol population with a mixed-model 
analysis using all these time points. Secondary endpoints included the occurrence 
of clinically relevant arrhythmias within 24 hours after reperfusion, the need for 
inotropic support, time to detubation, duration of stay in the intensive-care unit, and 
postoperative use of insulin. A per-protocol analysis was performed for all endpoints. 
Findings: we randomly assigned 111 patients to treatment (57 to metformin and 54 
to placebo). Five patients dropped out from the metformin group, and six from the 
placebo group. 52 patients in the metformin group and 48 patients in the placebo 
group were included in the per-protocol analysis. Geometric mean high-sensitive 
troponin I increased from 0 µg/L to 3.67 (95% CI 3.06-4.41) with metformin and to 3.32 
(2.75-4.01) µg/L with placebo at 6 hours after reperfusion; 2.84 (2.37-3.41) and 2.45 
(2.02-2.96), respectively, at 12 hours; and to 1.77 µg/L (1.47-2.12) and 1.60 µg/L 
(1.32-1.94) at 24 hours. The concentration did not differ significantly between the 
groups (difference 12.3% for all time points [95% CI – 12.4 to 44.1] p=0.35). 
Occurrence of arrhythmias did not differ between groups (three [5.8%] of 52 patients 
who received metformin vs three [6.3%] of 48 patients who received placebo; 
p=1.00). There was no difference between groups in the need for inotropic support, 
time to detubation, duration of stay in the intensive-care unit, or postoperative use of 
insulin. No patients died within 30 days after surgery. Occurrence of gastrointestinal 
discomfort (mostly diarrhea) was significantly higher with metformin than with 
placebo (11 [21.2%] of 52 vs two [4.2%] of 48 patients; p=0.01). 
Interpretation: Short-term metformin pretreatment, although safe, does not seem to 
be an effective strategy to reduce periprocedural myocardial injury in patients without 
diabetes undergoing CAGB surgery. 
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Introduction
Coronary artery disease is the leading cause of morbidity and mortality worldwide. 
For most patients with multiple vessel coronary artery disease, coronary artery 
bypass graft (CABG) surgery is the preferred strategy for revascularization.1 However, 
temporary myocardial ischemia during CABG surgery and the subsequent 
reperfusion that occurs causes damage to the cardiomyocytes, a marker of which is 
increased postoperative plasma concentration of troponin. Increased troponin 
release within the first 24 hours after surgery is independently associated with 
increased intermediate-term and long-term risk of mortality.2,3 Therefore, the 
prognosis after CABG might be improved by strategies that reduce myocardial isch-
emia-reperfusion injury.4 
Many preclinical studies report that giving the antihyperglycemic drug metformin 
either before ischemia occurs or at the moment of reperfusion potently reduces 
myocardial ischemia-reperfusion injury in the setting of coronary occlusion, both 
after one dose5 or when given as a chronic regimen of several doses.6  Several 
intracellular signaling cascades contribute to the cardioprotective effect of metformin 
in animal studies, such as activation of AMP-activated protein kinase (AMPK) and the 
prosurvival kinase Akt, and an increased intracellular formation of  adenosine.7-9 
Metformin is the most widely used drug in the treatment of type 2 diabetes and is 
associated with improved cardiovascular prognosis in patients with diabetes compared 
with other glucose-lowering agents.10,11 Most guidelines advise to stop metformin 
before cardiac surgery because of the presumed risk of lactate acidosis.12 The clinical 
benefit of this policy, however, is still without evidence. A retrospective analysis in 
patients with diabetes who underwent CABG even reports that the use of metformin 
on the day before surgery is associated with less overall morbidity than the use of 
non-metformin antihyperglycemic agents, although cardiac morbidity and mortality 
did not differ between treatments.13 
In this study (MetCAB), we investigated whether short-term pretreatment with metformin 
minimizes cardiac injury in patients without diabetes undergoing elective CABG 
surgery. In an accompanying exploratory experiments, we assessed whether 
treatment with metformin activates key signaling proteins that are involved in cardio-
protection. 
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Methods
Study design and participants
We did a randomised, placebo-controlled, double-blind, single-centre trial at the 
Radboud University Medical Center (Nijmegen, Netherlands). The study protocol 
was in accordance with the Declaration of Helsinki and was approved by one of the 
24 accredited Dutch Medical Research Ethics Committees (CMO Region Arnhem- 
Nijmegen). This protocol is available online.
We recruited consecutive patients aged at least 18 years accepted for an elective 
on-pump CABG with or without concomitant valve surgery. After obtaining written 
informed consent, we screened patients through history taking, physical examination, 
and laboratory analyses. Exclusion criteria were off-pump surgery, diabetes, renal 
insufficiency (modification of diet in renal disease glomerular filtration rate <60 ml/
min), raised concentrations of liver enzymes (alanine aminotransferase more than 
three times the upper reference limit), or a documented myocardial infarction within 2 
weeks of screening. Additionally, patients taking dipyridamole or xanthine derivatives 
were excluded because these agents interfere with the endogenous adenosine 
signaling. 
Randomisation and masking
Patients were randomly assigned (1:1) in blocks of ten to pretreatment with either 
metformin hydrochloride or placebo by an independent computer-generated 
randomization sequence (Department of Pharmacy, Radboud University Medical 
Center, Nijmegen, Netherlands). Patients were enrolled by one of the investigators 
(SEM). Patients, investigators, trials staff, and the statistician were all masked to 
treatment allocation, and masking was achieved by over-encapsulation of metformin 
tablets under Good Manufacturing Practice conditions at the Department of 
Pharmacy, and the manufacture of matching placebo capsules.
Procedures
We assigned patients to either metformin hydrochloride (500 mg three times per day) 
or placebo (three times per day) for 3 days before surgery. In case of postponed 
surgery, continuation of study drugs was allowed for a maximum of 7 days. Because 
caffeine is an adenosine receptor antagonist, all patients had to abstain from caffeine 
consumption for at least 24 hours before surgery. All surgical details are reported in 
the Appendix.
We measured plasma caffeine and metformin concentrations immediately before 
surgery. High-sensitive troponin I was measured with the Dimension Vista® system of 
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Siemens (Newark, USA). The 99th percentile of the reference range is 0.045 µg/l, and 
the 10% coefficient of variation is less than 0.04 µg/l. Additionally, we did AMPD1 
genotyping, because variation in this gene is associated with resistance against isch-
emia-reperfusion injury14 (analytic details in appendix). We estimated insulin 
resistance immediately before surgery using the homoeostasis model assessment 
(HOMA-IR) method, with a HOMA-IR threshold value of at least 2.0 suggesting insulin 
resistance. 15
We did two exploratory series of laboratory analyses on the right atrial appendage, 
which was harvested before the introduction of the extracorporal circulation in a 
subgroup of patients (appendix). First, we measured recovery of contractile function 
after simulated ischemia and reperfusion in the atrial trabeculae, a well establisched 
surrogate marker of ischemia-reperfusion injury.16 Additionaly, we measured phos-
phorylation of AMP-activated protein kinase and Akt and translocation of hexokinase 
II in atrial trabeculae with western blotting. 
Outcomes
Postoperative high-sensitive plasma troponin I concentration was the primary 
endpoint, measured before surgery and at 6, 12, and 24 h after release of the aortic 
clamp (after surgery). Values at all time points were used to calculate the primary 
endpoint. 
Secondary endpoints were the occurrence of clinically relevant arrhythmias during 
the first 24 h after reperfusion (retrieved from medical charts), the need for inotropic 
support, time to detubation, duration of stay in the intensive-care unit, use of exogenous 
insulin, recovery of contractile function of isolated atrial trabeculae after ex vivo- 
simulated ischemia-reperfusion, and expression and activation of AMP-activated 
protein kinase, Akt, and hexokinase II in isolated atrial trabeculae. We did not measure 
renal ischemia-reperfusion injury because of logistic reasons. 
For safety monitoring, plasma creatinine (to assess renal function), pH, and lactate 
concentrations were measured at 6, 12, and 24 h after surgery. An independent data 
safety monitoring board did a prespecified safety analysis after 50% of patients were 
enrolled. This analysis did not reveal any concerns with respect to safety.
Statistical analysis
We based the size calculation on the plasma troponin I concentrations at 12 hours 
after CABG in 880 patients from our own clinic in the period 2006-2008 (6.76 ug/L 
[SD 12.96). The mean plasma troponin I concentration after 10log transformation was 
0.53 [SD 0.41), which we used in our sample size calculation. We calculated a total 
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sample size of 80 patients would provide a power of 90% with an α of 0.05 to detect a 
50% reduction in postoperative troponin I release (i.e. a reduction from 6.76 µg/L to 
3.38  µg/L, which equals a reduction in the 10log transformed troponin I concentration 
from 0.53 µg/L to 0.23 µg/L). A reduction of 50% was expected on the basis of 
preclinical studies on the infarct size-limiting effect of metformin7,9 and on the effect 
of remote ischemic preconditioning on release of troponin I after CABG surgery.14 
To enable analysis of the primary endpoint in patients with the CC genotype of 
AMPD1, which is present in 80% of the white population,17 we added 20% to the 
calculated 80 patients, and therefore aimed to included 100 assessable patients in 
our study.
Plasma high-sensitive troponin I was not normally distributed, and results are 
therefore presented as geometric means with 95% CI. We used a log transformation 
to correct for these skewed data and a mixed-model analysis to assess differences 
in postoperative plasma high-sensitive troponin I to accommodate the repeated 
measurements by incorporating a participant-dependent intercept; the independent 
variables in this model were time after reperfusion and treatment group. We assessed 
possible differences between the two treatment groups over time by incorporating a 
time-by-treatment interaction. We did a covariate analysis to study the effect of 
propofol anesthesia on the effect of metformin. A two sided P- value of less than 0.05 
was regarded as significant. Continuous secondary endpoints that were normally 
distributed are presented as mean (SD) and analyzed using an unpaired student’s 
t-test. Discrete secondary endpoints were analyzed using a Chi-Square analysis or a 
Fisher’s exact test in case of few events. Continuous data that were not normally 
distributed are presented as medians (IQR) and were analyzed using a Mann-Whitney 
U test. We calculated correlations between the plasma metformin concentration and 
the duration of ischemia and the primary endpoint with a Spearman rank order 
correlation.  Because our study is a proof-of-concept study, we did a per-protocol 
analysis (we defined the per-protocol population as all patients who completed the 
protocol; i.e, all patients minus the drop-outs). Additionally, we did an intention-to-treat 
analysis of the primary endpoint.
For the laboratory experiments on the effect of simulated ischemia-reperfusion on 
contraction of atrial trabeculae, all data are presented as mean (SD). For each 
contraction of the trabeculae, we calculated developed force (difference between 
maximal tension during contraction and the minimum tension during relaxation). This 
variable was averaged for the last 5 minutes during equilibration and each subsequent 
5 minute period. Data are expressed as percentage of baseline developed force. A 
paired student’s t test was used to compare in-vitro treatment of trabeculae with 
control versus metformin during the last 10 minutes of final reperfusion. To assess the 
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effect of in-vivo treatment with metformin, an unpaired student’s t test was used to 
compare vehicle-treated trabeculae of both groups.
All Western blot data was normalized to placebo (dividing all individual values by the 
mean of the placebo group) and presented as mean (SE). We used an unpaired 
student’s t test was used to compare the metformin and placebo groups. SAS version 
9.2 was used for all statistical analyses. This study is registered with ClinicalTrials.gov, 
number NCT01438723.
Results
Between Nov 8, 2011, and Nov 22, 2013, 139 consecutive patients provided informed 
consent. 28 patients were ineligible (appendix), therefore we randomly assigned 111 
patients to treatment (57 to metformin and 54 to placebo). Five patients dropped out 
from the metformin group, and six from the placebo group. 52 patients in the 
metformin group and 48 patients in the placebo group were included in the 
per-protocol analysis (figure1). Baseline characteristics of the per-protocol population 
did not differ between the two groups (table 1). Surgical details are described in the 
appendix. 
Immediately before surgery, mean plasma metformin concentrations were 8.42 
µmol/L (SD 5.98) for the metformin pretreated group (range 1.16-24.91 µmol/L) and 
0.0 µmol/L (0.0) for the placebo group. Caffeine plasma concentrations were less 
than 5.2 µmol/L in 91 patients; nine had a concentration of more than 5.2 µmol/L 
(range 5.2-24.2 µmol/L). Analysis of the primary endpoint did not change after 
exclusion of these patients (data not shown). On the day of surgery plasma fasting 
glucose concentrations did not differ between groups (metformin group mean 5.3 
mmol/L [SD 0.9],  placebo group 5.2 [SD 2.2], p=0.35), nor did pre-operative plasma 
fasting insulin concentration  (metformin group 106.26 pmol/L [75.7], placebo 114.6 
pmol/L [86.12], p=0.59). HOMA-IR was also similar in both groups (metformin 4.8 
[SD 8.6], placebo 4.5 [SD 4.6], p=0.24) and showed insulin resistance in our study 
population. 
None of the patients died within the first 30 days after surgery. Baseline concentrations 
of  hs-troponin I were below the detection limit of  0.02 µg/L in the 79 patients. In 21 
patients baseline hs-troponin levels were more than 0.02 µg/L (11 [21.2%] of 52 
patients in the metformin group and 10 [20.8%] of 48 patients in the placebo group 
(P=0.97, Pearson’s chi square test), with a range of 0.21-1.88 µg/L in the metformin 
group and 0.03-0.49 µg/L in the placebo group (P=0.51, Mann Whitney U test). 
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Geometric mean high-sensitive troponin I increased from 0 µg/L to 3.67 µg/L (95% CI 
3.06-4.41) with metformin and to 3.32 µg/L (2.75-4.01) with placebo at 6 h after 
reperfusion; to 2.84 µg/L (2.37-3.41) with metformin and 2.45 µg/L (2.02-2.96) with 
placebo at 12 h; and to 1.77 µg/L(1.47-2.12) with metformin and 1.60 µg/L (1.32-1.94) 
with placebo at 24 h. We noted no significant interaction between time and treatment 
group (p = 0.73), so the interaction was dropped from the model. The concentrations 
of high-sensitive troponin I did not differ between the groups at 6, 12, and 24 h after 
reperfusion (difference 12.3% [95% CI: -12.4% to 44.1], p= 0.35; figure 2). An inten-
tion-to-treat analysis showed similar results: difference 15.2% (-11.1 to 41.5, p=0.26). 
In the metformin group, metformin concentrations did not correlate with high-sensitive 
troponin I concentrations (r= -0.14, p=0.33). With regard to the use of propofol 
Figure 1   Trial profile. 
CABG= coronary artery bypass grafting. GI= gastrointestinal. LAD= left anterior descending 
artery. PCI= percutaneous coronary intervention.
N=139 informed consent
N=111 randomised
and started study medication
 
Exclusion N=28
- 14 not meeting inclusion criteria
- 8 logistic reasons
- 5 withdrawal of informed consent
- 1 enrollement in a different trial
 
N=57 Metformin N=54 Placebo
N=52 completed study N=48 completed study
Drop outs N=5
- 2 off pump procedure
- 1 PCI performed instead of CABG
- 1 adverse event (GI-discomfort)
- 1 < 8 pills taken
Drop outs N=6
- 1 off pump procedure
- 1 PCI performed instead of CABG
- 1 logistic reason
- 1 adverse event (GI-discomfort)
- 1 < 8 pills taken
- 1 besides CABG also endarterectomy LAD
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Table 1   Baseline characteristics.
Metformin
(N=52)
Placebo
(N=48)
Age 65.2 (8.8) 64.5 (9.8)
Male 43 (83) 38 (79)
Body mass index, kg/m2 27.5 (4.1) 27.7 (3.5)
Blood pressure, mmHg
Systolic 147 (23) 147 (22)
Diastolic 82 (11) 83 (11)
Heart rate, beats/min 65 (9) 64 (11)
Heart rhythm at screening 49 (94.2) 47 (97.9)
Sinus rhythm 3 (5.8) 1 (2.1)
Atrial fibrillation 10 (19) 11 (22)
Concomitant valve surgery
Aortic valve 9 (17) 9 (19)
Mitral valve 1 (2) 1 (2)
Combination aortic/mitral 0 (0) 1 (2)
Cardiovascular related history
Angina pectoris CSS class
I 13 (25%) 10 (21%)
II 18 (35%) 17 (35%)
III 16 (31%) 16 (33%)
IV 5 (10%) 5 (10%)
Previous myocardial infarction 20 (38.5%) 12 (25%)
Previous CABG 3 (6%) 0 (0%)
Previous PCI 13 (25%) 13 (27%)
Left ventricular ejection fraction at screening
> 55% 21 (40%) 17 (35%)
35-55 9 (17%) 11 (23%)
< 35% 1 (2%) 2 (4%)
Unknown 21 (40%) 18 (38%)
Cardiovascular risk factors*
Hypertension 30 (58%) 30 (63%)
Smoking 15 (29%) 14 (29%)
Dyslipidemia 19 (37%) 15 (31%)
Positive family history (first degree, < 60 y) 25 (48%) 28 (58%)
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treatment (15 [29%] of 52 patients in the metformin group vs 19 [40%] of 48 in the 
control group), propofol treatment did not modulate the effect of metformin on 
high-sensitive troponin I concentration: in a covariate analysis, propofol had no effect 
(P=0.47), and we did not find a significant interaction with the treatment (P=0.98).
The AMPD1 34C>T CT or TT genotype was present in 18 (35%) of 52 patients in the 
metformin group and in 15 (31%) of 48 patients in the placebo group. No significant 
interaction between the genotype and the effect of metformin on high-sensitive 
troponin I release was noted (data  not shown).
Table 1   Continued.
Metformin
(N=52)
Placebo
(N=48)
Co-medication
Aspirin 45 (87%) 40 (83%)
β-blocker 43 (83%) 40 (83%)
Statin 40 (77%) 40 (83%)
ACE- inhibitor 21 (40%) 17 (35%)
AT2 receptor antagonist 8 (15%) 10 (21%)
Calcium channel blocker 10 (19%) 9 (19%)
Nitrates 34 (65%) 29 (60%)
Diuretic (loop and thiazide) 15 (29%) 15 (31%)
Clopidogrel 14 (27%) 6 (13%)
Laboratory values at screening
Glucose, mmol/L 6.2 (1.7) 6.4 (1.6)
Total cholesterol, mmol/L 4.7 (0.99) 4.7 (1.3)
Creatinine, mmol/L 81.9 (11.9) 81.9 (12.0)
GFR (MDRD) ml/min/1.73 m2 77.3 (9.3) 77.1 (9.7)
AMPD genotype
CC 34 (65%) 33 (69%)
CT 18 (35%) 13 (27%)
TT 0 (0%) 2 (4%)
Number of investigational pills taken, median (IQR) 9 (9-10) 9 (9-10)
Data are number (%), mean (SD), or median (IQR). CSS= Canadian Cardiovascular Association. CABG= 
coronary artery bypass grafting. PCI= percutaneous coronary intervention. ACE= angiotensin-converting 
enzyme. GFR= glomerular filtration rate. MDRD= modification of diet in renal disease formula. * according 
to the treating physician as noted in the medical files.
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The duration of ischemia (mean 68 minutes [SD 23; range 24-126]), was correlated 
with high-sensitive troponin I concentrations (r=0.41, p<0.0001). 
The occurrence of arrhythmia’s within 24 hours after surgery, including atrial fibrillation 
or atrial tachycardia did not differ between groups (three [5.8%] of 52 patients who 
received metformin vs  three [6.3%} of 48 patients who received placebo; p=1.00). 
Metformin did not affect time to detubation, length of stay at in an intensive care unit, 
or need for inotropic support. There was no difference between groups in the number 
of patients who received insulin treatment after surgery (median 18.9 units [IQR 
7.2-31.8] in 85% of patients in the metformin group vs median 19.7 units [11.1-29.0]) in 
85% of patients in the control group; table 2).
No differences were noted in post-operative changes in kidney function or pH levels 
between groups. Median creatinine concentrations at 6, 12, and 24 h after surgery 
were 86 µmol/L (IQR 74-97), 87 µmol/L (74-96), and 79 µmol/L (69-88), respectively, 
in the metformin group, versus 83 µmol/L (74-99), 79 µmol/L (68-94), and 73 µmol/L 
(61-91), respectively, in the placebo group (p=0.22). In the metformin group, median 
Figure 2   Post-operative hs-troponine I concentration in plasma. 
(geometric mean with 95% confidence interval). Solid line: metformin (N=52), dashed line: 
placebo (N=48). The two curves do not differ significantly (Mixed Model analysis after log 
transformation, p= 0.35). 
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lactate concentrations at 6, 12 and 24 hours after surgery were 1.4 (IQR 1.2-2.0), 1.8 
mmol/L (1.3-2.6) and 1.8 mmol/L (1.2-2.3), respectively, versus 1.2 mmol/L (1.0-2.2) 
mmol/L, 2.0 mmol/L (1.5-2.7) and 1.9 mmol/L (1.4-2.7) in the placebo group, p=0.21). 
Bleeding complications or need for additional surgical intervention did not differ 
between the groups. Common adverse events included the occurrence of gastroin-
testinal discomfort (mostly mild and self-limiting diarrhea), which was higher in the 
metformin group than in the placebo group (11 [21.2%] of 52 vs two [4.2%] of 48 
patients; see appendix for other details about other adverse events). 
Post-ischemic recovery of contractile function was determined in atrial trabeculae of 
16 patients (ten receiving metformin, six receiving placebo). The baseline character-
istics of the patients in whom these studies were undertaken are summarized in the 
appendix. Baseline contractile force was similar for all groups. Simulated ischemia 
reduced contractile force to a similar extent in trabeculae of patients pretreated with 
metformin or placebo before surgery. Post-ischemic recovery of contractile function 
did not differ between the control trabeculae (i.e. the trabeculae treated with vehicle 
in vitro) of the patients treated before surgery with metformin or placebo (30% [SD 14] 
vs 24% [10], p=0.38; figure 3). Irrespective of treatment before surgery, additional 
metformin added ex vivo did not enhance recovery of contractile function after isch-
emia-reperfusion (figure 3). Atrial tissue of 22 patients (12 in the placebo group, ten in 
Table 2   Secondary endpoints.
Metformin
(N=52)
Placebo
(N=48)
p-value
Days on ICU, median (IQ range) 1 (1-1) 1 (1-1) 0.78
Number of patients on inotropy 40 (77%) 31 (64%) 0.08
Duration of inotropic support, hours, median 
(IQ range)
15 (7.25-20) 14 (0-21) 0.74
Time to detubation, hours, median 
(IQ range)
12 (10-17.8) 12 (11-14.8) 0.71
Clinical relevant arrhythmias < 24 hours
None 49 (94.2%) 45 (93.7%) 1.0
AF/SVT de novo 2 (3.8%) 0 (0%) 0.50
Sinus bradycardia in need for pacemaker 1 (1.9%) 0 (0%) 1.00
AV conduction disturbance 0 (0%) 0 (0%) -
VT/VF 0 (0%) 2 (4.2%) 0.23
Other 0 (0%) 1 (2.1%) 0.48
ICU= intensive care unit. AF= atrial fibrillation. SVT= supraventricular tachycardia. AV= atrioventricular. 
VT= ventricular tachycardia. VF= ventricular fibrillation.
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the metformin group) was analyzed for phosphorylated AMP-activated protein kinase, 
phosphorylated Akt, and hexokinase II content by western blot (appendix). Compared 
with control, metformin treatment increased phosphorylated AMP-activated protein 
kinase by a mean of 10% (SE 3; p=0.03), without an effect on total AMP-activated 
protein kinase. Additionally, phosphorylated Akt was increased by a mean of 28% (SE 
7; p=0.005). We noted no effect of metformin on total Akt, total hexokinase II, or mi-
tochondrial-bound hexokinase II (appendix). 
Figure 3   The course of contractile force (expressed as percentage of baseline force) 
in time. 
Data are mean (SD). Contractile force from trabeculae harvested during surgery from six patients 
randomly assigned to pretreatment with placebo (A) and ten patients randomly assigned to 
pretreatment with metformin (B); one trabecula from each patient was treated ex vivo with 
metformin and the other was treated ex vivo with control (dimethyl sulfoxide). (C) Comparision 
of trabeculae treated with vehicle ex vivo from patients pretreated with metformin versus 
placebo before surgery.
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Figure 3   Continued.
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Discussion
In this study, metformin did not limit myocardial ischemia-reperfusion injury, detected 
with plasma high-sensitive troponin I concentration, in patients without diabetes 
undergoing CABG surgery. Additionally, metformin did not affect any of the secondary 
clinical endpoints. In accordance with these clinical endpoints, metformin did not 
improve the ex vivo post-ischemic recovery of contractile function in isolated atrial 
trabeculae, a well-established surrogate endpoint for ischemia reperfusion injury.
The search for direct cardioprotective effects of metformin has been fueled by the 
findings that patients with type 2 diabetes given metformin have a better cardiovascular 
outcome than patients given other glucose-lowering agents, despite similar glycem 
ic control.10,11 Additionally, many preclinical studies report beneficial effects of metformin 
on atherosclerosis development, cardiac remodelling, and myocardial ischemia- 
reperfusion injury. In murine models of myocardial infarction, giving metformin, either 
before ischemia or at reperfusion, consistently minimizes infarct size.5 Data from human 
beings that show a cardioprotective effect of metformin are scarce. In a retrospective 
analysis18, metformin-treated patients with diabetes who had a myocardial infarction 
seemed to have lower plasma troponin T concentrations than patients given other 
antidiabetic drugs, but this study design is prone to selection bias and confounding. 
In a randomised prospective pilot study19 in patients with metabolic syndrome, 1 week 
of treatment with metformin reduced plasma high- sensitive troponin I concentrations 
after elective percutaneous coronary intervention. This study, however, had an open- 
label design and only a minimum amount of cardiac ischemia, as substantiated by 
the very low troponin I concentrations after percutaneous coronary intervention. By 
contrast, metformin did not reduce endothelial ischemia-reperfusion injury in healthy 
people measured with flow-mediated dilation after induction of forearm ischemia by 
upper-arm cuff inflation.20 Our finding that the cardioprotective effects of metformin 
in preclinical studies do not translate into a reduction in troponin I concentration after 
CABG are in line with findings from other randomised controlled trials21,22 that 
showed that metformin does not limit atherosclerosis or postinfarct remodelling in 
patients. In patients with established coronary heart disease but without diabetes, 
long-term treatment with metformin tended to increase the concentration of circulating 
high-sensitive troponin T at 6, 12, and 18 months of treatment to a mean of 1.0 pg/mL 
(based on all time points), 95% CI 0.0-1.9; P=0.05.21 These findings raise the question 
of why the beneficial effects of metformin on cardiac ischemia-reperfusion injury in 
animal models do not translate to the clinical setting. First, post-operative troponin 
concentration might not be an accurate marker of myocardial ischemia-reperfusion 
injury. However, we noted a significant association between duration of myocardial 
ischemia and troponin I concentration. Moreover, many previous studies report that 
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interventions that specifically target ischemia-reperfusion injury reduce the 
concentration of troponin I after CABG surgery.4,14 Second, the duration or dose, or 
both of metformin in clinical trials might be insufficient to activate prosurvival pathways 
in cardiac tissue. However, in our study, ex vivo experiments show that metformin 
pretreatment did activate pivotal prosurvival proteins. Additionally, a much higher 
dose of metformin did not affect ischemia-reperfusion injury in isolated atrial 
trabeculae. In murine models of myocardial infarction, substantially lower doses of 
metformin induced profound cardioprotection, although plasma concentrations were 
not reported in these studies.7 With regard to the duration, both one dose and a 
chronic 4-week regimen of metformin reduces infarct size in rodents.6,7,9 Thus, it is 
unlikely that a longer duration of metformin pretreatment would have resulted in a 
clinically relevant protection. Third, a general explanation for absence of translation is 
that animal studies are predominantly done in young and otherwise healthy animals. 
By contrast, human patients with cardiovascular disease are older, and have 
comorbidities and co-medication, which can all interfere with cardioprotection.23 
Among other factors, older age and insulin resistance, which were present in our 
patients, are associated with an impaired  cardioprotective effect of preconditioning, 
and drugs such as statins (used in most of the patients in our study) offer cardio-
protective effects themselves.23-25 Propofol anesthesia can disrupt protection by 
remote ischemic preconditioning,4 but did not modulate the effect of metformin in our 
study. Additionally, publication bias might exist in preclinical studies resulting in 
selective publication of positive studies. 
Animal studies have identified several signaling cascades that contribute to metformin- 
induced cardioprotection, including activation of myocardial AMP-activated protein 
kinase and Akt.7,8 Also, increased intracellular formation of adenosine and subsequent 
adenosine receptor stimulation contribute to the direct cardioprotective effect of 
metformin.9 Finally, mitochondrial hexokinase II translocation increases resistance 
against ischemia-reperfusion injury, and metformin can induce mitochondrial 
hexokinase II translocation.26 In ex-vivo analyses of tissue from a subset of patients, 
we noted activation of AMP-activated protein kinase and Akt in atrial tissue, but to a 
smaller extent than in murine models.7,8 By contrast, we did not find hexokinase II 
translocation. Notably, cardioprotective signaling pathways show interspecies 
differences – e.g, Akt activation has been reported to be less important in ischemic 
post-conditioning in larger mammals than in rodents.27 We conclude that the mild 
activation of AMP-activated protein kinase and Akt by metformin might not have been 
sufficient to offer significant cardioprotection. 
AMPD is a key intracellular enzyme catalyzing the conversion of AMP into inosine 
monophosphate (IMP). The common loss-of-function variant 34C>T is associated 
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with an impaired conversion of AMP into IMP, which facilitates the formation of 
adenosine, and is associated with increased resistance against ischemia-reperfu-
sion injury and better outcome in patients with cardiovascular disease.17,28 We 
postulated that in patients with the variant allele, the metformin-induced increase in 
adenosine formation would be augmented, and we did a prespecified subgroup 
analysis for the primary endpoint in relation to this variant. This analysis, however, did 
not support our hypothesis; although our study was powered to detect an effect of 
metformin in the patients with the CC genotype, it was not powered to detect a larger 
effect of metformin in patients with the CT/TT genotype versus patients with the CC 
genotype. 
Current practice is to temporarily stop giving metformin before CABG surgery 
because of the presumed increased risk of lactic acidosis. From the scientific 
literature, however, evidence does not support this assumption, especially for patients 
with normal kidney function.29 In our study, giving metformin to patients with preserved 
renal function did not result in higher lactate concentration, a higher occurrence of 
lactate acidosis, or the occurrence of any serious adverse event. 
Our study has some limitations. First, it was not powered to detect differences in 
clinical endpoints. However, the plasma troponin I concentration within the first 24 
hours after surgery is a well-established surrogate marker of ischemia-reperfusion 
injury, which is independently associated with prognosis. Second, the clinical 
secondary endpoints, such as length of stay in the intensive-care unit, might be 
affected by factors other than the clinical condition of the patient (e.g. logistic 
reasons), but this is unlikely to have affected our results because of the block-ran-
domised, double-blind design. Third, we only measured plasma troponin I and 
creatinine for 24 hours after reperfusion. For troponin I, a longer follow-up would not 
have improved the statistical power because troponin I was already low at 24 hours. 
For creatinine, however, we might have missed the occurrence of acute kidney injury, 
because most CABG-related acute kidney injury is detected only on day 2 after 
surgery.30 Fourth, the exploratory laboratory analyses were done, for practical 
reasons, on right atrial tissue, but effects might differ from the left ventricular tissue. 
Together with the results of randomized controlled trials focusing on atherosclerosis 
and  post-infarct remodeling,21,22 results from our study show that the beneficial 
effects of metformin on atherosclerosis, myocardial ischemia-reperfusion injury and 
post-infarction remodelling that were noted in preclinical studies do not translate into 
a clinical benefit, at least in patients without diabetes. Thus, the improved cardio-
vascular prognosis that has previously been reported in patients with diabetes given 
metformin is likely to be due to effects on glucose metabolism and body weight, 
rather than due to direct cardiovascular protective effects.
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Abstract
Background: Dipyridamole reduces reperfusion-injury in preclinical trials and may 
be beneficial in patients undergoing coronary angioplasty, but its effect in patients 
undergoing coronary artery bypass grafting (CABG) is unknown. We hypothesized 
that dipyridamole limits myocardial reperfusion-injury in patients undergoing CABG. 
Trial design: Double-blind trial randomizing between pretreatment with dipyridamole 
or placebo. 
Methods and Results: 94 patients undergoing elective on-pump CABG were 
recruited between February 2010 and June 2012. The primary endpoint was plasma 
high-sensitive (hs-) troponin-I at 6, 12 and 24 hours after reperfusion. Secondary 
endpoints were the occurrence of bleeding, arrhythmias, need for inotropic support 
and intensive care unit length of stay. Finally, 79 patients (33 dipyridamole) were 
included in the per-protocol analysis. Dipyridamole did not significantly affect 
post-operative hs-troponin-I (change in plasma hs-troponin I -3% (95% CI from -23% 
to 36%); p >0.1). Secondary endpoints did not differ between groups.
Conclusion: Dipyridamole prior to CABG does not significantly reduce post-operative 
hs-troponin release.
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Introduction
During coronary artery bypass grafting (CABG), myocardial ischemia and reperfusion 
(IR-) injury contributes to postoperative appearance of circulating troponin. Importantly, 
postoperative troponin levels are associated with worse outcome.1, 2 Therefore, much 
effort is put into developing novel strategies to limit peri-procedural myocardial IR- 
injury, such as ischemic preconditioning.3, 4 Preclinical studies have shown that the 
endogenous nucleoside adenosine is a crucial mediator of ischemic preconditioning.5, 6 
Development of pharmacological strategies to mimic or to enhance cardioprotection 
by ischemic preconditioning might provide us with tools to induce a state of organ 
protection against IR-injury in patients at risk for acute ischemic events. 
Studies in which adenosine is administered to patients with a myocardial infarction 
have shown disappointing results, most likely due to the very short half-life of adenosine 
and the active metabolic barrier of the endothelium, preventing circulating adenosine 
from reaching myocardial cells.7, 8 Dipyridamole augments the endogenous interstitial 
adenosine concentration by inhibiting the equilibrative nucleoside transporter (ENT) 
transporter.9-11 In preclinical  animals studies12-15, and studies in healthy volunteers 
and patients undergoing coronary angioplasty (PCI), dipyridamole limits IR-injury.11, 
16-18 Protection by dipyridamole against peri-procedural cardiac injury in the setting 
of CABG has never been addressed. Therefore, this study was designed to test the 
hypothesis that oral pre-treatment with dipyridamole prevents IR-injury in patients 
who undergo elective CABG. We also studied whether the cardioprotective effect of 
dipyridamole was dependent on the genotype encoding for adenosine monophosphate 
deaminase (AMPD), which is a central enzyme in the intracellular metabolism of 
adenosine.19
Methods
Patients
We recruited consecutive adult patients accepted for elective on-pump CABG 
between February 2010 and June 2012 at the Radboud university medical center. We 
excluded patients who suffered from myocardial infarction within two weeks before 
screening and those with asthma, since dipyridamole could aggravate this pulmonary 
condition20 Additionally, patients taking xanthine derivatives (such as theophylline), 
sulphonylurea derivates, insulin or metformin were excluded since these agents 
interfere with the endogenous adenosine metabolism.21-23 To minimize an additive 
risk of bleeding we also excluded patients taking oral anticoagulants or antiplatelet 
drugs other than aspirin within 8 days before surgery. As caffeine is an effective 
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adenosine receptor antagonist, all patients had to abstain from caffeine consumption 
for at least 24 hours before surgery.24 Compliance to this restriction was controlled 
by measuring plasma caffeine concentration on the day of surgery. This study has 
been approved by the local ethics committee and is therefore been performed in 
accordance with the ethical standards laid down in the 1975 Declaration of Helsinki 
and its later amendments. All persons gave their informed consent prior to their 
inclusion in the study. 
Preparation, conduct and analysis of this trial complied to Good Clinical Practice 
guidelines. This trial was prospectively registered at www.clinicaltrials.gov (NCT01295567).
Pharmacological intervention and blinding
Patients randomly received either dipyridamole slow release (200 mg b.i.d.) or 
placebo (b.i.d.) for 3 days prior to surgery. The dose of 200 mg b.i.d. was selected 
because we have previously shown that this dose effectively blocks ex vivo nucleoside 
uptake in red blood cells in humans and significantly limits IR-injury in a forearm 
model of IR-injury.11 In case of postponed surgery, continuation of study medication 
was allowed for a maximum of 7 days, otherwise that patient was excluded. Compliance 
with this therapy was controlled by pill count and by measuring the plasma 
dipyridamole concentration on the day of surgery. To guarantee blinding of patients 
and investigators, dipyridamole was over-encapsulated under Good Manufacuring 
Practice (GMP) conditions at the department of Clinical Pharmacy of the Radboud 
University Medical Center. An independent Data Safety Monitoring Board performed 
a prespecified safety analysis after inclusion of 50 patients. This analysis did not 
reveal any concerns with respect to safety.
CABG procedure
Anesthesia was performed with sufentanil, midazolam, rocuronium and propofol 
according to clinical judgment. As sufentanil and propofol may influence IR-injury we 
recorded the administration of these substances and for sufentanil we also recorded 
the cumulative dose used.25 Only patients who underwent on-pump surgery were 
included in our efficacy analysis since only in these patients cardioplegia with global 
cardiac ischemia is applied. All patients were operated using standard cardiopulmonary 
bypass technique, aortic and right atrial (two stage) cannulation, with membrane 
oxygenator, moderate hemodilution and mild systemic hypothermia (32-34ºC). 
Conventional myocardial protection was performed by intermittent infusion of cold 
4ºC cardioplegic solution. The choice of the cardioplegic solution was left to the 
distinction of the surgeon. Distal anastomoses were performed during a single period 
of cross-clamping, proximal anastomoses using a partial occluding clamp. Before 
weaning the patient off extracorporeal circulation, rewarming was initiated to a rectal 
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temperature of 35ºC and the hematocrit was increased to a minimum value of 0.24 l/l. 
Surgical risk estimation was performed using the logistic EuroSCORE (see table 1).26
Outcome parameters
Plasma high-sensitive (hs-) troponin I was the primary endpoint of this trial and 
was determined before surgery and 6, 12, 24 h after reperfusion (defined as release 
of aortic clamp). Hs-troponin I concentrations were analysed on the Dimension Vista® 
System (Siemens®, Healthcare Diagnostic, The Hague, The Netherlands) at the 
department of Clinical Chemistry (KCH Laboratory), Jeroen Bosch Hospital, Den Bosch, 
The Netherlands. The method used is a homogeneous, sandwich chemiluminescent 
immunoassay based LOCI® technology. The lower limit of detection is 0.02 µg/L. 
We also collected the following clinical data prospectively (secondary endpoints): the 
occurrence of arrhythmias during the first 24 hours after reperfusion (as documented 
in clinical chart), the need for prolonged inotropic support (>24 hours), prolonged 
Intensive Care Unit (ICU) stay (>48 hours), clinically relevant bleeding complications 
(defined as bleeding complications that required additional surgical intervention 
and/or prolonged hospital stay) and cumulative volume of blood collected from 
chest tubes post-surgery. All adverse events that occurred during the treatment 
period and first 48 hours after surgery were documented according to Good Clinical 
Practice.
Plasma Lipoprotein-associated phospholipase A2 (Lp-PLA2) was determined with 
the ELISA kit from USCN Life Science  Inc. (Wuhan, People’s Republic of China). 
Interleukin-6 (IL-6) was measured with the ELISA kit from Sanquin (Pelipair; M9316). 
High-sensitive CRP (hs-CRP) was determined using the BNII Behring Nephelometer 
Analyser from Siemens. Matrix metalloproteinase 9 (MMP-9) was analysed using the 
ELISA kit from Invitrogen (Camarillo, CA). Monocyte chemotactic protein 1 (MCP-1) 
was measured using the ELISA kit from BD Bioscience (San Diego, CA). Pentraxin- 
related protein 3 (PTX-3) was determined with the ELISA kit from Adipo Bioscience 
(Santa Clara, CA) according the manufacturer’s instructions. Adiponectin was 
measured using the ELISA kit from R&D (Human adiponectin Duoset; DY1065). All 
these plasma markers for inflammation were determined before start and after 
completion of study medication (just before surgery). 
Plasma caffeine concentrations were determined by use of reversed-phase HPLC with 
ultraviolet detection set at 273 as described previously.27 Dipyridamole concentrations 
were determined with the use of LC-MS/MS quantification, using an Accela U-HPLC 
(Thermo Fischer Scientific) coupled to a TSQ Vantage (Thermo Fisher Scientific) 
triple quadropole mass spectrometer. The compounds were separated on a Grace 
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Vision HT C18 column (50x2.0 mm, 1.5 µm particle size). As internal standard we 
used dipyridamole-D20. Solvent A consisted of 5 mM NH4, Solvent B consisted of 
Methanol. Flow rate was 200 µl/min. Detection of dipyridamole and the internal 
standard was based on isolation of the protonated molecular ion, [M + H]+ and 
subsequent MS/MS fragmentations and a selected reaction monitoring (SRM) were 
carried out. For dipyridamole the parent was 505.3 m/z and products were 385.4 and 
429.4 m/z. For the internal standard the parent was 525.4 m/z and products were 
405.5 and 449.5 m/z.
For AMPD1-genotyping, blood was stored at -80 oC until DNA isolation. Genomic 
DNA isolation was performed using a standard desalting protocol.28 Genotyping of 
the genetic variant 34C>T (rs17602729) in the AMPD1 gene was performed by Taqman 
analysis (assay_ID C__33603912_10) according to the protocol of the manufacturer 
(Life Technologies Europe, Bleiswijk, The Netherlands). 
Statistical analysis
Plasma hs-troponin I was not normally distributed and is presented as median with 
interquartile range. A log transformation was used to correct for these skewed data 
and a mixed model analysis was used to assess difference in post-operative plasma 
hs-troponin I in order to accommodate the repeated measurements by incorporating 
a subject dependent intercept. A value of p<0·05 was regarded as significant (SAS 
version 9.2, Cary, NC). Continuous secondary endpoints that were normally distributed 
are presented as mean±SE and analysed using an unpaired t-test. Discrete secondary 
endpoints were analysed using a chi-square analysis or a Fisher’s Exact Test in case of 
small numbers of events. Lp-PLA2 was not normally distributed and therefore presented 
as median with interquartile range and analysed with a Mann-Whitney-U test. 
Based on previous studies and observational data from our own clinic, we calculated 
that a sample size of 80 patients (40 patients per treatment group) would provide a 
power of 90% with an alpha of 0.05 to detect a 50% reduction in post-operative 
troponin release. An expected effect size of 50% was based on previous observations 
on the effect of alternative preconditioning strategies on plasma troponin concentration 
after CABG 3 or PTCA 29 and  on protective effect of preconditioning strategies on 
infarct size in preclinical models of myocardial infarction. 5 Since this was a proof of 
principle study, a per-protocol analysis was used to assess the primary endpoint. 
The efficacy analysis was performed both with and without patients with the 34C>T 
variant of the AMPD1 gene which has previously been shown to limit the pharmaco-
logical action of dipyridamole on adenosine kinetics.19 Safety analysis was conducted 
in all patients exposed to study medication (as treated analysis), also including 
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patients that were included in the trial but in whom the surgeon changed plans from 
‘on-pump’ to ‘off-pump’ while patients were already on investigational product (figure 1). 
Results
Inclusion
In all, 110 patients provided informed consent and 33 patients (dipyridamole) vs. 
46 patients (placebo) were included in the per-protocol analysis (figure 1). Baseline 
characteristics did not differ between the two treatment arms (table 1). The mean 
duration of aortic cross-clamping was 65±19 (range: 18-107) minutes, this was not 
Figure 1   Study flow chart. 
ATA = as-treated analysis; PPA = per-protocol analysis. 
*: p<0.05 versus placebo arm (two-sided pearson chi-square analysis)
Informed consent (n=116) 
Excluded (n= 6) 
 Withdrawal consent (n=3) 
 Not meeting inclusion criteria (n=2) 
 CABG performed in other hospital (n=1) 
Dipyridamole (n=47) 
Randomized (n=110) 
Completed study medication (n=41) 
Drop outs (n=16, medication not started) 
 Logistic reasons (n=9) 
 Off pump procedure (n=1) 
 Adverse events (n=6) 
Placebo (n=47) 
Completed study medication (n=47) 
Drop outs  (n=6*, <5 pills taken) 
Analysis (n=33) Analysis (n=46) 
Drop outs (n=8) 
 Off pump procedure (n=5) 
ACS (n=3) 
Drop outs (n=1) 
 Off pump procedure (n=1) 
Enrollment  
 
safety analysis, ATA
efficacy analysis, PPA
96
CHAPTER 6
Table 1   Baseline characteristics.
Dipyridamole 
(N=33)
Placebo (N=46)
Age mean 62.7 (8.3) 63.7 (8.1)
Male 31 37
Body weight, kg 88.4 (9.3) 81.3 (12.7)
Height, cm 177 (7) 174 (10)
Blood pressure, mmHg
Systolic 138 (18) 141 (15)
Diastolic 81 (10) 80 (9)
Heart rate, beats/min 60 (10) 58 (8)
Previous myocardial infarction 12 (36.4%) 14 (30.4%)
Previous CABG 1 (3.0%) 0 (0%)
Previous PCI 6 (18.2%) 4 (8.7%)
Angina pectoris CSS class
I
II
III
IV
5 (17%)
13 (39%)
10 (30%)
5 (15%)
7 (15%)
22 (48%)
15 (33%)
2 (4%)
Co-medication
Aspirin 32 (97.0%) 45 (97.8%)
β-blocker 29 (87.9%) 46 (100%)
ACE- inhibitor 12 (36.4%) 20 (43.5%)
AT2 receptor antagonist 5 (15.2%) 3 (6.5%)
Diuretic 8 (24.2%) 4 (8.7%)
Calcium channel blocker 12 (36.4%) 9 (19.6%)
Nitrates 18 (54.5%) 26 (56.5%)
Statin 29 (87.9%) 41 (89.1%)
Laboratory values at screening
Total cholesterol, mmol/l 4.57 (0.92) 4.63 (0.92)
Triglycerides (non-fasting), mmol/l 2.37 (1.45) 1.96 (0.83)
HDL cholesterol, mmol/l 1.04 (0.23) 1.08 (0.23)
LDL cholesterol, mmol/l 2.48 (0.71) 2.67 (0.82)
Creatinin µmol/l, median (IQR) 84.0 (75.0 - 93.5) 76.0 (69.8 - 87.3)
GFR (MDRD) ml/1.73 m2,  median (IQR) 81.0 (69.5 - 89.0) 82.0 (74.0 - 89.0)
Glucose, mmol/l 6.48 (1.65) 6.32 (1.85)
AMPD genotype
CC
CT
TT
Number of investigational pills taken, median (IQR)
27
5
1
7.0 (6.0 - 9.0)
37
9
0
6.0 (6.0 - 8.3)
Data are number (%) or mean (SD) unless stated otherwise. CSS= Canadian Cardiovascular Association. 
ACE= angiotensin converting enzyme. AT2= Angiotensine II. 
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different between groups (dipyridamole 64±18 (29- 99) minutes and placebo group 
66±19 (18- 107) minutes, p >0.1). All patients received at least 1 arterial graft (internal 
mammary artery). Further surgical details are described in table 2.
Plasma concentration of dipyridamole and caffeine
Immediately before surgery, the plasma dipyridamole concentration averaged 
1.29±0.11µg/ml for the dipyridamole pre-treated group (range: 0.11 - 2.28 µg/ml) and 
0.0±0.0 µg/ml for the placebo group. The plasma caffeine concentration was 0.0 µg/
ml  in all patients, except for two in whom a low concentration was detected (0.17 
and 0.22 µg/ml). These patients were not excluded from analysis since these low 
concentrations do not relevantly antagonize adenosine receptors. 
Plasma troponin I
Baseline concentrations of hs-troponin I prior to surgery were below the detection 
limit of  0.02 µg/L in the majority of patients. In 11 patients baseline hs-troponin levels 
were >0.02 µg/L (four patients in the dipyridamole group and seven in the placebo 
group; p >0.1), with a range of the hs-troponin of 0.02-0.11 µg/L and 0.02-0.24 µg/L, 
respectively. In three patients these data were missing (one dipyridamole and two 
placebo). Peak high-sensitive troponin I was 3.7 (2.8-5.7) µg/L in the dipyridamole 
group and 3.4 (2.4-5.5) µg/L in the placebo group at 6 hours after release of the aortic 
clamp (figure 2). Dipyridamole did not significantly affect post-operative hs-troponin 
I concentration (change in plasma hs-troponin I -3%, 95% confidence interval [CI] 
from -23% to 36%; p > 0.1). The AMPD1 34C>T CT and TT genotype (rs17602729), 
associated with reduced AMPD activity, was found in six patients in the dipyridamole 
Table 2   Details of CABG procedure.
Dipyridamole
(N=33)
Placebo
(N=46)
Type of anesthesia
Midazolam/rocuronium/sufentanyl/propofol
Midazolam/rocuronium/sufentanyl
Sevoflurane 
Sufentanyl dose during surgery (µg), mean (SD)
Cross clamping time, minutes, mean (range)
Cardioplegic solution (%)
Crystalloid
Blood
Logistic Euroscore, median (IQR)
Number of grafts, median (IQR)
Number of distal anastomoses, median (IQR)
20 (60.6%)
13 (39.4%)
20 (60.6%)
441 (112)
64 (29-99)
26 (78.8%)
7 (21.2%)
1.4 (1.1 - 2.3)
2.0 (2.0 - 2.0)
4.0 (3.0 - 4.5)
14 (30.4%)
32 (69.6%)
36 (78.3%)
399 (131)
66 (18-107)
35 (76.1%)
11 (23.9%)
1.6 (1.1 - 2.2)
2.0 (2.0 - 2.0)
4.0 (3.0 - 5.0)
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group and in nine patients in the placebo group. When analysis of the course in 
plasma hs-troponin concentration was restricted to those individuals with the CC 
genotype, results remained essentially unchanged (data not shown). 
Duration of ischemia, defined as aortic cross-clamp time (65 ±19; range 18-107 minutes), 
was positively correlated with the amount of troponin release (r=0.3, p <0.01, Spearman 
correlation coefficient), supporting the assumption that the postoperative rise in 
hs-troponin is, at least partly, due to IR-injury.
In the dipyridamole group, the plasma dipyridamole concentration did not correlate 
with post-operative hs-troponin levels (Spearman correlation coefficient -0.15 and 
-0.13 for average and maximum hs-troponin concentration, respectively, p >0.1).
Markers of inflammation
Prior to treatment, the dipyridamole and placebo group did not significantly differ in 
plasma Lp-PLA2 concentration (0.57 [0.32-3.09] and 0.74 [0.30 – 1.57] µg/ml, 
respectively; p >0.1, Mann-Whitney U-test). In the dipyridamole-treated patients, the 
plasma Lp-PLA2 concentration was significantly reduced during drug treatment from 
baseline by 0.23 (0.05 - 0.83) µg/ml versus 0.03 (-0.13- 0.28) µg/ml in the placebo- 
treated individuals (p=0.007 for comparison of the change from baseline between 
the two treatment arms, Mann-Whitney-U test). Other inflammatory markers that were 
Figure 2   Post-operative hs-troponine I concentration in plasma (median with 
interquartile range). 
Solid line: dipyridamole; Dashed line: placebo. The two curves do not differ significantly (Mixed 
model analysis after log transformation, p >0.1).
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explored (IL-6, hs-CRP, MMP-9, MCP-1, PTX-3, adiponectin) did not change 
significantly in response to dipyridamole (table 3).
Arrhythmias, ICU-stay and need for inotropic support
Dipyridamole did  not affect the occurrence of arrhythmias, the need for inotropic 
support or the duration of ICU stay (table 4).
Safety
There was no mortality within the first 30 days after surgery. In the dipyridamole group 
an acute coronary syndrome (ACS) occurred in 3 patients versus none in the placebo 
group (p>0.05, Fisher’s Exact Test). In two of these cases, ACS resulted from a 
complicated surgical procedure: stenosis of an anastomosis and an endarterectomy 
of the left anterior descending artery. Since these patients did not experience 
appropriate reperfusion after release of the aortic clamp, they were not included in 
the per-protocol analysis. The third case of ACS occurred in the morning prior to 
surgery. Since this complication confounded plasma hs-troponin, this patient was 
also excluded from the per-protocol analysis.
Clinically relevant bleeding complications occurred in four patients, all on dipyridamole 
(p >0.10, Fisher’s Exact Test). In three a causal role for dipyridamole could not be 
excluded, whereas a fourth bleeding complication was related to a clear surgical 
complication. Total chest tube output was available in 38 patients on dipyridamole 
Table 4   Secondary endpoints.
Dipyridamole
(N=33)
Placebo
(N=46)
p-value
Days on ICU, median (IQ range)
Number of patients on inotropy
Duration of inotropic support , hours, median  
(IQ range)
Clinical relevant arrhythmias < 24 hours
None
AF/SVT de novo
Sinus bradycardia in need for pacemaker
AV conduction disturbance
VT/VF
1 (1-1)
17 (52%)
3.5 (0-14.3)
24 (72.7%)
7 (21.2%)
1 (3%)
0 (0%)
1 (3%)
1 (1-1)
21 (46%)
 (0-15)
35 (76.1)
7 (15.2%)
3 (6.5%)
1 (2.2%)
0 (0%)
0.71
0.52
0.79
0.74
0.49
0.64
0.58
0.42
ICU= intensive care unit. AF= atrial fibrillation. SVT= supraventricular tachycardia. AV= atrioventricular. 
VT= ventricular tachycardia. VF= ventricular fibrillation.
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and  41 patients on placebo and did not significantly differ between the two study 
arms 785 (620 – 1340) mL and 880 (558-1215) mL in dipyridamole and placebo 
group; respectively; median (interquartile range); p>0.1, Mann-Whitney-U test). One 
patient (on dipyridamole) experienced a delirium post-surgery which prolonged 
hospital stay. In total, 31 patients experienced a headache (22 on dipyridamole, 9 on 
placebo; p<0.005, Pearson chi-square test). In most cases the headache occurred 
immediately after intake of study medication. Four patients (two on dipyridamole, two 
on placebo, p=1.0) experienced chest pain without increase in plasma cardiac 
enzymes. Finally, 19 patients experienced various adverse events without further 
clinical significance (13 in the dipyridamole group and 6 in the placebo group and, 
p <0.10, Pearson chi-square Test). From 47 patients who started dipyridamole 
treatment, in 43 patients the plasma dipyridamole concentration was available 
(in 3 who took < 5 pills and 1 who was shifted to off-pump surgery, dipyridamole 
concentration was missing). The dipyridamole concentration did not significantly 
differ between those who developed any adverse event and those who did not 
(1.3±0.2 µg/ml (n =27) and 1.2±0.2 µg/ml (n =16) respectively; p >0.5, t-test). Similar 
results were obtained when this analysis was restricted to those who reported 
headache. 
Discussion
In this study we investigated whether short-term treatment with dipyridamole could 
reduce IR-injury in patients undergoing elective CABG surgery. Although preclinical 
data suggested a cardioprotective effect of dipyridamole, in our study dipyridamole 
did not limit myocardial IR-injury, as detected with post-operative plasma hs-troponin 
I release. Also, there was no effect on the occurrence of post-operative arrhythmias, 
the need for inotropic support or the duration of ICU stay. This lack of efficacy was 
combined with the occurrence of adverse events: mainly headaches and possibly 
also an increase in bleeding risk, although overall blood loss was not significantly 
affected.
Dipyridamole is a potent inhibitor of the human ENT transporter (hENT1).30 Inhibition 
of the hENT1 increases the interstitial concentration of adenosine and subsequent 
adenosine receptor stimulation 16, 31 which is an attractive target to prevent IR-injury.32 
Dipyridamole reduced myocardial and cerebral infarct size in animals12-15 and 
reduced IR-injury in humans in-vivo.11, 16-18 In contrast to our hypothesis, we did not 
observe any benefit of dipyridamole on plasma hs-troponin I after CABG. We will 
subsequently discuss methodological, pharmacokinetic and pharmacodynamic 
explanations for this unexpected result.
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The drop-out rate was higher during dipyridamole treatment (13 patients) than during 
placebo treatment (one patient). This was mainly driven by differences in adherence 
to therapy between the two groups, most likely resulting from side effects to dipyri - 
damole including headache. In theory, this drop-out could have occurred selectively 
in those individuals that would otherwise have responded well to dipyridamole 
therapy, for example by increased plasma exposure due to higher bioavailability of 
dipyridamole in this subset of patients. However, adverse events also occurred in 
those individuals who completed therapy. In these, the presence of adverse events 
was not associated with higher plasma dipyridamole concentration (data not shown). 
Furthermore, plasma hs-troponin (primary endpoint) did not differ between those 
who experienced adverse events and those who did not. Therefore, potential bias 
due to selective drop-outs in the dipyridamole group does not sufficiently explain the 
negative result of this trial.
Oral therapy with dipyridamole could have resulted in insufficient plasma dipyridamole 
concentrations. In a previous study in healthy volunteers by our group, oral dipyri - 
damole achieved an average plasma peak concentration of 1.33 (SD 0.33) µg/mL, 
significantly inhibited ex-vivo transmembranous adenosine transport in erythrocytes 
and reduced forearm IR-injury as imaged with annexin A5 scintigraphy.11 In our 
patients, average dipyridamole concentrations were 1.34 µg/mL, but ranged from 
0.11 - 3.04 µg/mL. Thus, the group average concentration well resembled the previously 
reported value in healthy volunteers, but dipyridamole exposure was variable in our 
patients and may have been insufficient in some of them to prevent IR- injury. 
Dipyridamole concentrations, however, did not directly correlate with post-operative 
troponin levels. 
We have previously shown that a genetic polymorphism resulting in reduced AMPD1 
activity (CT and TT genotype) limits the efficacy of dipyridamole to augment adenosine 
signaling during ischemia.19 Exclusion of patients with CT or TT genotype, however, 
did not alter the results of our trial. Therefore, this genetic variant did not mask a 
potential benefit of dipyridamole on our primary endpoint.
Our patient population is characterized by high age, co-morbidity (such as hyper -
tension) and the use of comedication such as statins. This obviously differs from the 
healthy volunteers that we have studied previously as well as from animal models that 
showed benefit from dipyridamole. We have recently shown that the efficacy of 
ischemic preconditioning to prevent brachial endothelial dysfunction after ischemia 
and reperfusion is reduced in the elderly.33 Since adenosine is involved in ischemic 
preconditioning, the reduced efficacy of this intervention in the elderly may reflect a 
reduced efficacy of endogenous adenosine to protect tissue against IR-injury and 
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may therefore also limit the efficacy of dipyridamole to reduce IR-injury. Furthermore, 
we and others have shown that statins augment adenosine signaling by activating 
ecto-5’-nucleotidase and prevent IR-injury in animals as well as healthy human 
volunteers and patients.34-36 Therefore, the almost universally used statins could 
have maximized the potential efficacy of endogenous adenosine to prevent IR-injury 
and this could have prevented dipyridamole from providing additional benefit. In 
addition, general translational failure of promising preclinical findings might be 
explained by methodological flaws in animal studies, e.g., lachk randomization, lack 
of blinding, lack of planning for missing data, and a willingness to accept post-hoc 
data analyses with results in hand.37
Finally, additional actions of dipyridamole could have offset the benefit of augmenting 
adenosine signaling. Interestingly, our exploratory data on Lp-PLA2 show that 
dipyridamole significantly reduces the plasma concentration of this enzyme. Lp-PLA2 
generates pro-inflammatory lipid molecules (such as lyso-phosphatidylcholine) from 
oxidized LDL particles.38, 39 Epidemiological data have shown a strong association 
between elevated levels of Lp-PLA2 and the risk of acute cardiovascular events in 
humans.40-42 In animal models, pharmacological inhibition of Lp-PLA2 reduces 
 atherosclerotic plaque formation.43 Lp-PLA2-knock-out animals show less formation 
of atherosclerosis.44 Finally, in humans with coronary atherosclerotic disease, pharma-
cological inhibition of Lp-PLA2 prevents development of signs of plaque instability on 
intravascular ultrasound.45 Thus, reduction of plasma Lp-PLA2 concentration and 
subsequent prevention of generation of vulnerable plaques could contribute to the 
previously observed benefit of dipyridamole to prevent atherothrombotic events.46 
However, Lp-PLA2 is also involved in the degradation of Platelet Activating Factor, 
a substance that augments IR-injury in various animal models. This action of 
dipyrida mole could therefore have offset the potential benefit of augmented adenosine 
signaling to prevent cardiac IR-injury.47-50 
In conclusion, in contrast to our hypothesis and previous preclinical studies, we could 
not detect any benefit from oral dipyridamole treatment on IR-related myocardial 
injury during CABG. At least three possible explanation may contribute to this negative 
finding: variable plasma exposure to dipyridamole, reduced benefit of augmented 
adenosine signaling in this population of elderly patients with co-morbidity and 
comedication and additional actions of dipyridamole including reduction of plasma 
Lp-PLA2 concentration. 
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Introduction 
  
Ticagrelor is a novel direct-acting and reversibly binding P2Y12 receptor antagonist. 
In the Platelet Inhibition and Patient Outcomes (PLATO) trial, the administration of 
ticagrelor to patients with an acute coronary syndrome resulted in a striking reduction 
in the primary endpoint of death from vascular causes, myocardial infarction, or stroke 
compared to clopidogrel.1 Moreover, all cause mortality was reduced, and this was 
driven not only by vascular mortality, but also by fewer deaths attributed to sepsis.2 
In addition, dyspnea and asymptomatic ventricular pauses were reported more often in 
the ticagrelor treated patients. These finding have instigated the search for pleiotropic 
effects of ticagrelor over and above the classical antiplatelet effect. 
In the past years, evidence is accumulating that ticagrelor inhibits the cellular uptake 
of the endogenous nucleoside adenosine by blockade of the Equilibrative Nucleoside 
Transporter (hENT1).3 Stimulation of membrane-bound adenosine receptors induces 
various beneficial cardiovascular effects, including vasodilation, inhibition of platelet 
aggregation, inhibition of inflammation, and increasing resistance against ischemia 
and reperfusion.4, 5 In addition, intravenous administration of adenosine induces 
dyspnea and potently inhibits atrioventricular conductance.5, 6 Adenosine is mainly 
formed by intra- and extracellular dephosphorylation of AMP, which is catalyzed by 
5’-nucleotidase. In contrast, degradation of adenosine in humans is mainly confined 
to the intracellular compartment, by adenosine kinase and adenosine deaminase. 
Consequently, in normal situations, the intracellular concentration is lower than the 
extracellular concentration, and extracellular adenosine is rapidly taken up via the 
hENT1 by surrounding cells, mainly red blood cells and endothelial cells.7 Therefore, 
inhibition of the hENT1 activity will increase the extracellular adenosine concentration, 
and this mechanism has been proposed to mediate the effects of ticagrelor observed 
in the PLATO study.3
Most of the current evidence on the effect of ticagrelor on adenosine metabolism is 
derived from in vitro studies, or from studies in patients in which the adenosine 
metabolism could be affected by other factors, such as co-medications. Therefore, in 
this study we aimed to test this hypothesis in healthy humans in vivo. We used the 
vasodilator response to the local administration of adenosine and to forearm ischemia 
as validated surrogates of adenosine uptake inhibition, as previously described.8-11 
Furthermore, the vasodilator response to dipyridamole, a potent inhibitor of hENT1, 
was used as a validated surrogate marker of endogenous adenosine formation.12, 13 
In addition, the effect of ticagrelor on adenosine and uridine uptake was investigated 
directly in isolated red blood cells and whole blood.
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Methods
Subjects
The study protocol was in accordance with the Declaration of Helsinki and was 
approved by the Institutional Review Board of the Radboud University Medical Center, 
Nijmegen, The Netherlands. After approval, 15 healthy male volunteers signed written 
informed consent statements before participation in the study, see also figure 1. 
They had no history of cardiovascular disease, bleeding tendency or asthma, and they 
were all non-smokers. Concomitant medication was not permitted. In all participants a 
physical examination, electrocardiography, and laboratory investigation were performed 
to exclude cardiovascular and pulmonary disease, hypertension, diabetes mellitus, 
renal dysfunction, liver enzyme abnormalities, and thrombocytopenia. 
Experimental protocol
The subjects were randomly assigned in a double-blinded cross-over design to a 
single dose of ticagrelor 180 mg (Brilique, 2 tabs of 90 mg, AstraZeneca) or 2 fully 
mimicking placebos (Apotheek Haagse Ziekenhuizen, the Hague, the Netherlands). 
The experiments were performed two hours after the intake of the study medication. 
The two experiments were separated by at least 14 days. The randomization code 
was kept at the department of Clinical Pharmacy of the Radboud University Medical 
Centre. The study medication was taken under supervision at the Clininal Research 
Centre of our hospital. 
This trial was prospectively registered at: clinicaltrials.gov (The effect of ticagrelor on 
the adenosine system; NCT01996735).
Venous occlusion plethysmography
On the experimental days, we studied the subjects in supine position after an 
overnight fast. All volunteers were asked to abstain from alcoholic drinks and  caffeine- 
containing beverages for at least 24 hours before the experiments. We performed 
the experiment in a temperature-controlled room (24±1 °C). A 27-gauge needle 
was inserted into the brachial artery of the non-dominant arm for intra-arterial drug 
administration. We measured the forearm blood flow (FBF) in both forearms 
simultaneously with venous occlusion plethysmography, using mercury-in-silastic 
strain gauges and an occluded hand circulation as described previously.14 The total 
intra-arterial infused volume was kept at a constant rate of 50 µL/min per dL of forearm 
volume. Thirty minutes after cannulation of the brachial artery, we started the infusion 
of normal saline at the calculated rate with concomitant measurement of the FBF. 
Normal saline (baseline) and the dosages of the intra-arterial administered drug were 
infused for 5 minutes. We performed four experiments, starting two hours after intake 
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of the study medication, which were all separated by a wash-out period of 30 minutes 
to prevent any cross-over effects. Figure 2 provides a schematic overview of the 
experiment.
1. We measured FBF during the administration of 4 incremental dosages of 
adenosine into the brachial artery. The dosages (0.15, 0.5, 1.5, and 5.0 µg/min/dL 
forearm volume) are similar to a previous study in which we demonstrated a 
significant potentiation of adenosine-induced vasodilation by the ENT inhibitor 
dipyridamole and draflazine.9, 10 Adenosine-induced forearm vasodilation is the 
primary endpoint of our study. Secondary endpoints include:  
2. The blood flow response to 2 and 5 minutes of forearm ischemia was measured 
(post-occlusive reactive hyperemia; PORH). Forearm ischemia was induced by 
inflation of an upper arm cuff to 200 mmHg, as described previously.14 We have 
previously demonstrated that dipyridamole potentiates the PORH response8 and 
that statins potentiate the PORH by an increase of the extracellular adenosine 
formation.15 
3. Subsequently, FBF was measured during intra-arterial administration of dipyri - 
damole (30 and 100 µl/min/dL forearm volume, which we also used in previous 
studies11). Dipyridamole induces vasodilation by ENT inhibition, thereby increasing 
the extracellular adenosine concentration at a rate proportionate to extracellular 
adenosine formation.  
4. Finally, we measured the FBF response to the administration of acetylcholine 
(0.5 and 2.0 µg/min/dL forearm volume) to exclude nonspecific effects on 
vascular reactivity. 
Blood sampling
Before intake of the study medication blood was drawn from an intravenous cannula 
in the dominant arm for the determination of the plasma ticagrelor and caffeine 
concentration, and for the ex vivo ENT transport measurements in isolated red blood 
cells. This measurement was repeated approximately 2 hours after the ingestion of 
the study medication and just before measurement of the vasodilator response to 
adenosine. Finally, the ticagrelor concentration was determined before intake of the 
ticagrelor dose, 2 hours after the intake, and subsequently before the start of each 
forearm blood flow experiment.
Analytic procedures  
We determined plasma caffeine concentrations using reversed-phase HPLC with 
ultra violet detection set at 273 nm, according to Schreiber-Deturmeny and Bruguerolle.16 
In isolated red blood cells, the uptake of adenosine and uridine was determined as 
described previously.17 In contrast to adenosine, uridine is not metabolized inside the 
cells, and therefore, uridine uptake is a more direct measure of ENT activity than 
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adenosine uptake.18 Ticagrelor concentrations were determined by LC-MSMS. Liquid 
chromatographic separation was performed at a temperature of 30°C with a mobile 
phase, consisting of solvent A (10 mM ammonium acetate in water) and solvent B 
(acetonitrile). For the mass spectrometric analysis, heated electrospray ionization 
(HESI) was operated at a spray voltage of -2.5kV, a capillary temperature of 225°C 
and a vaporizer temperature of 382°C. Argon was used as collision gas at a pressure 
of 1.5 mTorr. Negative ion mode was used with selected reaction monitoring (SRM) 
for the quantitative analysis of ticagrelor. The most abundant product ion was used 
for quantification. The quantification was performed using peak areas.
In vitro experiments
In isolated red blood cells from healthy volunteers not taking any medication, the 
effect of ticagrelor on uridine uptake was measured as described previously.17 Briefly, 
uridine was added to washed red blood cells to obtain a final concentration of 1000 
µM. The cells were pre-incubated with increasing concentrations of ticagrelor for ten 
minutes before the addition of uridine. After 3 seconds, uridine uptake was completely 
blocked by the addition of 10 µM dipyridamole and the amount of uridine in the cell 
was determined using HPLC with UV detection set at 254 nm.
Because of the high protein binding of ticagrelor of 99.8%, we also performed whole 
blood experiments, in which ticagrelor was added to 1 ml of whole blood for 10 or 60 
minutes. Next, the red blood cells were isolated by centrifugation and uridine was 
added as described above.
To measure the rate of disappearance of adenosine in the physiological situation, 
which is the overall result of uptake and intracellular degradation, we added 1 µM of 
adenosine to 1 ml of whole blood at 37°C, as previously described by Bonello et al.19 
After 0, 15, 30, 45, and 60 seconds, the transport, formation, and degradation of 
adenosine was completely blocked by a adding an equal volume of pharmacological 
blocking solution, including NaCl (118mM); KCl (5 mM); Na2EDTA (13.2 mM); 
dipyridamole (40 µM); iodotubercidin (ITU; 10µM);  EHNA (10µM); forskolin (11.5µM), 
and IBMX (115µM). After centrifugation the adenosine concentration was measured 
in the supernatant using LC-MSMS. Separation was performed with a Acquity UPLC 
HSS column. The mobile phase, consisting of solvent A (1 mM ammonium fluoride in 
water) and solvent B (methanol). For the mass spectrometric analysis, heated 
electrospray ionization (HESI) was operated at a spray voltage of +3kV, the capillary 
temperature and the vaporizer temperature were set at 300°C. Argon was used as 
collision gas at a pressure of 1.5 mTorr. Positive ion mode was used with selected 
reaction monitoring (SRM) for the quantitation. The following SRM transitions were 
used: m/z 268.1(parent ion) to m/z 119.0 and 136.1 (both product ions).
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Statistical analysis
The study was powered to detect a difference in the primary endpoint of adenos-
ine-induced vasodilation. The sample size calculation was based on the following 
assumptions: in previous studies from our own group, we found that the vasodilator 
response to the intrabrachial administration of adenosine averages 2.8±0.6, 4.4±1.0, 
9.0±1.7 ml/min per dl of forearm volume for 0.5, 1.5, and 5.0 µg/min/dl, respectively 
(mean±SEM, n=8). The pooled CV is 0.6, so after log transformation the SD averaged 
0.55. We expect that a (relative) difference between the treatments is independent of 
the adenosine dose. Hence, a linear mixed model will be used, with fixed factors 
treatment (ticagrelor vs placebo), adenosine dose, and period. Based on a correlation 
of 0.7 between the measurements for all doses and time points and an SD of 0.55, 
the SD of the contrast is 0.25. As a result, 13 evaluable subjects are needed to 
demonstrate an augmentation of adenosine-induced vasodilation with 1.25 (ie a 25% 
increase) with a power of 80% and a two-sided alpha of 0.05. To account for one 
drop-out, we aim to include 14 healthy volunteers. 
FBF analyses were done offline before unblinding of the study. Mean FBF values 
were calculated from the FBF responses to the different stimuli. We calculated the 
average FBF during last 4 minutes of the baseline FBF (normal saline), the last 2 
minutes of the FBF response to adenosine, dipyridamole and acetylcholine, and the 
first 3 minutes of the PORH. Results are expressed as the median absolute FBF (mL/
dL/min) with interquartile range (25-75%), unless otherwise stated.
A linear mixed model was used to compare the FBF results of both experiments, with 
the log FBF during placebo and ticagrelor treatment as the dependent variable, and 
treatment (ticagrelor versus placebo), adenosine dose, and period as fixed factors. 
We used a heterogeneous compound symmetry as the type of repeated covariance. 
A carry over effect was excluded calculating the interaction between ‘sequence’ and 
the primary endpoint in the mixed model analysis. For uridine uptake experiments, 
sigmoidal dose response curves were constructed with a variable slope and IC50 
were calculated for each series of experiments, using GraphPad Prism.
Results
Subjects
23 subjects were screened for eligibility. Four participants withdrew from participation 
and 4 participants were excluded, because of drug abuse, a history of asthma, a 
platelet count of 145*109/L, and a systolic heart murmur. Insertion of the arterial 
needle failed in 1 subject and this subject was replaced. Due to repeated dislocation 
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of the intra-arterial needle, we had to discontinue the experiment after the infusion of 
dipyridamole during a single visit in another subject. Thus, 13 fully evaluable subjects 
were included and one subject in whom acetylcholine responses were lacking during 
one (placebo) visit, see also figure 1. 
The baseline characteristics are depicted in table 1. The plasma caffeine concentration 
was < 1 mg/L in all subjects, showing adequate caffeine restriction. The ticagrelor 
concentration averaged 1.18±0.13, 1.01±0.11, 0.90±0.09, and 0.80±0.08 µM 
(mean±SE) at 2, 3, 4, and 4.5 hours after ticagrelor intake, respectively (see figure 2 
for the time points).
Figure 1   Schematic flow chart of the experiment. 
Assessed for eligibility (n=23)
Excluded (n=8)
Not meeting inclusion criteria (n=4)
Declined to participate (n=4)
Ticagrelor (n=7)
Randomized (n=15)
according to
cross-over design
Placebo (n=6)
Placebo (n=8)
Ticagrelor (n=8)
Drop out (n=1)
Due to technical problems
Analyzed (n=14)
Enrollment  
Allocation
Analysis
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Venous occlusion plethysmography
Baseline FBF in the experimental forearm was 1.2 (0.9-1.8) and 1.35 (0.9-1.7) mL/dL/
min during placebo and ticagrelor, respectively. There was no significant carry-over 
effect in this study (P=0.58). Intrabrachial administration of adenosine significantly 
increased FBF in the experimental forearm, but not in the control forearm (P<0.01; fig. 3A). 
Pretreatment with ticagrelor did not potentiate adenosine-induced vasodilation: the 
incremental dosages of adenosine increased the FBF to 1.3 (0.9-1.6), 1.8 (1.4-2.6), 3.6 
(2.0-4.1), and 6.3 (4.9-9.2) mL/dL/min during placebo, and to 1.3 (1.2-1.6), 2.3 (1.5-3.6), 
4.5 (2.4-7.8), and 9.0 (5.5-17.2) mL/dL/min after ticagrelor administration (P=0.33; 
figure 3A). Furthermore, we did not see any correlation between the plasma ticagrelor 
concentrations and the area under the curve for adenosine-induced FBF (Spearman 
correlation coefficient -0.13, P=0.67; figure 4).
Baseline FBF before arterial occlusion was 1.5 (0.8-3.0) mL/dL/min during placebo 
and 1.5 (0.6-1.9)  ml/dl/min during ticagrelor treatment. The hyperemic response after 
2 minutes of arterial occlusion was 7.9 (5.1-11.8), 1.2 (0.8-2.3), and 1.5 (1.0-3.1) during 
placebo and 8.1 (5.6-9.2), 1.4 (0.6-2.2), and 1.6 (0.8-2.0) during ticagrelor in the 1st, 
2nd and 3rd minute respectively (p=0.96 for the effect of ticagrelor) (figure 3B). 
Table 1  Baseline characteristics (means ± SD; n=14).
Characteristic Value
Age (years) 22.1 ± 2.2
Blood pressure (mmHg)
Systolic 125 ± 7
Diastolic 67 ± 10 
Heart rate (bpm) 62 ± 10
BMI (kg/m2) 22.3 ± 1.9
Blood plasma values
Platelet count  (*109/L) 230 ± 31
Creatinine (µmol/L) 80 ± 7
Non-fasting glucose (mmol/L) 5.1 ± 0.7
ALAT (U/L) 29 ± 14
Non-fasting cholesterol (mmol/L) 3.9 ± 0.7 
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After 5 minutes of arterial occlusion, the hyperemic response was 15.2 (11.1-23.7), 3.1 
(1.6-5.1), and 1.6 (1.1-3.3) mL/dL/min during placebo and 14.1 (11.5-20.3), 2.7 (1.9-5.6), 
and 2.1 (1.4-3.7) mL/dL/min in the 1st, 2nd and 3rd minute respectively (p=0.20 for 
effect of ticagrelor; figure 3C).
Figure 3   Forearm blood flow measurements.
FBF values in the experimental forearm (triangle) and non-experimental forearm (circle) after 
ticagrelor treatment (black symbols) or placebo treatment (open symbols, dashed line) during 
intrabrachial administration of adenosine (A), after five (B) and two (C) minutes of forearm ischemia, 
and during intrabrachial administration of dipyridamole (D). P-values represent the effect of 
ticagrelor on the FBF-values.
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Comparable to adenosine, intrabrachial administration of dipyridamole significantly 
increased FBF in the experimental forearm but not in the control forearm (P<0.01, 
figure 3D). Again, the vasodilator response to dipyridamole did not differ between 
placebo and ticagrelor treatment. The FBF in the experimental forearm was 1.2 mL/
dL/min (0.9-2.6) at baseline and 1.9 (1.1-4.1) and 2.7 (1.8-6.1) during administration of 
the two doses of dipyridamole after treatment with placebo, versus 1.3 (0.9-2.0), 2.3 
(1.4-3.6), and 3.2(1.5-4.8) after treatment with ticagrelor (p=0.29 for effect of tica-
grelor,figure 3D).
Similarly, ACh-induced vasodilation did not differ between both experiments. The FBF at 
baseline and during administration of the two doses of acetylcholine was 3.5 mL/dL/
min (2.0-5.3), 10.8 (7.8-19.1), and 17.3 (12.5-31.2) after treatment with placebo, versus 
3.9 (3.0-6.5), 8.1 (4.4-19.3), and 16.8 (10.4-28.6) after treatment with ticagrelor (p=0.11 
for effect of ticagrelor). 
Ex vivo nucleoside uptake inhibition
Red blood cells were isolated from blood samples taken before and 2 hours after 
intake of the study drug. The uptake of adenosine in these cells was not affected by 
oral ticagrelor, when compared to baseline (P=0.87; Fig 5A). Uridine uptake was 
inhibited by an average of 11%, but this did not reach statistical significance (P=0.056) 
(Fig 5B). 
Figure 4   The correlation between the plasma ticagrelor concentration and the area 
under the curve (AUC) of adenosine-induced forearm vasodilation.
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In vitro nucleoside uptake inhibition
In isolated red blood cells, ticagrelor dose-dependently inhibited uridine uptake with 
an IC50 value of 3.0*10-7 M (95% CI 2.0*10-7 to 4.5*10-7, n=3; Fig 6A). In the 
experiments in which ticagrelor was added to whole blood before isolation of the red 
blood cells, the IC50 of ticagrelor for uridine uptake inhibition was 7.3*10-6 M (95% CI 
6.0*10-6 to 1.3*10-5, n=3; Fig 6B). In addition, in whole blood, the disappearance of 
adenosine was only inhibited significantly by the highest concentration of ticagrelor 
used (10-4 M) (n=2; Fig 6C).
Figure 5   Ex vivo uptake of adenosine (A) and uridine (B) in red blood cells isolated 
from the subjects before (pre-tica) and two hours after intake of ticagrelor 
(post-tica).
In A, the adenosine concentration in the supernatant is expressed as the percentage of the 
baseline adenosine concentration (n= 13; P >0.1). In B, the uridine uptake is expressed for each 
individual subjects before and after intake of ticagrelor (n=13, P=0.056 for comparison between 
before and after).
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Discussion & conclusions
The main finding of our study is that in healthy subjects a single dose of 180 mg of 
ticagrelor does not potentiate the forearm vasodilator response to adenosine, nor 
post-occlusive reactive hyperemia and dipyridamole-induced vasodilation. In addition, 
we observed no significant ex vivo nucleoside uptake inhibition in isolated red blood 
cells in these subjects after oral treatment with ticagrelor. These in vivo and ex vivo 
findings are consistent with additional in vitro studies in isolated red blood cells 
demonstrating that ticagrelor only inhibits nucleoside transport in concentrations that 
Figure 6   Forearm blood flow measurements.
FBF values in the experimental forearm (triangle) and non-experimental forearm (circle) after 
ticagrelor treatment (black symbols) or placebo treatment (open symbols, dashed line) during 
intrabrachial administration of adenosine (A), after five (B) and two (C) minutes of forearm ischemia, 
and during intrabrachial administration of dipyridamole (D). P-values represent the effect of 
ticagrelor on the FBF-values.
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are considerably higher than those obtained after normal dosing. Together, our findings 
argue against a role for increased adenosine receptor stimulation as a relevant pleio - 
tropic effect of ticagrelor.
In the last few years, several papers suggest that ticagrelor increases the extracellular 
concentration of endogenous adenosine and it is speculated that this contributes to 
the effects of ticagrelor that are observed in clinical studies that cannot easily be 
explained by platelet aggregation inhibition, including reduced mortality, dyspnea, 
ventricular pauses, limitation of myocardial infarct size, and effects on inflammation.3, 
20 Adenosine induces various effects by stimulation of membrane-bound adenosine 
receptors, including direct vasodilation, platelet aggregation inhibition, modulation of 
sympathetic nervous system activity, modulation of inflammation, and limitation of 
(myocardial) ischemia and reperfusion injury.4, 5 In addition, the intravenous administration 
of adenosine has negative dromotropic effects on the heart, and induces a sensation 
of dyspnea.5, 6
Previous in vitro studies have demonstrated two different effects of ticagrelor on adenosine 
metabolism: first, ticagrelor augments the release of adenosine triphosphate (ATP), 
which acts as a precursor for extracellular adenosine formation, from isolated red 
blood cells, with an IC50 value of 14 µM 21. Secondly, ticagrelor inhibits adenosine 
uptake via the ENT with a reported IC50 value of 100-260 nmol/l.22, 23 It needs to be 
emphasized, however, that these experiments were performed in isolated cells without 
plasma. Given the > 99% plasma protein binding of ticagrelor in human blood, these 
IC50 values cannot easily be compared to the whole blood tica - grelor concentration 
of 0.5-1.5 µM observed during normal dosing in patients. Ticagrelor does not have a direct 
effect on adenosine receptors itself, does not affect the breakdown of adenosine by 
adenosine deaminase, nor is it converted into adenosine.19
Our experiment was designed to investigate both the effect of ticagrelor on adenosine 
uptake as well as the effect of ticagrelor on extracellular adenosine formation (e.g. by 
increased ATP release). Direct measurement of the extracellular adenosine 
concentration is technically highly demanding given the extremely short half-life of 
adenosine and there is great controversy about the normal extracellular concentration 
in human plasma.24 Therefore, we used well-validated surrogates of extracellular 
adenosine formation and uptake. In the absence of any effects of ticagrelor on 
adenosine receptors or adenosine degradation, the vasodilator response to the 
intrabrachial administration of adenosine is a well-validated surrogate of adenosine 
transporter function, as we have previously described.9, 10 We also studied PORH 
because this is mediated, at least in part, by an increased endogenous formation of 
adenosine.8 Dipyridamole is a potent hENT1 blocker and increases the extracellular 
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adenosine concentration at a rate proportional to the extracellular formation of 
adenosine, as demonstrated previously.12 We did not observe an effect of ticagrelor 
on any of these stimuli, demonstrating that there is no relevant increase in extracellular 
adenosine formation and adenosine transport. Nonspecific effects of ticagrelor on 
vascular reactivity were ruled out using acetylcholine-induced vasodilation. 
Consistent with these in vivo findings, there was no significant inhibition of ex vivo 
adenosine uptake in red blood cells, isolated before and after ticagrelor-intake. 
Uridine uptake was inhibited with 11%, but this did not reach statistical significance 
(P=0.056). For the interpretation of these results, it is important to realize that after 
facilitated diffusion via the ENT, adenosine is rapidly metabolized, and that intracellular 
deamination of adenosine is rate limiting for adenosine uptake rather than ENT 
activity.25 Only after pharmacological inhibition of >80% of ENT activity, the ENT 
transporter becomes rate limiting, and adenosine uptake is reduced.25 As such, 11% 
ENT inhibition will not have any effect on extracellular adenosine concentration. 
Indeed, also in whole blood experiments, ticagrelor did not affect adenosine 
disappearance at relevant concentrations.
The results of our series of experiments contradict previous studies. In vitro Van 
Giezen et al reported in a canine model that ticagrelor augmented adenosine-in-
duced vasodilation in the coronary artery.22 However, this effect was observed only 
at a ticagrelor plasma concentration of 13.4 µM and not with the lower concentration 
of 4.1 µM, which is still considerably higher than the plasma concentration in patients 
treated with ticagrelor. In contrast, in another in vitro study, the addition of 1 µM of 
ticagrelor to whole blood resulted in a slightly but significantly higher adenosine 
concentration 1 minute after the addition of 7.1 µM of adenosine.26 In healthy subjects 
in vivo Wittfeldt et al showed that a single dose of 180 mg of ticagrelor augmented the 
coronary blood flow velocity after intravenous adenosine infusion, which was 
prevented by concomitant administration of the adenosine receptor antagonist 
theophylline.27 Similar results were obtained by Alexopoulos et al in patients with a 
recent non-ST-elevation acute coronary syndrome.28 The route of administration in 
these studies is the major and important difference with our study: in our model 
adenosine is administered into the brachial artery, resulting in a high local arterial 
adenosine concentration, but without any systemic effects. Intravenous administration 
of adenosine, however, induces major systemic hemodynamic effects consisting of 
increased systolic blood pressure and heart rate and decrease of diastolic blood 
pressure by the combination of a direct vasodilator effect and a pronounced activation 
of sympathetic nervous system activity by stimulation of peripheral chemoreceptors.29 
Therefore, the coronary blood flow response in the Wittfeldt and Alexopoulos papers 
is driven by different effects, whereas adenosine-induced vasodilation in our study 
was not confounded by systemic hemodynamic and nervous effects. Finally, the 
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plasma concentration of ticagrelor in the study by Wittfeldt et al was slightly higher 
than in our study, despite the fact that in both studies the plasma concentration was 
determined 2 hours after intake of 180 mg ticagrelor in healthy subjects. Bonello et al 
measured plasma adenosine concentration in patients with an acute coronary 
syndrome who were randomized to either ticagrelor or clopidogrel at a time point of 
6 hours after the loading dose.19 They observed a significantly higher adenosine 
concentration in the patients treated with ticagrelor, and they observed a significant 
inhibition of ex vivo adenosine uptake in whole blood. It is likely that in the patients in 
this study, just as in the study by Alexopoulos et al, the adenosine metabolism is 
affected by the myocardial ischemia, the profound activation of the sympathetic 
nervous system by the coronary event, and by the comedication (e.g. statins that will 
increase the extracellular formation of adenosine by activation of the ecto-5’-nucleo-
tidase12, 15). In addition, the pharmacological blocking solution that is used to 
completely block adenosine metabolism in the ex vivo whole blood experiments 
differs from the solution that we previously have validated to result in an almost 
complete recovery of adenosine.24 The inconsistent results of our study and the 
Bonello study might be caused, at least in part, by these differences.
Study limitations
Our study has several potential limitations. First, our experiments were performed in 
healthy subjects without cardiovascular disease and without concomitant cardio-
vascular drugs, such as in the study by Bonello et al.19 Therefore, the results of our 
study do not exclude any effect of ticagrelor on the adenosine system in patients with 
acute coronary events. Secondly, we investigated adenosine formation and uptake 
in the forearm, in contrast to the coronary circulation that was studied by Wittfeldt 
et al.27 However, ENT is not known to differ between heart and forearm and therefore 
we believe that extrapolation from forearm to heart is valid for this particular research 
question.  
Conclusions
Ticagrelor dose-dependently inhibits nucleoside transporter activity in isolated red 
blood cells of healthy volunteers. However, the plasma concentration of ticagrelor 
after normal dosing in humans is too low to result in a significant increase in 
extracellular adenosine and adenosine receptor stimulation via this mechanism. In 
addition, the lack of any effect of ticagrelor on dipyridamole-induced vasodilation 
suggests that ticagrelor does not augment endogenous extracellular adenosine 
formation. Our findings, therefore, argue against a role these mechanisms as an 
explanation for the effects of ticagrelor, including lower mortality, dyspnea, ventricular 
pauses, and modulation of inflammation, as observed in recent clinical studies. 
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Ischemic preconditioning and pharmacological preconditioning are powerful tools to 
reduce ischemia-reperfusion injury. Extensive research has been done in this field 
and promising results have been reported in different organs (e.g. the myocardium, 
brain and kidneys). Most of these results are based on animal experiments. In this 
thesis we have tried to translate these findings to the human in vivo setting. From the 
basic assumption that the adenosine pathway plays a crucial role in the cardioprotec-
tive effect of ischemic preconditioning, we investigated the effect of three different 
drugs that (might) target this pathway and that are already used in common clinical 
practise: metformin, dipyridamole and ticagrelor.  
First, in an effort to develop a novel model of IR injury in humans, in chapter 2 we 
explored whether strenuous exercise could be used to induce mild myocardial IR 
injury, detected by a rise in the plasma hs-troponin I concentration. We aimed to 
validate this model using remote ischemic preconditioning (RIPC). RIPC is a powerful 
strategy to limit IR-injury and therefore we expected RIPC to prevent post-exercise 
hs-troponin release. In a randomized controlled cross-over study in healthy volunteers, 
we studied the effect of RIPC on exercise-induced troponin I release. Although 
exercise indeed resulted in a temporary rise in troponin I, RIPC could not prevent or 
reduce this increase. Therefore, we argued that IR does not importantly contribute to 
this rise in troponin. Strenuous exercise, therefore, is not a valid model to study 
myocardial IR-injury.
In chapter 3 we gave a more detailed introduction of the cardioprotective effects of 
the glucose lowering drug metformin. Large observational clinical trials reported that 
metformin has a positive effect on cardiovascular morbidity and mortality independent 
of glycemic control. In animal studies, metformin not only might affect cardiovascular 
risk factors for the development of atherosclerosis (e.g. lipid profile, bodyweight, 
blood pressure), but animal research has also revealed a direct cardio-protective 
effect via activation of the RISK pathway, AMPK and the adenosine pathway. Animal 
models (in both diabetic as well as non-diabetic animals) have provided consistent 
evidence that metformin can limit myocardial IR-injury. Based on these data, 
metformin would  be an attractive candidate to limit myocardial IR injury in the clinical 
setting. 
In chapter 4 we performed the first human in vivo study investigating the effect of 
short-term pre-treatment with metformin on endothelial IR-injury. As a model we used 
flow mediated dilation of the brachial artery before and after prolonged ischemia and 
reperfusion of the forearm. The IR protocol significantly reduced FMD, but this was 
not prevented by metformin treatment.
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The results of chapter 4, however, do not exclude a beneficial effect of metformin on 
myocardial IR-injury in the clinical setting for several reasons. First, the mechanism of 
endothelial IR-injury might differ from IR-injury in cardiomyocytes. In addition, our 
findings in the brachial artery might not be representative for the coronary circulation. 
Finally, the study presented in chapter 4 involved young healthy subjects, which differ 
substantially from the older patients with coronary artery disease. Therefore we 
readdressed our hypothesis in chapter 5 in a prospective randomised clinical trial 
among non-diabetic patients undergoing elective coronary artery bypass surgery. 
We investigated whether metformin was able to reduce IR-injury associated with on 
pump heart surgery. We recruited 100 patients who were randomised between 
pre-treatment with metformin or placebo and measured post-operative hs-troponin I 
release as a measure of post-surgery myocardial damage. Secondary endpoints 
included the postoperative occurrence of arrhythmias, the need for inotropic support, 
time to detubation and ICU length of stay. Another secondary outcome was ex-vivo 
post-ischemic recovery of contractile function of isolated atrial trabeculae. In addition, 
we explored ex-vivo the activation of cardioprotective signaling pathways in isolated 
right atrial tissue. Our results showed that metformin did not limit IR-injury, detected 
with post-surgical plasma hs-troponin I release. Nor was there any effect on the 
secondary clinical endpoints. In accordance with these clinical endpoints, metformin 
did not improve the ex vivo post-ischemic recovery of contractile function in isolated 
atrial trabeculae. In our study we confirmed activation of AMPK and the RISK-pathway 
in atrial tissue, but to a smaller extent than in murine models. We concluded that the 
mild activation of AMPK and Akt by metformin was not sufficient to offer significant 
cardioprotection.
An alternative pharmacological agent to reduce IR-injury is dipyridamole. Dipyridamole 
augments the endogenous interstitial adenosine concentration by inhibiting the 
equilibrative nucleoside transporter (ENT). In preclinical  animal studies, and studies 
in healthy volunteers and in  patients undergoing coronary angioplasty (PCI), dipyridamole 
limits IR-injury.1-8 In chapter 6 we describe the results of a second randomised 
clinical trial that we have designed to test the hypothesis that oral pre-treatment with 
dipyridamole prevents IR-injury in patients who undergo elective CABG.  79 patients 
were included in the analysis that showed that dipyridamole did not limit myocardial 
IR-injury, as measured by post-operative hs-troponin I release. Also, there was no 
effect on the occurrence of post-operative arrhythmias, the need for inotropic support 
or the duration of ICU stay (secondary endpoints).
With adenosine as a key element in the modulation of IR-injury, the novel P2Y12 
receptor blocker ticagrelor presents a potential alternative strategy to influence 
myocardial damage caused by ischemia and reperfusion. In the PLatelet inhibition 
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And paTient Outcomes (PLATO) study ticagrelor reduced death from vascular 
causes, myocardial infarction or stroke compared to clopidogrel.9 In the past years, 
evidence has accumulated that ticagrelor inhibits the cellular uptake of the 
endogenous nucleoside adenosine by blockade of the ENT and this mechanism has 
been proposed to contribute to the benefits of ticagrelor observed in the PLATO 
study.10 Most of the evidence on the effect of ticagrelor on adenosine metabolism is 
based on in vitro studies, or from studies in patients in which the adenosine 
metabolism could be affected by other factors, such as co-medication. In chapter 7 
we aimed to test whether ticagrelor inhibits the ENT transporter in humans in vivo 
in relevant concentrations in a randomised placebo-controlled cross-over trial in 
14 healthy male volunteers. We tested whether ticagrelor affects adenosine- and 
dipyridamole-induced forearm vasodilation measured by venous occlusion plethys-
mography. Adenosine- and dipyridamole-induced vasodilation is used as pharma-
cological tool to study adenosine uptake and extracellular adenosine formation, 
respectively. Change in forearm blood flow represent adenosine receptor activation. 
Finally, ex vivo uptake of adenosine and uridine in isolated red blood cells was 
measured. The main finding of our study was that a single dose of ticagrelor does not 
potentiate the forearm vasodilator response to adenosine and dipyridamole. 
In addition, there was no significant ex vivo nucleoside uptake inhibition observed 
in isolated red blood cells in these subjects after oral treatment with ticagrelor. These 
in vivo and ex vivo findings were consistent with additional in vitro studies in isolated 
red blood cells demonstrating that ticagrelor only inhibits nucleoside transport in 
concentrations that are considerably higher than those obtained after normal dosing. 
Altogether, our findings argue against a role for increased adenosine receptor 
stimulation as an explanation for the pleiotroptic effects of ticagrelor
Future perspectives and conclusions
Now that rapid reperfusion of the occluded artery in patients with an acute myocardial 
infarction is obtained in most patients, further efforts to improve tissue salvage after 
an ischemic event are based on limiting IR-injury. Animal data show profound benefit 
of (pharmacological) conditioning to limit IR-injury. Translation of these promising 
preclinical findings to the clinical setting appears to be notoriously difficult. There are 
many examples of this translation gap in the recent literature. Van den Worp et al. 
reported that in animal models of acute ischemic stroke, 500 ‘neuroprotective’ 
strategies are effective in limiting infarct size, but only two of these are effective in 
humans.11 With regard to metformin, preclinical studies report that metformin can 
reduce atherosclerosis, myocardial infarct size, and improve post-infarction 
remodeling in animal models. In the last two years, however, three randomized 
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clinical trials (including our MetCAB trial) demonstrated no relevant clinical benefit of 
metformin treatment on atherosclerosis, IR injury, nor post-infarction remodeling.12-14
The findings in this thesis are coherent with this phenomenon. There are several 
potential explanations for this discrepancy between preclinical and (our) clinical trial 
results. In general, failure of translation of promising preclinical findings to the clinical 
setting might be explained by methodological flaws in animal studies, e.g. lack of 
randomisation, lack of blinding, the lack of a formal sample size calculation and 
inadequate statistical analyses.15, 16 Furthermore, translational failure can be caused 
by fundamental differences in biology and pathophysiology between laboratory animals 
and the patients for whom the treatment is intended. In addition, animal studies are 
predominantly performed in young and otherwise healthy animals. In contrast, cardio - 
vascular patients are older, and have co-morbidities and co-medication, which can 
all interfere with cardioprotection.17 An older age is associated with an impaired 
 cardioprotective effect of preconditioning.17, 18 Nowadays almost all cardiovascular 
patients, also the patients in our trials, use co-medication such as statins, nitrates 
and antiplatelet agents which offer cardioprotective effects themselves and limit 
potential additional value of novel agents.17, 19 Finally, it is essential that the endpoint 
used in clinical trials resembles the preclinical experimental design. In the field of 
IR-injury, the vast majority of preclinical data concerns histological infarct size 
reduction with ischemic conditioning. Primary determinants of infarct size, such as 
area at risk and duration of the ischemic stimulus are well-controlled in the preclinical 
setting. Assessment of these relevant factors is more difficult in the clinical setting. In 
our thesis, we have used the setting of coronary artery bypass surgery as a model for 
the occurrence of ischemia reperfusion injury and we have determined post-operative 
hs-troponin I as a marker for IR-injury. The mechanism of troponin release in CABG 
might however differ from acute myocardial infarction. Where in acute myocardial 
infarction troponin release is inherently related to oxygen demand and supply 
mismatch, in CABG other mechanisms of injury such as direct trauma from surgical 
manipulation, intracoronary embolization and inflammation might affect plasma 
troponin concentrations.20 Another complicating factor of the CABG-model, is that 
peri-operative use of anesthesia could also affect the results: propofol anesthesia 
can disrupt protection by ischemic preconditioning, while sufentanil and opioids have 
cardioprotective effects themselves thus may provide limited scope for added 
benefit. Indeed, although initial proof-of-concept studies on remote ischemic precon-
ditioning in patients undergoing CABG showed promising results21, 22, more recent 
large multicenter RCT’s could confirm relevant protective effects of RIPC. Recently, 
the results of the Effect of Remote Ischemic Preconditioning on Clinical Outcomes in 
Coronary Artery Bypass Grafting Surgery (ERRICA) multicenter trial were published: 
not only the largest study up to now in the field of myocardial ischemia reperfusion 
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injury and the effect of RIPC in the setting of CABG, but also the first study to report 
on hard clinical endpoints.23 The study included 1612 patients undergoing CABG 
surgery. Half of the patients were randomly selected to undergo RIPC induced by four 
5-minute inflations and deflations of a standard blood pressure cuff while the other 
half underwent a sham procedure. Although the study did reveal a statistically 
significant reduction in post-operative hs-troponin by about 10% in the RIPC group, 
at 1 year there was no difference in the primary endpoint of MACCE (cardiovascular 
death, MI, stroke, and coronary revascularization) or any of its individual outcomes 
between the study and control groups. In the same issue of the New England Journal 
of Medicine, Meybohm et al reported that in 1403 patients undergoing CABG surgery, 
upper-limb RIPC performed while patients were under propofol-induced anesthesia 
did not show a relevant benefit among patients undergoing elective cardiac surgery.24 
In combination with the above mentioned pitfalls of the CABG-model, these 
disappointing results of RIPC and pharmacological precondition on long-term clinical 
endpoints in the setting of CABG, seem to close the curtain for clinical application of 
preconditioning in this specific arena of cardiac surgery. In the clinical setting of an 
acute myocardial infarction, but also in the field of transplantation medicine, the 
concept of preconditioning, however, is still very promising. At this moment a number 
of large clinical trials are being conducted to further explore the effect of (pharmaco-
logical) conditioning on hard clinical endpoints in the setting of an ST-elevation 
myocardial infarction.25-27 The results of these studies will determine future perspectives 
and value of preconditioning-based strategies to prevent reperfusion injury.
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Ischemische en farmacologische preconditionering zijn krachtige manieren om de 
schade die aan de hartspier ontstaat tijdens ischemie en het herstel van bloedtoevoer 
(ischemie-reperfusieschade), te verminderen. Verschillende onderzoeken op dit gebied 
(bijvoorbeeld in de hartspier, het brein en de nieren) hebben veelbelovende resultaten 
laten zien. De meeste van deze bevindingen zijn echter gebaseerd op dierexperimentele 
modellen. In dit proefschrift hebben wij geprobeerd deze bevindingen uit dierexperi-
mentele modellen te vertalen naar de humane in vivo situatie. Het is bekend dat het 
beschermende effect van ischemische preconditionering voor een belangrijk deel 
loopt via adenosinereceptorstimulatie door endogeen adenosine. Daarom hebben 
wij in dit proefschrift drie geneesmiddelen onderzocht die een effect hebben op 
endogeen adenosine: metformine, dipyridamol en ticagrelor. 
In hoofdstuk 2 hebben wij een nieuw humaan model onderzocht voor het nabootsen 
van ischemie-reperfusieschade. Door mensen bloot te stellen aan intensieve fysieke 
inspanning werd geprobeerd milde myocardiale ischemie-reperfusieschade te induceren. 
Als maat voor deze schade werd de high-sensitive troponine I concentratie in het 
bloed gemeten. Ter validatie van dit model hebben wij gebruik gemaakt van Remote 
Ischemic Preconditioning (RIPC, ischemische preconditionering op afstand). RIPC is 
een bewezen effectieve manier om ischemie-reperfusieschade te verminderen en de 
verwachting was dan ook dat indien er ischemie-reperfusieschade op zou treden in 
dit model, RIPC deze schade zou verminderen dit zich zou vertalen in lagere high- 
sensitive troponine plasma spiegels na inspanning. In tegenstelling tot onze verwachting 
steeg het high-sensitive tropine I wel na intensieve inspanning,  maar werd deze 
stijging niet beïnvloed door RIPC. Wij concludeerden dan ook dat dit protocol van 
intensieve inspanning geen goed model is om myocardiale ischemie-reperfusie-
schade te onderzoeken. 
In hoofdstuk 3 geven wij een gedetailleerd overzicht van de cardioprotectieve 
effecten van het glucoseverlagende medicijn metformine. Grote observationele 
studies hebben aangetoond dat metformine een gunstig effect heeft op de cardio-
vasculaire morbiditeit en mortaliteit van patiënten met diabetes mellitus type 2. Dit 
effect lijkt onafhankelijk van het effect van dit geneesmiddel op de glucoseregulatie. 
In dierexperimentele studies is aangetoond dat metformine niet enkel een invloed 
heeft op klassieke cardiovasculaire risicofactoren voor het ontwikkelen van athero-
sclerose (zoals bijvoorbeeld het lipidenprofiel, het lichaamsgewicht en de bloeddruk), 
maar dat er ook sprake is van een direct cardioprotectief effect via activatie van 
diverse cardioprotectieve signaaltransductieroutes, zoals de RISK-pathway, de 
AMPK- en de adenosine-pathway. Dierexperimentele studies (in zowel dieren met 
diabetes als zonder diabetes) hebben daarbij consistent aangetoond dat metformine 
myocardiale ischemie-reperfusieschade kan verminderen. Metformine is daarmee 
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een aantrekkelijke kandidaat om ook in patiënten myocardiale ischemie-reperfusie-
schade te verminderen.
In hoofdstuk 4 beschrijven wij de resultaten van de eerste humane in vivo studie met 
metformine, waarbij het effect van kortdurende voorbehandeling met metformine op 
endotheliale ischemie-reperfusieschade is onderzocht bij gezonde vrijwilligers. Als 
model voor ischemie-reperfusieschade is gebruik gemaakt van flow-gemedieerde 
dilatatie (FMD) van de arteria brachialis. FMD is gemeten voorafgaand aan en na een 
periode van langdurige ischemie en reperfusie van de onderarm, waarbij de proef -
personen al dan niet waren voorbehandeld met metformine. Ischemie-reperfusie 
zorgde voor een significante afname van de FMD, maar deze afname werd niet 
voorkomen door voorbehandeling met metformine.  
Dat wij in hoofdstuk 4 geen effect zagen van metformine op de endotheliale ischemie- 
reperfusieschade, hoeft niet meteen te betekenen dat er ook geen gunstige effecten 
van metformine te verwachten zijn op ischemie-reperfusieschade in het hart van 
patiënten. Het zou namelijk zo kunnen zijn dat het mechanisme van endotheliale 
ischemie-reperfusieschade anders is dan dat van myocardcellen. Verder zou het 
kunnen zijn dat onze bevindingen in de arteria brachialis niet representatief zijn voor 
de coronaire circulatie.  Daarbij hebben wij onze studie zoals beschreven in hoofdstuk 4 
uitgevoerd in jonge gezonde vrijwilligers, een studiepopulatie die op veel punten 
verschilt van de veelal oudere patiënten met coronaire hartziekte. Om deze redenen 
hebben wij in hoofdstuk 5 onze hypothese opnieuw getoetst in een prospectieve 
gerandomiseerde klinische trial, uitgevoerd in patiënten (zonder diabetes mellitus) 
die een electieve coronary artery bypass grafting (CABG; bypassoperatie) zouden 
ondergaan. Wij onderzochten bij deze patiënten het effect van voorbehandeling met 
metformine op ischemie-reperfusieschade die optreedt tijdens de uitvoer van 
on-pump open hartoperatie. Wij includeerden 100 patiënten en randomiseerden 
deze naar voorbehandeling met metformine of met placebo. Als maat voor ischemie- 
reperfusieschade hebben wij hs-troponine I concentraties gemeten op verschillende 
tijdstippen na het verwijderen van de klem op de aorta. Secundaire eindpunten waren 
het optreden van ritmestoornissen na de operatie, de noodzaak voor inotropische 
ondersteuning, tijd tot detubatie en duur van de opname op de intensive care. Bij alle 
patiënten werd tevens een klein stukje atriaal weefsel weggehaald tijdens de operatie 
dat wij in het laboratorium hebben onderzocht. Dit weefsel hebben we gebruikt om 
ex-vivo post-ischemisch herstel van de contractiliteit van geïsoleerde atriale trabeculae 
te meten. Daarnaast hebben wij ex-vivo ook de activatie van verschillende cardio-
protectieve signaaltransductieroutes in geïsoleerde trabeculae onderzocht. Onze 
resultaten toonden aan dat metformine geen effect had op de postoperatieve hs- 
troponineconcentratie in plasma, noch op de klinische secundaire uitkomstmaten. 
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In lijn met deze bevindingen, werd er ook geen effect van metformine op het ex-vivo 
post-ischemische herstel van de contractiliteit van geïsoleerde atriale trabeculae 
gevonden. In onze analyse zagen wij wel dat er sprake was van activatie van AMPK 
en van de RISK-pathway in atriaal weefsel, maar in een veel mindere mate dan in 
dierexperimentele modellen is beschreven. Wij concluderen dat de milde activatie 
van AMPK en Akt door metformine niet voldoende is geweest om te leiden tot 
(klinisch) relevante cardioprotectie. 
Een andere mogelijkheid om farmacologisch ischemie-reperfusieschade te kunnen 
reduceren is het middel dipyridamol. Dipyridamol verhoogt de endogene interstitiële 
adenosineconcentratie door de equilibrative nucleoside transporter (ENT) te remmen. 
In preklinische dierstudies, studies bij gezonde vrijwilligers en bij patiënten die een 
percutane coronaire angioplastiek (PCI) ondergaan, is aangetoond dat dipyridamol 
ischemie-reperfusiesschade vermindert.1-8 In hoofdstuk 6 beschrijven wij de 
resultaten van een tweede gerandomiseerde klinische trial bij patiënten die een 
electieve CABG ondergaan die wij hebben ontworpen om te onderzoeken of voor-
behandeling met dipyridamol ischemie-reperfusieschade kan verminderen. In deze 
studie werden 79 patiënten geïncludeerd en gerandomiseerd naar voorbehandeling 
met dipyridamol of placebo. Ook dipyridamol had bij deze patiënten geen effect op 
de myocardiale ischemie-reperfusieschade (gekwantificeerd door middel van 
postoperatieve hs-troponine I concentraties). Ook was er geen effect op het 
voorkomen van post-operatieve ritmestoornissen, de noodzaak voor inotropie of de 
duur van opname op de intensive care (secundaire eindpunten). 
Uitgaande van de centrale rol die adenosine speelt in de modulatie van ischemie 
reperfusieschade, biedt de (relatief nieuwe) P2Y12 receptorblokker ticagrelor potentieel 
nieuwe mogelijkheden om myocardiale ischemie reperfusieschade te beïnvloeden. 
De PLatelet inhibition And paTient Outcomes (PLATO) studie toont dat behandeling 
met ticagrelor in vergelijking met clopidogrel een reductie geeft van cardiovasculaire 
mortaliteit, het optreden van myocardinfarcten of ischemische cerebro vasculaire 
accidenten bij patiënten met een acuut coronair syndroom.9 Dit effect was groter dan 
redelijkerwijs alleen kon worden toegewezen aan het plaatjes remmende effect. De 
afgelopen jaren is er steeds meer bewijs gekomen dat ticagrelor mogelijk ook de 
cellulaire opname van endogeen adenosine vermindert door inhibitie van de ENT, 
waardoor er meer extracellulair adenosine beschikbaar is om te binden aan de 
adenosinereceptor. Dit fenomeen wordt nu aangedragen als potentiële verklaring 
van de extra gunstige effecten van ticagrelor in de PLATO studie.10 Het bewijs dat 
ticagrelor een effect heeft op het metabolisme van adenosine is grotendeels 
gebaseerd op in vitro studies of op studies in patiënten waarbij het adenosinemeta-
bolisme ook beïnvloed zou kunnen zijn door andere factoren, zoals co-medicatie. 
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In hoofdstuk 7 hebben wij onderzocht of ticagrelor daadwerkelijk de ENT transporter 
blokkeert in 14 mannelijke gezonde vrijwilligers, in een gerandomiseerde placebo 
gecontroleerde cross-over studie. Wij hebben daarbij onderzocht of ticagrelor een 
effect heeft op adenosine- en dipyridamol-geïnduceerde vasodilatatie in de onderarm, 
gemeten met behulp van veneuze occlusie plethysmografie. Wij hebben adenosine- en 
dipyridamol-geïnduceerde vasodilatatie als parameters gebruikt om respectievelijk 
cellulaire adenosine-opname en extracellulaire adenosine vorming te bestuderen. 
Daarbij is de mate van toename van de onderarmsdoorbloeding een maat voor 
activatie van de adenosinereceptor. Wij hebben ook ex vivo de opname van adenosine 
en uridine gemeten in geïsoleerde rode bloedcellen. De hoofdbevinding van onze 
studie was dat een enkele gift ticagrelor niet leidt tot een toename van de vasodilatatie 
van de onderarmsbloedvaten in respons op adenosine en dipyridamol. Ook leidt 
voorbehandeling met ticagrelor niet tot een significante inhibitie van opname van 
adenosine in geïsoleerde rode bloedcellen. Deze in vivo en ex vivo bevindingen 
waren in overeenstemming met aanvullende in vitro onderzoeken in geïsoleerde rode 
bloedcellen die aantoonden dat ticagrelor enkel de nucleosidetransporter remt in 
concentraties die veel hoger zijn dan de concentraties die verkregen worden tijdens 
normaal klinisch gebruik bij patiënten. Al met al pleiten onze bevindingen tegen de 
hypothese dat de pleiotrope effecten van ticagrelor in de klinische setting verklaard 
kunnen worden door een toename in adenosinereceptorstimulatie. 
Toekomstperspectieven en conclusies
Op dit moment bestaat de behandeling van patiënten met een acuut myocardinfarct 
uit het zo snel mogelijk openen van de afgesloten kransslagader op de catheterisa-
tiekamer. Ondanks deze behandeling is de mortaliteit en morbiditeit (het optreden 
van hartfalen) aanzienlijk. De schade die ontstaat ten gevolge van het openen van 
het vat (ischemie-reperfusieschade) speelt daar een rol in. Het is daarom belangrijk 
om te proberen de ischemie-reperfusieschade van het myocard verder te 
verminderen. Dierexperimentele studies toonden duidelijk hoopvolle effecten van 
(farmacologische) preconditionering. De resultaten van deze veelbelovende 
preklinische studies laten zich echter niet zo makkelijk vertalen naar de klinische 
(humane) setting. Deze ‘translatiekloof’ is niet ongewoon in de  literatuur. Zo beschreef 
Van den Worp et al dat in dierexperimentele modellen van een acuut herseninfarct 
zich in totaal 500 ‘neuroprotectieve’ strategieën bewezen hebben in het effectief 
reduceren van infarctgrootte, maar dat slechts 2 van deze strategieën uiteindelijk 
effectief zijn gebleken in de klinische humane setting.11 
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Ook wij zien een soortgelijk fenomeen. Ten aanzien van metformine zijn er veel 
preklinische studies die aantonen dat metformine een gunstig effect heeft op 
atherosclerose, op hartinfarctgrootte en op post-infarct remodeling. Recent daaren - 
tegen zijn er drie gerandomiseerde klinische studies verricht (inclusief onze eigen 
MetCAB studie), die geen gunstig effect van metformine laten zien op atherosclerose, 
ischemie-reperfusieschade of op postinfarct remodeling in patiënten.12-14 
Ook in dit proefschrift is het herhaaldelijk niet gelukt om veelbelovende preklinische 
bevindingen te vertalen naar de klinische praktijk. Er zijn verschillende mogelijke 
verklaringen voor deze discrepantie tussen preklinische bevindingen en (onze) 
klinische resultaten. Een eerste mogelijke verklaring betreft een probleem met de 
interne validiteit: namelijk de methodologische beperkingen van dierstudies. Zo is er 
in dierstudies vaak geen sprake van randomisatie tussen de verschillende behandel-
armen, is er vaak geen blindering van de onderzoeker voor de behandeling, worden 
er zelden sample size calculaties uitgevoerd en kan er sprake zijn van onjuiste 
statistische analyses.15, 16 Een andere verklaring betreft een beperkte externe 
validiteit: het falen van vertalen van bevindingen vanuit de preklinische studies naar 
de klinische praktijk kan ook verklaard worden door fundamentele verschillen in 
biologie en pathofysiologie tussen (laboratorium)dieren en de patiënten voor wie de 
therapie uiteindelijk bedoeld is. Daarbij is het zo dat dierexperimentele studies veelal 
worden uitgevoerd in jonge, gezonde dieren.  Patiënten met hart- en vaatziekten 
daarentegen zijn veelal ouder en hebben vaak ook veel co-morbiditeit en gebruiken 
diverse medicijnen. Al deze factoren kunnen invloed kunnen hebben op de effectiviteit 
van cardioprotectieve interventies.17 Oudere leeftijd is geassocieerd met een verminderd 
cardioprotectief effect van precondionering.17, 18 Tegenwoordig gebruiken vrijwel alle 
patiënten met hart- en vaatziekten, ook de patiënten in onze studies, medicatie, zoals 
statines en trombocytenaggregatieremmers die zelf ook al kunnen beschermen 
tegen ischemie-reperfusieschade en zo potentieel minder ruimte laten voor additionele 
bescherming door ischemische of farmacologische preconditionering.17, 19 Ten slotte 
is het essentieel dat de eindpunten die gebruikt worden in de klinische trials ook 
overeenkomen met het design van de preklinische experimenten. Op het gebied van 
ischemie-reperfusieschade betreft het in het merendeel van de dierstudies reductie 
van histologisch bepaalde infarctgrootte door middel van ischemische preconditio-
nering. Eindpunten zoals infarctgrootte, area at risk en duur van de ischemische 
stimulus zijn uitermate gecontroleerd in de preklinische experimenten. In de klinische 
praktijk daarentegen is het meten van dit soort eindpunten zeer moeilijk of niet 
mogelijk. In dit proefschrift is het ondergaan van een electieve CABG (hartoperatie) 
als model gesteld voor het optreden van ischemie-reperfusieschade. Als maat voor 
de opgetreden ischemie-reperfusieschade en daarmee primair eindpunt, is gekozen 
voor de plasmaconcentratie (verandering) van hs-troponine. De vraag rijst of het 
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mechanisme dat ten grondslag ligt aan de troponine-afgifte rondom een CABG gelijk 
is aan de situatie tijdens een acuut hartinfarct. Tijdens het acute hartinfarct is de 
(verhoogde) afgifte van hs-troponine (enkel) het gevolg van celverval door een 
mismatch tussen zuurstofbehoefte en aanbod. Rond een CABG kunnen ook andere 
mechanismes een rol spelen, zoals schade veroorzaakt  door chirurgische manipulatie, 
het optreden van intracoronaire embolisatie en het ontstaan van een ontstekings-
reactie. Al deze elementen kunnen een direct effect hebben op de afgifte van 
troponine.20 Een andere complicerende factor van het CABG model is dat er rondom 
een dergelijke operatie gebruik wordt gemaakt van diverse anesthetica, middelen die 
op hun beurt ook een effect kunnen hebben op de resultaten: propofol kan het 
protectieve effect van preconditonering tegengaan, terwijl sufentanyl en opiaten zelf 
ook een cardioprotectief effect kunnen hebben, waardoor er wellicht weinig ruimte 
overblijft voor een additioneel gunstig effect van de door ons gebruikte medicamenten. 
In het verleden hebben verschillende studies met ischemische preconditionering op 
afstand bij patiënten die een CABG ondergingen veelbelovende resultaten laten 
zien.21, 22 Recent zijn de resultaten van de  ‘Effect of Remote Ischemic Preconditioning 
on Clinical Outcomes in Coronary Artery Bypass Grafting surgery’ (ERRICA) multicenter 
trial gepubliceerd: niet alleen de grootste studie tot nu toe op het gebied van RIPC 
bij patiënten die een CABG ondergaan, maar ook de eerste studie die effect van 
RIPC onderzocht opharde klinische eindpunten.23 In deze studie zijn in totaal 1612 
patiënten geïncludeerd die een CABG zouden ondergaan. De helft van de patiënten 
werd gerandomiseerd naar RIPC (vier episodes van 5 minuten van ischemie van de 
onderarm door oppompen van een bloeddrukmanchet) terwijl de andere helft een 
sham (nep) procedure onderging. Hoewel de studie een statistisch significante 
reductie in post-operatieve hs-troponine van ongeveer 10% aantoonde in de RIPC 
groep, was er na 1 jaar geen verschil tussen de twee groepen wat betreft het primaire 
eindpunt: een combinatie van cardiovasculaire sterfte, het optreden van een myo-
cardinfarct, beroerte of coronaire revascularisatie of elk van deze eindpunten 
afzonderlijk. In dezelfde uitgave van de New England Journal of Medicine rapporteerden 
Meybohm et al hun studieresultaten in 1403 patiënten die een CABG ondergingen, 
waarbij RIPC van de bovenarm werd uitgevoerd terwijl patiënten onder anesthesie 
waren met propofol: ook in deze studie waren er geen verschillen in vergelijking met 
patiënten die deze voorbehandeling niet kregen.24 
Door de teleurstellende uitkomsten van onderzoeken naar het effect van RIPC en 
farmacologische preconditionering op de relevante klinische  eindpunten, lijkt het doek 
te vallen voor  preconditonering als strategie om ischemie-reperfusieschade te 
verminderen in de setting van CABG operaties. In de setting van een acuut myo-
cardinfarct daarentegen, maar ook op het gebied van de transplantatiegeneeskunde, 
is het concept van preconditionering nog steeds veelbelovend. Op dit moment is er 
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een aantal grote klinische trials bezig om het effect van (farmacologische) pre - 
con ditionering op harde klinische eindpunten te onderzoeken bij patiënten met een 
ST-elevatie myocardinfarct.25-27 De resultaten van deze studies zullen de toekomst-
perspectieven en de waarde van preconditioneringsstrategieën om ischemie-reperfusie-
schade te voorkomen verder bepalen. 
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Als ik terug kijk op de afgelopen periode, overheersen er een aantal gevoelens: trots, 
dankbaarheid en vreugde. Ik heb het voorrecht gehad mij te mogen omgeven met 
een “gouden team” van promotoren, collegae, vrienden en familie en mede door hen 
is dit boekje bijna als vanzelf tot stand gekomen. Natuurlijk ging niet alles zonder slag 
of stoot, maar nooit heb ik hoeven twijfelen aan de steun en hulp van de mensen die 
ik om mij heen had. 
Als eerste gaat mijn dank uit naar alle patiënten en vrijwilligers die vol overgave 
hebben deelgenomen aan mijn studies. Het verdient het diepste respect dat patiënten 
juist aan de vooravond van een grote openhartoperatie, bereid waren om voor de 
wetenschap extra medicijnen te slikken. Een diepe buiging voor de toewijding en het 
vertrouwen. Dit zelfde geldt natuurlijk ook voor de tientallen gezonde vrijwilligers die 
belangeloos deelnamen aan de experimenten. Zonder deze mensen is onderzoek 
en vooruitgang in de Geneeskunde simpelweg onmogelijk. 
Professor dr. Riksen, beste Niels. Wat ben ik trots dat ik de eerste promovenda ben, 
waarvan jij officieel de promotor bent. En wat is die rol jou op het lijf geschreven! Hoe 
jong jij ook nog bent, jij bent geboren voor de wetenschap in al haar facetten. Jouw 
intelligentie, maar ook jouw zorgvuldigheid, integriteit en toewijding maken jou uniek. 
Zoals je me vaker hebt horen zeggen: kennis is één ding, maar het kunnen overbrengen 
van kennis op anderen is een kunst, een kunst die jij absoluut beheerst. Voor ons is het 
afsluiten van dit promotietraject gelukkig geen afscheid, maar hopelijk het begin van 
een mooie samenwerking in de toekomst. De eerste stap hiervoor is gezet, aangezien 
ik een deel van mijn verdieping doorbreng op jouw afdeling Vasculaire Geneeskunde. 
Professor dr. Rongen, beste Gerard, mijn dank is groot. Jij bent immers degene die 
mij de kans heeft gegeven om aan dit promotietraject te beginnen. Zoals het vuur 
voor de wetenschap in jouw hart brandt, is ongekend! Hoe motiverend is het om met 
jou in gesprek te zijn. Het maakt niet uit over welk onderwerp, de ideeën voor onder- 
zoek vliegen je om de oren. De twinkeling in je ogen en de brede lach op je gezicht 
als je weer eens wat moois had bedacht, zo oprecht, prachtig. Voor mij sta jij voor 
zuiverheid en integriteit, twee zaken die onmisbaar zijn in de wetenschap. Dank je wel 
Gerard, voor je jarenlange inzet en toewijding en alles wat ik van jou heb mogen leren.
Professor dr. Paul Smits, heel hartelijk dank dat u mij de mogelijkheid heeft geboden 
om op (toen nog) uw afdeling aan dit traject te mogen beginnen. Hoe fijn is het ook 
om te zien, dat heel belangrijke mensen toch zo ongelofelijk vriendelijk en dichtbij 
zichzelf kunnen blijven. 
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De manuscriptcommissie bestaande uit professor dr. Cees Tack, professor dr. Wim 
Morshuis en professor dr. Dirk J. Duncker wil ik graag danken voor hun kritische 
beschouwing en enthousiaste goedkeuring van het manuscript. Prof. Tack, beste 
Cees, het is voor mij een eer dat jij de voorzitter van mijn manuscriptcommissie bent. 
Mijn eerste stappen op het gebied van de wetenschap waren tenslotte onder jouw 
toeziend oog tijdens mijn wetenschappelijke stage. Aan het begin van mijn promotie-
traject hebben wij samen nog gekeken of wij een project zouden kunnen schrijven. 
Hoewel ik vervolgens bij Gerard en bij Niels ben gepromoveerd, vind ik het wel een 
heel fijne gedachte dat je nu in deze hoedanigheid toch bij de afsluiting kunt zijn. 
Geachte professor Morshuis, graag wil ik ook u bedanken. Ik ken u natuurlijk 
voornamelijk uit de kliniek en ik heb u leren kennen als een gedreven en zeer kundig 
hoofd van onze afdeling Cardio-thoracale chirurgie. Wat bent u een aanwinst voor 
ons ziekenhuis. 
Geachte professor dr. Freek Verheugt, u bent degene geweest die mij heeft aan- 
genomen voor de opleiding tot cardioloog. Zonder dat u dat zich misschien beseft, 
heeft u daarmee mijn grootste wens in vervulling doen gaan. Veel dank voor uw 
vertrouwen in mij als dokter en als toekomstig cardioloog. Nooit zal ik uw woorden 
vergeten: ‘je bent in opleiding, maar luister nu maar naar mij, je moet straks nog wel 
gaan promoveren’. Professor, ik heb geluisterd!
Professor dr. Menko-Jan de Boer, hoofd van onze afdeling Cardiologie. Onder uw 
supervisie ben ik momenteel mijn opleiding aan het afronden. U heeft de afgelopen 
jaren veel bereikt op onze afdeling, mijn diepe respect. Ik leer niet enkel medisch 
inhoudelijk veel van u, uw anekdotes en visie op keuzes in de gezondheidszorg zijn 
ook inspirerend. Naast uw wijsheid kan ik ook uw humor erg waarderen. Dank u wel 
professor voor uw vertrouwen in mij nu, maar ook voor de toekomst. 
Waar zou dit boekje zijn, zonder de inzet en de hulp van mijn gedreven studenten. 
Agnes Vissers, lieve Agnes, nauwkeurig en kritisch, maar altijd opgewekt, ging je 
ochtend na ochtend weer aan de slag. Dank je wel! Coen Bandell, onze psychiater 
in wording. Heerlijk jouw sarcasme. Als ik  terugdenk moet ik nog steeds lachen om 
bepaalde uitspraken. Ook jij bedankt en tot ziens in de kliniek! Roel Kengen, beste 
Roel, hoeveel vertrouwen moet jij hebben gehad in ons onderzoek: niet alleen was jij 
ooit zelf proefpersoon voor een van mijn studies, hierna heb je je samen met mij 
ingezet voor onze onderarmsstudie. Wat heb jij hard gewerkt en dat naast jouw 
Geneeskunde studie. Over passie en inzet gesproken, dank je wel!
155
DANKWOORD
Research verpleegkundigen, Anja Rasing, Marielle Verstegen en Karin Saïni. 
Dames, wat werken jullie hard en wat leveren jullie fantastisch werk. Anja, jij bent de 
spin in het web geweest bij de uitvoer van de meeste van mijn studies. Jouw inzet en 
enthousiasme zijn bewonderenswaardig. Ik zal nooit onze momenten samen in de 
‘-20 gradenvriezer’ vergeten: labsamples uitzoeken compleet in skipak, urenlang 
vernachelen in de kou, terwijl buiten de zon scheen en het +30 graden was. Terwijl ik 
dit opschrijf, vraag ik me af of we niet alsnog een brief van de arbodienst kunnen 
verwachten. Niets was ooit teveel gevraagd, dank je wel lieve Anja. Marielle en Karin, 
ook met jullie heb ik zo fijn gewerkt, bedankt voor alles. Graag wil ik ook Evertine 
Abbink en de rest van het team van het CRCN bedanken, voor alle hulp en natuurlijk 
de gezelligheid tijdens de meetdagen op de klinische fysiologie en later op het 
CRCN. 
Petra van den Broek, hoofd-analiste bij de Farmacologie-Toxicologie en tevens mijn 
kamergenootje. Jouw expertise als analist en inhoudsdeskundigheid hebben mij 
enorm geholpen, immers, wat te doen met alle bepalingen die nog nooit eerder 
gedaan waren? En Petra, mijn god, wat hebben wij toch wat afgelachen samen. Jij 
hebt er echt voor gezorgd dat ik een mooie tijd heb om op terug te kijken, dank je wel. 
Ik wens jou en ‘R’ het allermooiste toe. Ab Bilos, lieve Ab, mede namens Petra, sorry 
dat wij je af en toe van je werk hebben gehouden en bedankt voor de lieve woorden, 
het werk dat je verzet hebt en de rustgevende theetjes die op zijn tijd nodig waren. 
Ook de andere analisten van de afdeling Farmacologie-Toxicologie wil ik bedanken: 
Annemieke Vos en Vivienne Verweij, waar zou ons hartoortjesonderzoek zijn 
zonder jullie? Niets is zo grillig als de operatieplanning op een acute afdeling zoals de 
hartchirurgie. Toch zat jij Annemieke, vaak buiten je normale werktijden om,  geduldig 
te wachten tot je de (uren durende) experimenten keer op keer weer keurig kon 
uitvoeren. Hetzelfde geldt natuurlijk voor Vivienne en later ook Fons Wouterse, dank 
jullie wel. Janny Peters, dank je wel voor alle analyses die je hebt uitgevoerd voor de 
CABG-dipyridamol studie. Jeanne Pertijs, wij hebben dan misschien niet heel direct 
met elkaar samengewerkt, maar ik wil je toch danken voor je kritische blik bij het 
lezen van verschillende protocollen en manuscripten. 
De afdeling Cardio-thoracale chirurgie onder leiding van aanvankelijk professor 
Henry van Swieten en vervolgens professor Wim Morshuis. Op jullie afdeling heb ik 
zoveel geleerd en leer ik nog elke dag in de kliniek. Ik wil alle hartchirurgen ongelofelijk 
bedanken, voor hun medewerking en hun geduld. Jullie inzet is een belangrijk 
fundament geweest voor het succes van de CABG-studies.  
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Daarnaast wil ik de dames het planbureau van de Cardio-thoracale chirurgie 
bedanken: Petra Budde, Jacqueline Blauwbroek, Daphne Maassen en Tanja Derks. 
Zoals ik al eerder schreef, niets is zo grillig als een operatieplanning op een acute 
afdeling, maar elke dag opnieuw krijgen jullie het toch maar weer mooi voor 
elkaar! Dank voor het meedenken en voor het schuiven in de planning zodat onze 
geïncludeerde patiënten deel konden blijven nemen aan de CAGB-studies. 
Ik bedank ook graag de afdeling Intensive Care, waar een team van research- 
verpleegkundigen onder het toezicht van professor dr. Peter Pickkers als een geoliede 
machine dag en nacht werkt. Aanvankelijk heb ik veel zaken gedaan met Tijn Bouw, 
later met Marieke van der A. Tijdens mijn onderzoek was ik zwaar onder de indruk 
over de manier waarop jullie werken, zo secuur, ongeacht wisselende diensten, niets 
werd aan het toeval overgelaten. En dat ook nog eens met een vriendelijke lach en 
altijd tijd voor een kop koffie. Dames en heren, chapeau. 
Graag zou ik ook de medewerkers van de afdeling Fysiologie willen bedanken. 
Professor dr. Dick Thijssen, het was mij altijd een genoegen om onderzoeken met 
je te bediscussiëren. Dank voor je deskundigheid wat betreft de FMD-experimenten. 
Tim Schreuder, het was fantastisch om samen de krachten te bundelen, wat heeft 
geresulteerd in de ‘Koningenstudie’.  
Collega arts-onderzoeker Stijn Wouters, jij maakte dat ik een vliegende start kon 
maken met mijn onderzoek. Dank daarvoor.  
Waarde collegae van de afdeling Cardiologie van het Radboudumc. Jullie hebben 
ervoor gezorgd dat ik mij vanaf dag één ‘thuis’ voel in het Radboud. Nergens heb ik 
zoveel passie gezien voor ons vak en voor de patiëntenzorg. Dank jullie wel dat ik 
elke dag zoveel van jullie kan leren en dat ik met een glimlach naar mijn werk kan 
gaan. Ik kan oprecht zeggen dat ik onder jullie hoede de afgelopen jaren gegroeid 
ben als dokter, als cardioloog en als mens. 
Collegae van de afdeling Cardiologie van het Rijnstate ziekenhuis. Onder jullie 
begeleiding is de basis gelegd voor de cardioloog die ik in de toekomst hoop te 
kunnen zijn. Jullie oprechte interesse in mij als persoon en in mijn carrière, maken dat 
ik mij altijd verbonden zal voelen met het Rijnstate ziekenhuis. 
Afdeling Interne Geneeskunde van het Canisius Wilhelmina ziekenhuis. De kennis 
die ik bij jullie heb opgedaan is van onschatbare waarde en ik val er nog dagelijks op 
terug. Dank voor de fijne opleiding. 
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Beste paranimfen. Lieve Annemarie. De rollen zijn nu omgedraaid, het is voor mij 
een eer dat jij naast mij staat bij mijn verdediging. Wij hebben samen veel kunnen 
delen, tijdens ons onderzoek, maar ook daarbuiten. Het is natuurlijk fantastisch dat jij 
een mooi plekje hebt gevonden in Eindhoven, maar dat maakt wel dat ik jou nu meer 
moet missen. Hopelijk zullen wij elkaar nog veel zien in de toekomst. Lieve Danielle, 
voor mij is het niet meer dan vanzelfsprekend dat jij naast mij staat bij mijn verdediging. 
Ik heb je leren kennen als een gedreven dokter, een talentvolle onderzoeker, maar 
vooral als een heel fijne collega en vriendin. De volgende keer zal jij er staan, ik weet 
nu al dat jij het fantastisch zal doen!
Lieve familie en vrienden, bedankt voor al jullie steun en vertrouwen, maar ook voor 
al jullie geduld de afgelopen jaren. Het boekje is nu af en dat betekent maar een ding, 
vanaf nu kunnen wij hopelijk alleen maar meer van elkaar genieten. 
Lieve papa en mama. Ik hou zoveel van jullie. Dankzij jullie vertrouwen en steun ben 
ik geworden wie ik ben. Jullie hebben mij altijd geleerd dat er geen onmogelijkheden 
bestaan, dat ik altijd moet gaan voor datgene dat ik wil bereiken. Met jullie liefde blijkt 
deze theorie tot op heden te kloppen. Lieve Ilham en Islah. Hoe mooi is het om 
elkaars gedachten te kunnen lezen, om elkaars kleren te passen, om samen te 
kunnen huilen om vervolgens weer te kunnen lachen. Ik hou van jullie. Redouan, wat 
ben ik trots op jou. De gesprekken die wij samen kunnen voeren zijn mij heel 
waardevol. De discussies overigens ook. Bedankt voor jouw liefde. Lieve Imane, 
lieve mama: kan je het geloven?!  December, ik kan niet wachten! Ik ben zo trots en 
zo benieuwd. Chaima en Amin, onze kleintjes. Hoe bijzonder is onze band, mijn 
liefde voor jullie is zo diep!
Marc, jij hebt geen idee welke rol jij hebt gespeeld in het tot stand komen van dit 
boekje. Een ding weet ik zeker, zonder jou was het nooit gelukt. Woorden zullen hier 
nooit kunnen ondervangen hoe gelukkig ik ben dat jij naast en achter mij staat.
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CURRICULUM VITAE
Saloua El Messaoudi werd op 26 december 1982 geboren in Arnhem. Na het behalen 
van haar eindexamen van het Atheneum B aan het Thomas à Kempis College te 
Arnhem, startte zij in 2002 met haar Geneeskunde opleiding aan het Radboudumc te 
Nijmegen. Al tijdens haar geneeskundestudie raakte zij geïnteresseerd in weten-
schappelijk onderzoek, hetgeen in 2006 resulteerde in haar eerste publicatie in het 
Nederlands Tijdschrift voor de Geneeskunde. Ook tijdens haar wetenschappelijke 
stage heeft zij zich verdienstelijk gemaakt voor de wetenschap en onderzoek gedaan 
naar het effect van vitamine C op het sympatisch zenuwstelsel. Al vroeg in haar 
opleiding bleek er een sterke voorliefde te zijn voor de Cardiologie. Na het afronden 
van haar geneeskundestudie, werd zij na een korte periode in het Radboudumc te 
hebben gewerkt, in juli 2008 door prof. dr. F.W.A. Verheugt voor de opleiding tot 
cardioloog aangenomen. Aangezien haar ambities verder strekten dan alleen het 
afronden van haar specialisme, werd al snel besloten de opleiding te combineren 
met een promotietraject. Onder leiding en toezicht van prof dr. G. Rongen en prof. Dr. 
N.P. Riksen werd een subsidie van de hartstichting verworven die haar in staat stelde 
haar promotietraject aan te vangen. Het feit dat het onderwerp raakvlakken had met 
de Cardiologie, Vasculaire Geneeskunde en Cardio-thoracale Chirurgie, gaf haar de 
mogelijkheid als verbinding tussen deze specialismen op te treden en zij onderhoud 
nog steeds warme banden met de verschillende groepen.  Haar vooropleiding 
Interne Geneeskunde volgde zij in het Canisius Wilhelmina Ziekenhuis te Nijmegen 
(opleider: dr. T. Dofferhof) en zij maakt nog dagelijks gebruik van de kennis die zij 
daar heeft opgedaan. Haar B-jaar cardiologie volgde zij met veel plezier aan de 
afdeling Cardiologie van het Rijnstate Ziekenhuis te Arnhem (opleider: dr. H. Bosker) 
en haar ervaringen met deze opleidingsgroep hebben de belangrijke basis gelegd 
voor de cardioloog die zij in de toekomst hoopt te worden. Sinds 2015 is zij als AIOS 
Cardiologie weer werkzaam op de afdeling Cardiologie van  het Radboudumc en op 
1 juli 2017 zal zij haar opleiding tot cardioloog afronden. Tijdens haar opleiding heeft 
zij altijd geprobeerd zich zo breed mogelijk te ontwikkelen, zo is zij o.a. lid van het 
dagelijks bestuur van de Centrale Opleidingscommissie en is zij actief binnen de 
AAVR. Daarnaast heeft onderwijs haar passie en zij heeft o.a. gewerkt als gastdocent 
op de Hoge School Arnhem Nijmegen.
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